Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2019.
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 001-38129
Mersana Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or Other Jurisdiction of Incorporation or Organization)
840 Memorial Drive Cambridge, MA
(Address of Principal Executive Offices)
04-3562403
(I.R.S. Employer Identification No.)
02139
(Zip Code)
Registrant’s telephone number, including area code (617) 498-0020
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Common Stock, $0.0001 par value
Trading symbol(s)
MRSN
Name of each exchange on which registered
The Nasdaq Global Select Market
Securities registered pursuant to Section 12(g) of the Act:
NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No
☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of
this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Non-accelerated filer
☐
☐
Accelerated filer
Smaller reporting company
Emerging growth company
☒
☒
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☒
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
As of June 28, 2019, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s common stock held by
non-affiliates was $163,614,650, based on the last reported sale price of such stock on the Nasdaq Global Select Market as of such date.
As of February 25, 2020, the registrant had 45,429,985 shares of common stock outstanding at a par value $0.0001 per share.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement that will be filed for the 2020 Annual Meeting of Stockholders are incorporated by reference in Part III.
Table of Contents
TABLE OF CONTENTS
PART I
Page
FORWARD LOOKING STATEMENTS
ITEM 1.
BUSINESS
ITEM 1A.
RISK FACTORS
ITEM 1B.
UNRESOLVED STAFF COMMENTS
ITEM 2.
ITEM 3.
ITEM 4.
ITEM 5.
ITEM 6.
ITEM 7.
PROPERTIES
LEGAL PROCEEDINGS
MINE SAFETY DISCLOSURES
PART II
FOR
MARKET
STOCKHOLDER MATTERS AND
SECURITIES
REGISTRANT’S
COMMON
RELATED
ISSUER PURCHASES OF EQUITY
EQUITY,
SELECTED FINANCIAL DATA
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
ITEM 7A.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
ITEM 8.
ITEM 9.
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
CHANGES
ACCOUNTING AND FINANCIAL DISCLOSURE
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ITEM 9A.
CONTROLS AND PROCEDURES
ITEM 9B.
OTHER INFORMATION
PART III
ITEM 10.
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
ITEM 11
EXECUTIVE COMPENSATION
ITEM 12.
ITEM 13.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND
DIRECTOR INDEPENDENCE
ITEM 14.
PRINCIPAL ACCOUNTING FEES AND SERVICES
ITEM 15.
EXHIBITS, FINANCIAL STATEMENT SCHEDULES
ITEM 16.
FORM 10-K SUMMARY
PART IV
EXHIBIT INDEX
SIGNATURES
1
2
2
27
63
64
64
64
65
66
67
80
81
116
116
117
118
118
118
118
118
119
119
119
123
Table of Contents
FORWARD LOOKING STATEMENTS
PART I
This Annual Report on Form 10-K contains forward‑looking statements. Forward‑looking statements are neither historical
facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions
regarding the future of our business, future plans and strategies, our clinical results and other future conditions. The words
“aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,”
“possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would” or the negative of these terms or
other similar expressions are intended to identify forward‑looking statements, although not all forward‑looking statements
contain these identifying words.
These forward‑looking statements include, among other things, statements about:
·
·
·
·
·
·
·
·
the initiation, cost, timing, progress and results of our current and future research and development activities,
preclinical and clinical studies;
the timing of, and our ability to obtain and maintain, regulatory approvals for our product candidates;
unmet need of ovarian cancer and non-small cell lung cancer;
our ability to quickly and efficiently identify and develop additional product candidates;
our ability to advance any product candidate into, and successfully complete clinical studies;
our intellectual property position, including with respect to our trade secrets;
the potential benefits of strategic partnership agreements and our ability to enter into selective strategic partnerships;
and
our estimates regarding expenses, future revenues, capital requirements, the sufficiency of our current and expected
cash resources and our need for additional financing.
We may not actually achieve the plans, intentions or expectations disclosed in our forward‑looking statements, and you
should not place undue reliance on our forward‑looking statements. Actual results or events could differ materially from the
plans, intentions and expectations disclosed in the forward‑looking statements we make. We have included important factors
in the cautionary statements included in this Annual Report on Form 10-K, particularly in the “Risk factors” section, that we
believe could cause actual results or events to differ materially from the forward‑looking statements that we make. Our
forward‑looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures
or investments we may make.
The forward‑looking statements contained herein represent our views as of the date of this Annual Report on Form 10-K. We
anticipate that subsequent events and developments will cause our views to change. However, although we may elect to
update these forward‑looking statements at some point in the future, we have no current intention of doing so except to the
extent required by applicable law. You should, therefore, not rely on these forward‑looking statements as representing our
views as of any date subsequent to the date of this Annual Report on Form 10-K.
ITEM 1. BUSINESS
Overview
We are a clinical-stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a
clinically meaningful benefit for cancer patients with significant unmet need. We have leveraged 20 years of industry
2
Table of Contents
learning in the ADC field to develop proprietary and differentiated technology platforms that enable us to design ADCs to
have improved efficacy, safety and tolerability relative to existing ADC therapies.
Our innovative platforms, which include Dolaflexin and Dolasynthen, delivering our DolaLock payload, as well as
Immunosynthen, delivering a novel stimulator of interferon genes, or STING, agonist, compose a highly efficient product
engine that has enabled a robust discovery pipeline for us and our partners. Our ADCs in preclinical and clinical studies are
first-in-class molecules that target multiple tumor types with high unmet medical need and have exhibited improved safety
and efficacy compared to ADCs developed using first-generation technology.
We have assembled a management team with extensive and relevant experience, including specific ADC experience, from
prior work at leading pharmaceutical companies such as Millennium Pharmaceuticals, Inc., Takeda, Biogen, Inc.,
MedImmune, Inc., Bayer AG, Genzyme, Tesaro, Roche and Bristol-Myers Squibb. We are supported by our board of
directors and scientific advisory board, who offer complementary experience in drug discovery and development, as well as
expertise in building public companies, management and business development. We believe that our highly differentiated
platforms, together with the team we have assembled, position us well to generate best-in-class ADCs with the potential to
transform the lives of cancer patients.
Strategy
Our goal is to become a leading oncology company by leveraging the potential of our innovative and differentiated ADC
technologies and the experience and competencies of our management team to discover and develop promising ADC product
candidates and to commercialize cancer therapeutics that address unmet medical needs or provide significant benefit to
patients. Key components of our strategy to achieve this goal are as follows:
·
·
·
·
·
Rapidly advance XMT‑1536. Our lead product candidate, XMT-1536, is a first-in-class Dolaflexin ADC in a
Phase 1 proof-of-concept clinical trial in patients with tumors likely to express NaPi2b, an antigen broadly
expressed in ovarian cancer and non-small cell lung cancer, or NSCLC, adenocarcinoma. We expect to report
multiple data disclosures in 2020 as we advance our proof-of-concept studies and prepare to initiate registrational
enabling studies.
Rapidly Advance XMT-1592. Mersana’s second product candidate targeting NaPi2b-expressing tumors, XMT-
1592, is an ADC created using our Dolasynthen platform. We expect to file an Investigational New Drug, or IND,
application and initiate a Phase 1 dose escalation study of XMT-1592 in patients with tumors likely to express
NaPi2b in the first half of 2020. We believe that we have a path to advance XMT-1592 through rapid dose escalation
and clinical validation.
Expand our ADC pipeline. We intend to establish a leading position in the field of ADCs by continuing to
advance platform innovations that further broaden the potential of our ADCs to deliver clinically meaningful benefit
for cancer patients, by focusing on first-in-class targets and payloads, and by pursuing fast-to-market opportunities.
We are advancing a new, potentially first-in-class ADC targeting B7-H4 which leverages our DolaLock payload
towards IND-enabling studies. We have taken ADCs beyond cytotoxics by developing the Immunosynthen
platform, an approach that may allow activation of the innate immune system in a targeted way.
Attract and retain talented and experienced people. In addition to our team’s deep experience with ADC
science, drug development and operational management, we believe that our accomplishments are a testament to the
talent and commitment of our people. Our team is driven by a shared passion to advance therapies that make a
significant difference in the lives of cancer patients. We will continue to cultivate the collaborative and passionate
workplace culture that has allowed us to advance this mission.
Build strategic partnerships to maximize the value of our programs and platforms. Our platform technologies,
and product discovery and development capabilities, drive the potential for multiple clinically meaningful
opportunities for cancer patients. In order to preserve a disciplined drug development and commercialization focus,
we may choose to enter into strategic partnerships that facilitate our ability to bring
3
Table of Contents
differentiated product candidates to more patients. Our current partnerships with Merck KGaA and Asana
Biosciences exemplify different aspects of this strategy.
Our current pipeline is summarized in the chart below:
ADC Background
Traditional ADCs are a class of cancer biotherapeutics that combine the targeting capabilities of monoclonal antibodies with
the cancer-killing ability of cytotoxic drug payloads. Antibodies and payloads are chemically linked, allowing specific drug
delivery to cancer cells targeted by the antibody. After ADCs enter a cell, the conjugated payload is released and kills the
cell. Despite the promise of ADCs, companies in the field have faced certain challenges in developing product candidates
that achieve the optimal therapeutic index, or the balance between efficacy and tolerability. These challenges are
characterized as follows:
·
·
·
·
Linker stability: Linkers must be stable in the bloodstream to ensure that free payload is not released into
circulation prior to delivery into the tumor. Free payload in circulation causes toxicity. Efforts to design better
linkers to increase stability have, in turn, reduced the efficiency of payload release once the ADC is internalized in
the tumor cell, resulting in decreased efficacy.
Drug‑to‑antibody ratio: Increasing the number of payload molecules delivered per antibody internalization event
increases potency. However, the drug-to-antibody ratio, or DAR, has typically been limited to three to four payload
molecules per antibody due to aggregation, poor pharmacokinetics and loss of drug‑like properties of the ADC at
levels above this threshold. Other attempts to increase efficacy have involved the introduction of ultra‑potent
payloads, however these efforts appear to face safety and tolerability challenges, necessitating even further reduced
DAR to maintain acceptable pharmacokinetics and drug‑like properties.
Target antigen expression level: Tumor cells typically require a threshold number of payload molecules to be
internalized in order to kill the cell. Antigens with lower levels of expression have proven less desirable as targets
for ADCs, as a result of fewer binding, internalization and payload delivery events to drive cell‑killing activity. In
turn, this has limited the number of cancers amenable to treatment with low-DAR ADC approaches, as the use of
ADCs requires antigen targets to be highly expressed on tumor cells.
Bystander effect: Once ADCs release their cytotoxic payload into targeted cells, the drug is often able to cross cell
membranes, entering and potentially killing neighboring cells whether those cells are cancerous or not. This
4
Table of Contents
is known as the ‘bystander effect,’ which is advantageous when bystander cells are cancerous, but toxic if the
cytotoxic drug is able to enter adjacent healthy cells, leading to dose-limiting toxicities such as neutropenia,
peripheral neuropathy, or ocular toxicity.
Our Technologies and Platforms
The development of ADCs is not a one-size-fits-all approach. In fact, a number of diverse factors impact the properties of an
ADC, including payload, drug-to-antibody ratio, site of conjugation and homogeneity. For each target antigen, there is an
optimal combination of these factors. Our novel and highly differentiated platforms are designed to allow us to optimize
these properties for a given target and develop ADCs that best address patient needs.
DolaLock Payload
Our DolaLock payload is a proprietary auristatin cytotoxic drug and is a highly potent anti-tubulin agent selectively toxic to
rapidly dividing cells. The DolaLock payload has been shown in preclinical studies to control the bystander effect by locking
the cytotoxic drug inside cells after allowing a short period of diffusion throughout the tumor. As the drug diffuses through
neighboring tissue, the DolaLock payload is metabolized to a form that is still highly potent but is no longer able to cross the
cell membrane, effectively locking the drug inside cells and controlling the bystander effect for a safer and more effective
cancer therapy.
A common mechanism of resistance in cancer is the up-regulation of multi-drug resistance, or MDR, pumps, such as P-
glycoproteins, or PgPs, which actively pump drugs out of cancer cells to help them survive. Once metabolized, our DolaLock
payload cannot be pumped out by PgPs, thereby avoiding this resistance mechanism. In addition, our proprietary auristatin
payload has also been shown in preclinical studies to cause immunogenic cell death and to stimulate the immune system
through dendritic cell activation. Because of this, synergy with immuno-oncology agents such as PD-1 inhibitors has been
observed in preclinical models. Our DolaLock payload with controlled bystander effect is designed to allow us to create
ADCs that produce a highly potent, well-tolerated and specifically-targeted cancer therapy.
Figure 1. DolaLock Payload with Controlled Bystander Effect
Dolaflexin Platform
The Dolaflexin platform was designed to increase the efficacy, safety and tolerability of ADCs. Dolaflexin utilizes our
proprietary Fleximer polymer, a biodegradable, highly biocompatible, water-soluble polymer able to carry multiple drug
molecules. Instead of direct conjugation to an antibody, drug molecules are attached through a cleavable linker to the
Fleximer scaffold, which is then conjugated to the antibody through a non-cleavable linker. Fleximer has demonstrated
dramatically improved drug solubility, pharmacokinetics and immunogenicity, and an increased number of drug molecules
carried by each ADC compared with traditional ADC therapies.
5
Table of Contents
As a result, we believe Dolaflexin has the potential to offer the following benefits relative to traditional ADCs:
·
Proprietary DolaLock Payload: Dolaflexin is loaded with our proprietary auristatin chemotherapeutic drug, which
is a highly potent anti-tubulin agent selectively toxic to rapidly dividing cells, with the advantages of the DolaLock
controlled bystander effect.
· Higher Drug-to-Antibody Ratio: Historically, ADCs have been limited to a DAR of 3-4. The Dolaflexin platform
can deliver ADCs with DAR between 10-12, allowing for greater efficacy while also maintaining pharmacokinetics
and drug-like properties.
·
Expanded Range of Addressable Tumor Targets: The higher DAR enabled by Dolaflexin results in more
chemotherapeutic drug released into the tumor cell for every ADC internalized. As a result, Dolaflexin ADCs can
have efficacy against tumor targets with lower levels of antigen expression where traditional ADCs have not been
effective.
We believe these advantageous characteristics of our Dolaflexin platform provide a substantial opportunity to develop
clinically meaningful ADC therapies with potential to address a broader range of cancers than traditional ADC-based
approaches. Our lead clinical candidate, XMT-1536, is a Dolaflexin ADC that targets NaPi2b. XMT-1536 is currently in a
proof-of-concept study in patients with ovarian cancer and NSCLC adenocarcinoma.
Dolasynthen Platform
The Dolasynthen platform enables an iterative approach to develop the right ADC for a given indication through
customization and optimization. Dolasynthen utilizes a synthetic scaffold for precise control of DAR, from 2-24, and site-
specific antibody bioconjugation. The platform is also able to homogeneously generate ADCs with precisely defined DARs
for consistent drug delivery to cancer cells. The Dolasynthen scaffold has been precisely designed to provide optimal water
solubility, charge balance, linker stability and DAR. We believe that Dolasynthen retains the favorable properties of
Dolaflexin, including our proprietary DolaLock technology for a controlled bystander effect, with superior physicochemical
and pharmacokinetic properties.
Illustrated by our preclinical data, optimized Dolasynthen ADCs exhibit a broad therapeutic index as a cancer therapy. These
data demonstrate the ability of the Dolasynthen platform to generate and identify the optimal ADC for a given target and
antibody.
We believe that Dolasynthen offers the benefits of Dolaflexin, including the proprietary DolaLock payload, and has the
potential to offer the following benefits relative to traditional ADCs:
·
·
Precise Control of DAR: The optimal DAR may vary between different targets and antigens. Dolasynthen allows
for precise DARs between 2-24, enabling optimization of the DAR for specific antigens and antibodies.
Site-Specific Bioconjugation: The site of scaffold bioconjugation to an antibody impacts the overall properties of
that ADC. Dolasynthen enables site-specific bioconjugation allowing further ADC optimization.
· Homogenous ADC Development: The DAR and antibody bioconjugation is consistent throughout ADCs
developed with the Dolasynthen platform allowing for consistent and precise drug delivery to targeted cancer cells.
·
Increased Hydrophilicity: The precise optimization of the hydrophilic moiety on Dolasynthen ADCs allows for
increased aqueous solubility and enhanced pharmacokinetic properties.
We have selected XMT-1592, an ADC created using the Dolasynthen platform, as our next clinical candidate.
6
Table of Contents
Immunosynthen Platform
Immunosynthen is our proprietary immunostimulatory ADC platform that is designed to take ADCs beyond delivery of
traditional cytotoxic drugs to immunomodulatory molecules that can stimulate an anti-tumor innate immune response in a
targeted manner. Through the efficient delivery of immunomodulatory molecules, Immunosynthen ADCs have the potential
to address the challenges of systemic delivery and tolerability. The Immunosynthen platform utilizes a novel STING agonist,
which has emerged as an innate immune pathway capable of inducing anti-tumor immune activity. Preclinical data
demonstrate that our STING agonist ADCs result in a greater than 100-fold increase in in vitro activity compared to a free
agonist. In addition, treatment with our STING agonist ADCs resulted in complete regression of tumors in vivo after a single,
well-tolerated dose in a variety of preclinical tumor models. Increased immune cell infiltration and cytokine expression
within the tumor after dosing was also observed after treatment, consistent with the activation of STING. During preclinical
studies, Immunosynthen ADCs achieved extended plasma exposure yet limited induction of systemic cytokines.
Immunosynthen ADCs are suited to potentially overcome the limitations of free STING agonists due to the following:
·
·
·
Systemic Administration with Targeted Delivery: Immunosynthen ADCs have the convenience of systemic
administration while providing targeted delivery specifically to the tumor, including metastatic lesions.
Improved Therapeutic Index: Conjugation of the STING agonist provides protection in the systemic circulation to
minimize off-target effects while simultaneously providing targeted delivery to maximize effects in the tumor and
metastatic lesions.
Enhanced Pharmacokinetic Properties: The prolonged pharmacokinetics of ADCs and active uptake through
targeting can overcome pharmacokinetic and permeability issues of the free agonists, resulting in sustained delivery
and activation of the innate immune response.
Our product candidates
We are leveraging our platforms to develop a robust pipeline of clinically meaningful cancer therapies. Our pipeline strategy
focuses on targets that have been biologically validated (either as ADCs or through another modality), where the advantages
of our platforms may lead to clinically superior therapeutic benefits, where we have the potential to achieve first-in-class
status, and where fast-to-market opportunities are available. Our lead product candidate, XMT-1536, is in Phase 1 dose
escalation and proof-of-concept expansion studies in ovarian cancer and NSCLC adenocarcinoma. Our next product
candidate, XMT-1592, is expected to initiate a Phase 1 dose escalation study in the first half of 2020. We are also advancing
a potentially first-in-class DolaLock ADC targeting B7-H4 towards IND-enabling studies and are progressing towards
nomination of an Immunosynthen development candidate. In addition, our partners have multiple ADC product candidates
leveraging our technology in development.
XMT‑1536: our NaPi2b‑targeted Dolaflexin ADC
XMT-1536, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin
platform to deliver an average of 10-12 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed
in NSCLC adenocarcinoma and ovarian cancer with limited expression in normal tissue. We are actively recruiting and
dosing patients with ovarian cancer and NSCLC adenocarcinoma, where a majority of patients express NaPi2b, in a Phase 1
clinical trial.
In June 2019, we presented interim data from the ongoing XMT-1536 Phase 1 dose escalation study at the Annual Meeting of
the American Society of Clinical Oncology, or the ASCO Meeting, showing encouraging clinical activity with confirmed
responses and prolonged stable disease in heavily pretreated patients, without pre-selection for NaPi2b expression. The
interim data showed that XMT-1536 was well-tolerated without the severe toxicities commonly seen with other ADCs such
as neutropenia, ocular toxicities or peripheral neuropathy. Since the ASCO Meeting, we have made further progress in
demonstrating both safety and activity at higher doses. Specifically, XMT-1536 has been well tolerated by patients at both the
36 mg/m once-every-four-week and 43 mg/m once-every-four-week dosing regimens initiated
2
2
7
Table of Contents
during the Phase 1 dose escalation study. The doses have been well-tolerated with primarily Grade 1 and Grade 2 treatment-
related adverse events without the severe toxicities seen with other ADCs, such as neutropenia, neuropathy, or ocular
toxicities. To date, a maximum tolerated dose, or MTD, has not been determined, and we have initiated evaluation of a 52
mg/m once-every-four-week dose escalation cohort.
2
Since the ASCO Meeting, we have also expanded in more homogenous, earlier line patient populations, and we are
developing a patient selection strategy. Specifically, and in parallel with dose escalation, we have initiated proof-of-concept
expansion cohorts in more homogeneous earlier line patient populations in ovarian cancer and NSCLC adenocarcinoma.
Expansion cohorts were initiated at 36 mg/m once-every-four-week dose regimens, and the dose regimen has been increased
to 43 mg/m once-every-four-week for newly-dosed patients. We have also developed a proprietary biomarker assay for
patient selection and entered into a collaboration with a partner with expertise in the development of companion diagnostics.
2
2
XMT-1592: our NaPi2b targeted Dolasynthen ADC
We have selected our next clinical product candidate, XMT-1592. XMT-1592 was created using our Dolasynthen platform
and also targets NaPi2b. XMT-1592 comprises the same proprietary NaPi2b antibody and potent auristatin DolaLock
payload with controlled bystander effect as XMT-1536, with the additional features of homogeneous, site-specific
bioconjugation and precise DAR. Preclinically, XMT-1592 has shown a differentiated profile particularly in NSCLC
adenocarcinoma, where it was four times more efficacious than XMT-1536, consistent with higher tumor penetration, as
described in below in Figure 2. Based on these preclinical data, we believe that XMT-1592 has the potential to provide us
with a second opportunity to treat NSCLC adenocarcinoma patients. We plan to evaluate the clinical differentiation of
Dolasynthen by leveraging our experience in NaPi2b to rapidly progress XMT-1592 through dose escalation.
Figure 2. XMT-1592 Shows Four-Fold Greater Efficacy in Lung Tumor Model
8
Table of Contents
Our B7-H4 targeted ADC candidate
Our early stage programs include a potentially first-in-class B7-H4-targeted DolaLock ADC candidate addressing areas of
high unmet medical need. The expression profile of B7-H4 is well suited for our unique DolaLock payload. B7-H4 can be
expressed in two places: on tumor cells and on immunosuppressive tumor associated macrophages, or TAMs, which may
lead to additional processing of the ADC and more payload in the tumor environment. DolaLock’s dual mechanisms of
action with a direct cytotoxic effect as well as an immunostimulatory effect through dendritic cell activation and
immunogenic cell death are well suited to the biology of the B7-H4 target. We have favorable efficacy and non-human
primate tolerability data with both Dolaflexin and Dolasynthen ADCs targeting B7-H4. Our objective is to rapidly progress
through IND-enabling studies and scale up manufacturing activities with third parties. B7-H4 provides significant
opportunities for development in areas of high unmet need such as breast cancer, NSCLC and ovarian cancer. We anticipate
potential fast-to-market clinical development opportunities because expressions of B7-H4 and PD-L1 are mutually exclusive,
creating an opportunity for high unmet need tumors where patients are ineligible for immune checkpoint inhibitors.
Ovarian cancer unmet need and epidemiology
Worldwide, ovarian cancer had incidence of approximately 295,000 and caused an estimated 185,000 deaths in 2018. With a
U.S. incidence of approximately 25,000 new cases and mortality of 14,000 in 2018, ovarian cancer was the second most
common gynecologic malignancy and the most common cause of gynecologic cancer death in the United States. The
majority of ovarian malignancies (approximately 90%) are derived from epithelial cells. Diagnosis is made histologically,
and evaluation is commonly performed following surgical removal of an ovary or fallopian tube or biopsies of the
peritoneum. The ovarian cancer standard of care is characterized by initial surgery followed by platinum-containing
chemotherapy followed by periods of either observation or maintenance. Nearly 85% of ovarian cancer patients typically
relapse following initial treatment. Subsequent treatment depends on the depth and duration of response to initial platinum
treatment. Ovarian cancer patients who progress within six months of completion of platinum-based therapy are considered
to have platinum-resistant disease. Unmet medical need is significant for patients with platinum-resistant ovarian cancer as
treatment options are mainly limited to single agent chemotherapies such as pegylated liposomal doxorubicin, topotecan and
paclitaxel. Multiple Phase 3 studies of single agent chemotherapies in patients with platinum-resistant disease and one to
three prior therapies have exhibited an overall response rate of 4-12% and median progression-free survival of 3-4 months.
With targeted agents approved in platinum-resistant disease increasingly being prescribed in earlier lines of therapy, the
unmet need is expected to remain severe. Bevacizumab in combination with chemotherapy is indicated to treat a subset of
platinum-resistant ovarian cancer patients with no more than two prior therapies but it is not always well-tolerated and has
shown no overall survival benefit. Use of bevacizumab in combination with platinum-containing chemotherapy in the
frontline and platinum-sensitive recurrent settings mean an increasing number of platinum-resistant patients are pre-treated
with bevacizumab and are not candidates for additional bevacizumab combination treatment. More recently, PARP inhibitors
have been approved for heavily-pretreated ovarian cancer including platinum-resistant disease. However, they are
predominantly used in a subset of patients with cancers harboring BRCA1 and BRCA2 mutations. Similarly, use of PARP
inhibitors in earlier lines of recurrent platinum-sensitive maintenance and more recently frontline maintenance therapy
following platinum-based chemotherapy means an increasing number of platinum-resistant patients are pre-treated with
PARP inhibitors and are not candidates for additional PARP therapy.
NSCLC unmet need and epidemiology
Worldwide, lung cancer had an incidence of approximately 2.1 million and caused an estimated 1.7 million deaths in 2018.
With a U.S. incidence of approximately 230,000 new cases and over 150,000 deaths in 2018, lung cancer was the most
deadly form of cancer in the United States. The five year survival rate is less than 20% on average. Approximately 95% of
all lung cancers are classified as either small cell lung cancer or NSCLC. NSCLC can be further divided into squamous or
non-squamous. The majority of non-squamous NSCLC is classified as adenocarcinoma. These histological distinctions are
important for proper staging, treatment and prognosis. For patients with NSCLC, initial treatment is largely determined by
the stage of disease. Surgical resection offers the best opportunity for long-term survival and cure in patients with resectable
early-stage NSCLC. Locally-advanced NSCLC is treated by combinations of radiotherapy, immunotherapy,
9
Table of Contents
chemotherapy and surgery. The majority of patients present with inoperable disease. Metastatic NSCLC is managed with
systemic chemotherapy and immunotherapy.
The standard of care is evolving for NSCLC with the introduction of immunotherapies for patients without oncogenic driver
mutations and new targeted therapies for patients with EGFR, ALK, ROS-1, NTRK or BRAF mutations. For patients with
metastatic disease without oncogenic driver mutations, frontline platinum-based chemotherapy is being combined with, or
depending on PD-L1 expression status, replaced by immunotherapy using anti-PD-1 or anti-PD-L1 monoclonal antibodies.
For patients with metastatic disease harboring oncogenic driver mutations, several generations of targeted agents are
available with different resistance profiles. Frontline therapy is often followed by relapse and recurrence and treatment
options for these patients are substantially more limited. The standard of care of docetaxel alone or in combination with
targeted agents has an overall response rate of 14-23%, median progression-free survival of 3-4 months and median overall
survival of 9-12 months.
With PD-1 and PD-L1 inhibitors and next generation targeted therapies moving into frontline, the unmet need in recurrent
lung cancer is expected to remain severe.
NaPi2b Background
NaPi2b is a member of the SLC34 family of sodium-dependent transporters and plays an important role in maintaining
phosphate homeostasis. NaPi2b is expressed in a high proportion of ovarian cancer and NSCLC adenocarcinoma. There are
currently no FDA‑approved tests to measure NaPi2b expression on tumor cells. Given the prevalence of its expression on
epithelial ovarian and NSCLC adenocarcinoma tumors, however, our initial clinical studies of XMT‑1536 are being
conducted without prospective identification of patients with NaPi2b‑expressing tumors. Nonetheless, we have developed
and technically validated an immunohistochemistry assay to measure NaPi2b expression which we intend to use
retrospectively to confirm the broad prevalence of NaPi2b expression in our target patient populations while correlating those
expression levels with the efficacy observed in such patients. We are currently collaborating with a third party to create and
obtain regulatory approval for our assay as a companion diagnostic.
Strategic partnerships
Strategic partnerships with leading biopharmaceutical companies to advance Fleximer ADC product candidates
We believe that our ADC platforms have broad applicability across a number of targets. We have used strategic partnering to
accelerate bringing Fleximer ADCs to patients. Fleximer is our proprietary, biodegradable, highly biocompatible and water-
soluble polymer that is able to carry multiple drug molecules, and it is a key component of our Dolaflexin platform. Since
2012, we have entered into strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC
(by assignment from Endo Pharmaceuticals Inc.) to enable development of certain ADC product candidates utilizing
Fleximer. In establishing each of these partnerships, our primary objectives were to collaborate with leading
biopharmaceutical companies to validate the potential of ADC product candidates utilizing Fleximer, gain meaningful
near‑term funding and drive significant long‑term value. Under each of our partnerships, we own the rights to any
improvements to our ADC platform. The details of our material existing strategic partnerships are as follows:
Merck KGaA strategic research and development partnership
In June 2014, we entered into a collaboration agreement with Merck KGaA for the development and commercialization of
ADC product candidates utilizing Fleximer for up to six target antigens. We formed a strategic partnership with Merck KGaA
because of their expertise in oncology drug development. Under this agreement, we are responsible for generating ADC
product candidates against Merck KGaA‑selected target antigens. Merck KGaA received rights to select up to six target
antigens, of which it has selected all six. Merck KGaA is responsible for generating antibodies against the target antigens,
and we are responsible for generating Fleximer and our proprietary payloads and conjugating this to such antibodies to create
the ADC product candidates. With respect to each target antigen selected by Merck KGaA, we granted Merck KGaA an
exclusive, worldwide license under certain of our Fleximer ADC‑related patents and know‑how to develop, manufacture and
commercialize ADC product candidates directed to such target antigen. Merck KGaA is then responsible for the further
development and commercialization of these ADC product candidates. In addition, if Merck
10
Table of Contents
KGaA advances candidates, we are responsible for manufacturing these ADC product candidates for GLP toxicology studies
and Phase 1 clinical studies at Merck KGaA’s expense and Merck KGaA is responsible for all further manufacture of these
ADC product candidates. Merck KGaA is required to pay its own costs in the development, commercialization and
manufacture of these ADC product candidates and to reimburse us for our costs incurred in performing our research activities
under this agreement. The most advanced product candidates in this partnership are in the lead optimization stage.
Through December 31, 2019, we have received an upfront payment of $12 million and milestone payments of $3 million
under this agreement. If products are successfully developed and commercialized against all six target antigens, we are
entitled to receive future development, regulatory and commercial milestones of up to $777 million. We are entitled to
receive tiered royalties in the low‑ to mid‑single digit percentages on net sales of products targeting Merck KGaA’s target
antigens during the applicable royalty term if products are successfully developed and commercialized by Merck KGaA
under this agreement.
Unless earlier terminated, this agreement will expire upon the expiration of the last royalty term for a product under the
agreement in all countries or, if Merck KGaA does not designate any ADC product candidates produced by us under the
agreement as preclinical development candidates, upon the expiration of the last‑to‑expire research program. The royalty
term means, on a product‑by‑product and country‑by‑country basis, the period commencing upon the first commercial sale
of a product and ending upon the later to occur of: (i) the expiration of the last Mersana patent right that covers or claims the
exploitation of such product in such country, or (ii) 10 years from the date of first commercial sale of such product in such
country. Upon the expiration of each royalty term for each product on a country‑by‑country basis, Merck KGaA’s exclusive
license will convert to a perpetual, non‑exclusive, royalty‑free license with respect to such product in such country. Merck
KGaA may terminate this agreement in its entirety or with respect to any target antigen for convenience upon 60 days’ prior
written notice. Each party may terminate this agreement in its entirety upon an uncured material breach of the agreement by
the other party.
Asana Biosciences collaboration agreement
In March 2012, we entered to a collaboration agreement with Asana Biosciences, or Asana, formerly part of Endo
Pharmaceuticals, to develop next-generation ADCs. Under this agreement, Asana paid us an upfront fee for the right to
utilize our Fleximer technology to develop novel ADC candidates against a single cancer target. We are responsible for
conducting research and creating ADCs that are conjugates of our diverse, highly potent cytotoxic payloads, our Fleximer
polymer and custom linkers, and Asana’s novel antibodies. In addition to providing novel antibodies, Asana is responsible for
product development, manufacturing and commercialization of any Fleximer ADC products. Through December 31, 2019,
we have received an upfront payment of $0.8 million and milestone payments of $3.3 million under this agreement.
Strategic partnerships to access antibodies to progress our proprietary pipeline
Our focus is to progress our proprietary pipeline of ADCs. For this reason, we have partnered with biotechnology companies
that have the capability to generate high quality antibodies or that have existing antibodies that we can license for inclusion in
our ADCs. These strategic partnerships have facilitated the acceleration of our proprietary pipeline.
Recepta license for the NaPi2b antibody
In July 2015, we entered into a license agreement with Recepta Biopharma S.A., or Recepta, a Brazilian biopharmaceutical
company, licensing Recepta’s NaPi2b antibody for use in XMT‑1536 and XMT-1592 and granting Recepta the exclusive
right to commercialize XMT‑1536 and XMT-1592 in Brazil. Under this agreement, Recepta granted us an exclusive license
and sub‑license with respect to certain patents licensed by Recepta from Ludwig Institute for Cancer Research and
technology owned by Recepta to develop and exploit products containing Recepta’s NaPi2b antibody, including XMT‑1536
and XMT-1592, worldwide for the diagnosis, prophylaxis and treatment of human cancer. We granted Recepta an exclusive
license under our rights in such patents and technology and certain of our ADC‑related patents and technology to
commercialize any such products developed by us, including XMT‑1536 and XMT-1592, in Brazil. We are responsible for
the worldwide development and commercialization of products under this agreement at our own expense in certain major
markets, including at least one study site in our Phase 3 clinical studies in Brazil. Recepta may conduct development
11
Table of Contents
activities in Brazil at its own expense after providing us the opportunity to first conduct such activities at Recepta’s expense.
If a product is successfully developed and commercialized by Recepta in Brazil, we will use diligent efforts to enter into an
agreement for the supply of such products to Recepta for sale in Brazil.
Under this agreement, we paid Recepta an upfront payment of $1 million during the year ended December 31, 2015 and are
obligated to pay Recepta up to $65.5 million in development, regulatory and commercial milestones and tiered royalties in
the low‑single digit percentages on net sales of products outside of Brazil until the expiration of the royalty term if products
are successfully developed and commercialized. Through December 31, 2019, we have paid $1.9 million in milestone
payments. We are entitled to receive tiered royalties in the low‑ to mid‑single digit percentages on net sales of products in
Brazil until the expiration of the royalty term if products are successfully developed and commercialized. The royalty term
means, on a product‑by‑product and country‑by‑country basis, the period ending upon the later of (i) with respect to products
commercialized by Mersana, the expiration of the last‑to‑expire Recepta patent that covers the product in such country
(including the term of any applicable supplementary protection certificate) or with respect to products commercialized by
Recepta, the expiration of the last‑to‑expire Mersana Patent that covers the product in Brazil (including the term of any
applicable supplementary protection certificate) or (ii) 10 years from the date of first commercial sale of such product in such
country. Upon the expiration of each royalty term in each country for each applicable product, the exclusive licenses granted
to each party under the agreement will become fully‑paid up and royalty‑free. This agreement will remain in effect until
otherwise terminated as set forth below. We may terminate this agreement for convenience in its entirety or on a
country‑by‑country basis (except with respect to Brazil) or product‑by‑product basis upon 180 days’ prior written notice for
a termination in its entirety or upon 45 days’ prior written notice for a termination in part. Each party may terminate this
agreement in its entirety upon bankruptcy or similar proceedings of the other party, upon a patent challenge by the other party
or upon an uncured material breach of the agreement by the other party. However, if such breach only relates to one country,
the agreement may only be terminated with respect to such country.
Manufacturing
We do not own or operate and currently have no plans to establish any cGMP compliant manufacturing facilities. We
currently rely, and expect to continue to rely, on external Contract Manufacturing Organizations, or CMOs, for the
manufacture of product to support clinical study. In the future, we expect to use CMOs to manufacture commercial supply of
our products. The Dolaflexin manufacturing process involves readily available starting materials and uses unit operations that
are well‑precedented in the field of chemical/pharmaceutical production. The current XMT-1536 supply chain utilizes the
same vendors the company could use for commercialization.
Government regulation
Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions,
including the European Union, extensively regulate, among other things, the research, development, clinical and preclinical
studies, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing and import
and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign
countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory
authorities, require the expenditure of substantial time and financial resources. Failure to comply with the applicable
requirements at any time during the product development process, approval process or after approval may subject an
applicant and/or sponsor to a variety of administrative or judicial sanctions, including imposition of a clinical hold, refusal to
approve marketing applications, withdrawal of an approval, import/export delays, issuance of warning letters and other types
of enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions,
fines, refusals of government contracts, restitution, disgorgement of profits or civil or criminal investigations and penalties.
12
Table of Contents
Review and approval in the United States
In the United States, our ADC product candidates are subject to regulation by the FDA as biologics. The FDA regulates
biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Service Act, or PHS Act, and
associated implementing regulations. The failure to comply with the FDCA, the PHS Act and other applicable U.S.
requirements at any time during the product development process, approval process or after approval may subject an
applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending
applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of
enforcement‑related letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or criminal investigations and
penalties brought by the FDA and the Department of Justice, or DOJ, or other governmental entities.
The steps before a biological product may be approved for marketing in the United States generally include:
·
·
·
·
·
·
·
·
·
·
completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA’s GLP
regulations;
the submission to the FDA of an Investigational New Drug, or IND application which must take effect before
human clinical studies may begin in the United States;
approval by an independent Institutional Review Board, or IRB representing each clinical site before each clinical
study may be initiated;
performance of adequate and well‑controlled clinical studies to establish the safety and efficacy of the proposed
product for each indication, conducted in accordance with GCP;
preparation and submission to the FDA of a Biologics License Application, or BLA;
FDA acceptance, review and approval of the BLA, which might include an Advisory Committee review;
satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the
product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the
facilities, methods and controls are adequate to preserve the product’s identity, strength, quality and purity;
satisfactory completion of any FDA audits of clinical study sites to assure compliance with GCPs and the integrity
of the clinical data;
payment of user fees, if any, for FDA review of the BLA; and
compliance with any post‑approval requirements, including a Risk Evaluation and Mitigation Strategy, or REMS,
where applicable, and post‑approval studies required by the FDA as a condition of approval.
The testing and approval process requires substantial time, effort and financial resources, and the receipt and timing of any
approval is uncertain.
Preclinical studies
Preclinical studies include laboratory evaluation of the product candidate, as well as in vitro and animal studies to assess the
potential safety and efficacy of the product candidate for use in humans. The conduct of preclinical studies is subject to
federal regulations and requirements, including GLP regulations. The results of the preclinical studies, together with
manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other
things, are submitted to the FDA as part of an IND. Additional preclinical testing, such as toxicity studies, may continue after
the IND is submitted.
13
Table of Contents
Clinical studies
Clinical studies involve the administration of the product candidate to human subjects under the supervision of qualified
investigators in accordance with GCP requirements. GCP requirements include, among other things, conducting the study in
accordance with a written protocol, obtaining informed consent from study subjects and approval and ongoing review of the
study by an IRB at each site where the study will be conducted.
A protocol for each clinical study and any subsequent protocol amendments must be submitted to the FDA as part of the
IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises
concerns or questions related to a proposed clinical study or places the study on clinical hold. In such a case, the IND sponsor
and the FDA must resolve any outstanding concerns before the clinical study can begin.
Clinical studies are typically conducted in three sequential phases prior to approval, which may overlap or be combined:
Phase 1: The product candidate is initially introduced into healthy human subjects or, in some cases, patients with
the target disease (e.g., cancer) or condition. In Phase 1, the product candidate is typically tested for safety, dosage
tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its
effectiveness and to determine optimal dosage.
Phase 2: The product candidate is administered to a limited patient population to preliminarily evaluate the efficacy
of the product for specific targeted diseases, to identify possible adverse effects and safety risks and to determine
dosage tolerance and optimal dosage.
Phase 3: The product candidate is administered to an expanded patient population, generally at geographically
dispersed clinical study sites, in well‑controlled clinical studies to generate enough data to statistically evaluate the
efficacy and safety of the product for approval, to establish the overall risk‑benefit profile of the product and to
provide adequate information for the labeling of the product.
Phase 4 clinical studies may be conducted after initial marketing approval. These studies are used to gain additional
experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case
of products approved under accelerated approval regulations or when otherwise requested by the FDA in the form of
post‑market requirements or commitments.
Clinical studies at each phase of development may not be completed successfully within any specified period, or at all.
Furthermore, the FDA, an IRB, the sponsor or the data monitoring committee, if applicable, may suspend or terminate a
clinical study at any time on various grounds, including a finding that the research subjects are being exposed to an
unacceptable health risk. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the
integrity of the clinical data submitted.
Submission of a marketing application to the FDA
Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and
clinical studies, together with detailed information relating to the product’s chemistry, manufacture, controls and proposed
labeling, among other things, are submitted to the FDA as part of a BLA requesting approval to market the product for one or
more indications.
BLA pathway
Our ADC product candidates must be licensed via FDA approval of a BLA under Section 351 of the PHS Act on the basis of
a demonstration that the product is safe, pure and potent. Once a BLA has been accepted for filing, the FDA’s goal is to
review BLAs within ten months of the filing date for standard review or six months of the filing date for priority review. The
review process is often significantly extended by FDA requests for additional information or clarification. The FDA may
refer the application to an advisory committee for review, evaluation and recommendation as to whether the
14
Table of Contents
application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally
follows such recommendations.
Before approving the BLA, the FDA will inspect the facilities at which the biological product is manufactured and will not
approve the product unless the facility is compliant with cGMPs. Additionally, the FDA will typically inspect one or more
clinical study sites for compliance with GCP and integrity of the data supporting safety and efficacy.
During the approval process, the FDA also will determine whether to require post‑approval testing, including Phase 4 clinical
studies and surveillance programs to monitor the effect of approved biologics after they are commercialized. In addition, the
FDA will determine whether the biologic will require a REMS to ensure that the benefits of the product outweigh its risks,
which could include medication guides, physician communication plans or elements to assure safe use, such as restricted
distribution methods, patient registries and other risk minimization tools.
On the basis of the FDA’s evaluation of the BLA and accompanying information, including the results of the inspection of
the manufacturing facilities, the FDA will issue either an approval of the BLA or a Complete Response Letter, detailing the
deficiencies in the submission and the additional testing or information required for reconsideration of the application. Even
with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the
regulatory criteria for approval.
If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications,
warnings or precautions be included in the product labeling, require that post‑approval studies, including Phase 4 clinical
studies, be conducted to further assess the product’s safety after approval, require testing and surveillance programs to
monitor the product after commercialization or impose other conditions, including a REMS, which can materially affect the
potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the
results of post‑market studies or surveillance programs. After approval, many types of changes to the approved product, such
as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements
and FDA review and approval.
Fast track, breakthrough therapy and priority review designations
The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical
need in the treatment of a serious or life‑threatening disease or condition. These programs are fast track designation,
breakthrough therapy designation and priority review designation.
First, the FDA may designate a product for “fast track” review if it is intended for the treatment of a serious or
life‑threatening disease or condition and it demonstrates the potential to address unmet medical needs for such disease or
condition. For fast track products, sponsors may have greater interactions with the FDA, and the FDA may initiate review of
sections of a fast track product’s BLA before the application is complete. This “rolling review” is available if the FDA
determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective.
The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and
the sponsor must pay applicable user fees.
Second, the FDA may designate a product as a breakthrough therapy if it is intended to treat a serious or life‑threatening
disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints. The FDA may take certain actions with respect to
breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely
advice to the product sponsor regarding development and approval, involving more senior staff in the review process,
assigning a cross‑disciplinary project lead for the review team and taking other steps to design the clinical studies in an
efficient manner.
Third, the FDA may designate a product for priority review if it treats a serious condition and, if approved, would provide a
significant improvement in safety or effectiveness. A priority designation is intended to direct overall attention and resources
to the evaluation of such applications and shortens the FDA’s goal for taking action on a marketing application from ten
months to six months from the filing date.
15
Table of Contents
Accelerated approval pathway
The FDA may grant accelerated approval to a product for a serious or life‑threatening condition that provides meaningful
therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on
the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be
measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible
morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the
availability or lack of alternative treatments.
The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended
period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or
intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and
approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or
decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large studies to demonstrate
a clinical or survival benefit.
The accelerated approval pathway is usually contingent on a sponsor’s agreement to conduct, in a diligent manner, additional
post‑approval confirmatory studies to verify and describe the product’s clinical benefit. As a result, a product candidate
approved on this basis is subject to rigorous post‑marketing compliance requirements, including the completion of Phase 4 or
post‑approval clinical studies to confirm the effect on the clinical endpoint. Failure to conduct required post‑approval studies,
or to confirm a clinical benefit during post‑marketing studies, would allow the FDA to withdraw the product from the market
on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to
prior review by the FDA.
Post‑approval requirements
Products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the
FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and
distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes
to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and
approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which
such products are manufactured, as well as new application fees for certain supplemental applications.
In addition, manufacturers and other entities involved in the manufacture and distribution of approved products are required
to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the
FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly
regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and
correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any
third‑party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time,
money and effort in the area of production and quality control to maintain cGMP compliance.
Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards
is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems
with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to
comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information,
imposition of post‑market studies or clinical studies to assess new safety risks or imposition of distribution or other
restrictions under a REMS program. Other potential consequences include, among other things:
·
·
restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of
the product from the market or product recalls;
fines, warning or other enforcement‑related letters or holds on post‑approval clinical studies;
16
Table of Contents
·
·
·
refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of
product license approvals;
product seizure or detention, or refusal to permit the import or export of products; or
injunctions or the imposition of civil or criminal penalties.
The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Such
products may be promoted only for the approved indications and in accordance with the provisions of the approved label.
The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off‑label uses, and a
company that is found to have improperly promoted off‑label uses may be subject to significant liability.
Biosimilars and exclusivity
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, signed
into law on March 23, 2010, or the Health Care Reform Act, includes a subtitle called the Biologics Price Competition and
Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products shown to be
biosimilar to, or interchangeable with, an FDA‑licensed reference biological product. Biosimilarity requires a showing that
the product is “highly similar” to the reference product notwithstanding minor differences in clinically inactive components
and that there are no clinically meaningful differences between the biological product and the reference product in terms of
safety, purity and potency. Interchangeability requires that a product is biosimilar to the reference product and the product
must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient
and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been
previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the
reference biologic. To date, the FDA has approved more than 25 biosimilar applications, although less than half of those
products are currently being marketed due largely to ongoing patent litigation or as a result of patent settlements. The FDA
has yet to approve an interchangeable biosimilar and is continuing to issue guidance documents outlining its approach to the
review and approval of interchangeable biosimilars.
A reference biologic is entitled to 12 years of exclusivity from the time of first licensure of the product. In addition, the first
biological product submitted under the abbreviated approval pathway that is determined to be interchangeable with, not just
biosimilar to, the reference product has exclusivity against other biologics submitting under the abbreviated approval
pathway for the lesser of (i) one year after the first commercial marketing, (ii) 18 months after approval if there is no legal
challenge, (iii) 18 months after the resolution in the applicant’s favor of a lawsuit challenging the biologics’ patents if an
application has been submitted or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the
42‑month period.
The BPCIA is complex and as noted above, elements of the law, such as interchangeability, are still being developed by the
FDA. In addition, there is continued debate as to whether recent government proposals that have sought to reduce the 12-
year reference product exclusivity period should be reduced. Further, since the BPCIA was enacted as part of the overall
Health Care Reform Act, current litigation challenges to that Act, discussed more in full below, could impact the validity of
the BPCIA. As a result, there still remains significant uncertainty as to the ultimate impact, implementation and meaning of
the BPCIA.
Pediatric studies and exclusivity
Under the Pediatric Research Equity Act of 2003, all applications for new active ingredients, new indications, new dosage
forms, new dosing regimens or new routes of administration are required to contain an assessment of the safety and
effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred or
inapplicable.
Under the Best Pharmaceuticals for Children Act, a product may be eligible for pediatric exclusivity, which, if granted, adds
six months to existing exclusivity periods and patent terms. This six‑month exclusivity, which runs from the end of
17
Table of Contents
other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in
accordance with an FDA‑issued written request for such a study.
Orphan drug designation and exclusivity
Under the Orphan Drug Act, the FDA may designate a product, including a biological product, as an “orphan drug” if it is
intended to treat a rare disease that affects fewer than 200,000 individuals in the United States or, if it affects more than
200,000 individuals in the United States, a disease for which there is no reasonable expectation that the cost of developing
and making the product for this type of disease or condition will be recovered from sales in the United States.
A product that receives the first FDA approval for a product for the indication for which it has orphan designation is entitled
to orphan drug exclusivity, which means the FDA may not approve any other application to market the same product for the
same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over
the product with orphan exclusivity.
Patent term restoration
A patent claiming a new product may be eligible for a limited patent term extension under the Hatch‑Waxman Amendments,
which permits a patent restoration of up to five years for patent term lost during product development and the FDA
regulatory review. The restoration period granted is typically one‑half the time between the effective date of an IND and the
submission date of a BLA, plus the time between the submission date of a BLA and the ultimate approval date. Patent term
restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product’s approval date.
Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension
must be submitted prior to the expiration of the patent in question. The USPTO, reviews and approves the application for any
patent term extension or restoration in consultation with the FDA.
Review and approval outside the United States
In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory
requirements of other countries and jurisdictions governing, among other things, clinical studies, marketing authorization,
commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to
obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical studies or
marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to
the United States apply similarly in the context of the European Union and other geographies, the approval process varies
between countries and jurisdictions and can involve additional product testing and additional administrative review periods.
The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to
obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but
a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process
in others.
Certain countries outside of the United States have a process that requires the submission of a clinical trial application, or
CTA, much like the IND prior to the commencement of human clinical studies. In the European Union, for example, a CTA
must be submitted for each clinical trial to the national health authority and an independent ethics committee in each country
in which the company intends to conduct clinical trials. Once the CTA is approved in accordance with a country’s
requirements, the clinical trial may proceed. In all cases, the clinical trials must be conducted in accordance with GCPs and
other applicable regulatory requirements and ethical principles.
To obtain regulatory approval of an investigational product under European Union regulatory systems, we must submit a
marketing authorization application under either a centralized or decentralized procedure. The centralized procedure is
compulsory for medicinal products produced by biotechnology. The application used to file the BLA in the United States is
similar to that required in the European Union, with the exception of, among other things, region-specific document
requirements.
18
Table of Contents
The European Union also provides opportunities for market exclusivity. For example, upon receiving marketing
authorization, innovative medicinal products generally receive eight years of data exclusivity and an additional two years of
market exclusivity. If grated, data exclusivity prevents regulatory authorities in the European Union from referencing the
innovator’s data to assess a generic or biosimilar application. There is no guarantee that a product will be considered by the
European Union’s regulatory authorities to be an innovative medicinal product, and products may not qualify for data
exclusivity. Products receiving orphan designation in the European Union can receive ten years of market exclusivity, during
which time no similar medicinal product for the same indication may be placed on the market. An orphan product can also
obtain an additional two years of market exclusivity in the European Union for pediatric studies. No extension to any
supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.
The collection, use, disclosure, transfer or other processing of personal data regarding individuals in the European Economic
Area, including personal health data, is subject to the Regulation (EU) 2016/679 (General Data Protection Regulation, or
GDPR), which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements
on companies that process personal data, including requirements relating to processing health and other sensitive data,
obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data
processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing
notification of data breaches and taking certain measures when engaging third-party data processors. The GDPR also imposes
strict rules on the transfer of personal data to countries outside the European Economic Area, including the United States, and
permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to €20
million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data
subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain
compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-
intensive process that may increase the cost of doing business or require companies to change their business practices to
ensure full compliance.
If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines,
suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal
prosecution.
Pharmaceutical coverage, pricing and reimbursement
Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other
government authorities. Sales of pharmaceutical products depend in significant part on the availability and adequacy of
third‑party reimbursement. Third‑party payors include government health administrative authorities, including authorities at
the U.S. federal and state level, managed care providers, private health insurers and other organizations. Third‑party payors
are increasingly challenging the prices charged for, examining the medical necessity of and assessing the cost‑effectiveness
of medical products and services.
In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to
conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost‑effectiveness of the
product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. A payor’s decision to
provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Third‑party
reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in
product development.
The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of
drugs and biologics have been a focus in this effort. Governments have shown significant interest in implementing
cost‑containment programs, including price controls, restrictions on reimbursement and requirements for substitution of
generic products. Adoption of price controls and cost‑containment measures, and adoption of more restrictive policies in
jurisdictions with existing controls and measures, could further limit a company’s revenue generated from the sale of any
approved products. Coverage policies and third‑party reimbursement rates may change at any time. Even if favorable
coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive
marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
19
Table of Contents
In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide
that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion
of additional studies that compare the cost‑effectiveness of a particular product candidate to currently available therapies, or
so called health technology assessments, to obtain reimbursement or pricing approval. For example, the European Union
provides options for its member states to restrict the range of products for which their national health insurance systems
provide reimbursement and to control the prices of medicinal products for human use. European Union member states may
approve a specific price for a product or may instead adopt a system of direct or indirect controls on the profitability of the
company.
The downward pressure on healthcare costs in general, particularly prescription drugs and biologics, has become intense. As
a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross‑border
imports from low‑priced markets exert competitive pressure that may reduce pricing within a country. Any country that has
price controls or reimbursement limitations for products may not allow favorable reimbursement and pricing arrangements.
Healthcare law and regulation
Within the United States, the activities of pharmaceutical companies are subject to extensive regulation and our activities
could possibly be subject to challenge as a result. Laws and regulations that may affect our ability to operate (including
certain laws that will apply if and when we have a product approved for marketing) include:
·
·
·
·
·
·
·
federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person
from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly
making, or causing to be made, a false statement to get a false claim paid;
the federal anti‑kickback law, which prohibits, among other things, persons from soliciting, offering, receiving or
providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or
the purchasing or ordering of a good or service, for which payment may be made, under federal healthcare programs
such as Medicare and Medicaid;
the federal anti-kickback prohibition known as Eliminating Kickbacks in Recovery Act or EKRA, enacted in 2018,
which prohibits certain payments related to referrals of patients to certain providers (recovery homes, clinical
treatment facilities and laboratories) and applies to services reimbursed by private health plans as well as
government health care programs;
the federal law known as HIPAA, which, in addition to privacy protections applicable to healthcare providers and
other entities (see “Government regulation – Data privacy and security”), prohibits executing a scheme to defraud
any healthcare benefit program (which may include private health plans) or making false statements relating to
healthcare matters;
the FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing
such products for off-label use and regulates the distribution of samples;
the federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the
government or provide certain discounts or rebates to government authorities or private entities, often as a condition
of reimbursement under government healthcare programs;
the so-called “federal sunshine” law, which requires pharmaceutical and medical device companies to monitor and
report certain financial interactions with certain healthcare providers to the federal government for re-disclosure to
the public (the scope of which reportable interactions will increase for interactions occurring on or after 2021); and
20
Table of Contents
·
state law analogues of the above federal laws, such as anti‑kickback and false claims laws which may apply to items
or services reimbursed by any third‑party payor, including private health plans, and state laws regulating interactions
between pharmaceutical manufacturers and healthcare providers, many of which differ from each other in
significant ways and often are not preempted by federal laws, thus complicating compliance efforts.
We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply
with applicable healthcare laws and regulations. Violations of these laws can subject us to criminal, civil and administrative
sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from
participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements
and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of
non‑compliance with these laws, and reputational harm. Additionally, we may be required to curtail or restructure our
operations. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and
implemented, that could impact our future operations and business.
Healthcare reform
Our revenue and operations could be affected by changes in healthcare spending and policy in the United States and
elsewhere. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of
existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare
products and services could negatively impact our business, operations and financial condition.
In the United States, there have been and continue to be a number of significant legislative initiatives to contain healthcare
costs. Federal and state governments continue to propose and pass legislation designed to reform delivery of, or payment for,
health care, which include initiatives to reduce the cost of healthcare. For example, the Healthcare Reform Act, which
expanded health care coverage through Medicaid expansion and the implementation of the individual mandate for health
insurance coverage and which included changes to the coverage and reimbursement of drug products under government
healthcare programs. Under the Trump administration, there have been ongoing efforts to modify or repeal all or certain
provisions of the Healthcare Reform Act. For example, tax reform legislation was enacted at the end of 2017 that eliminated
the tax penalty established under Healthcare Reform Act for individuals who do not maintain mandated health insurance
coverage beginning in 2019. The Healthcare Reform Act has also been subject to judicial challenge. In December 2018, a
federal district court, in a challenge brought by a number of state attorneys general, found the Healthcare Reform Act
unconstitutional in its entirety because, once Congress repealed the individual mandate provision, there was no longer a basis
to rely on Congressional taxing authority to support enactment of the law. In December 2019, a federal appeals court agreed
that the individual mandate provision was unconstitutional, but remanded the case back to the district court to assess more
carefully whether any provisions of the Healthcare Reform Act were severable and could survive. Pending action by the
district court and resolution of any appeals, which could take some time, the Healthcare Reform Act is still operational in all
respects.
There have also been other reform initiatives under the Trump Administration, including initiatives focused on drug pricing.
For example, the Bipartisan Budget Act of 2018 contained various provisions that affect coverage and reimbursement of
drugs, including an increase in the discount that manufacturers of Medicare Part D brand name drugs must provide to
Medicare Part D beneficiaries during the coverage gap from 50% to 70% which started in 2019. As another example, in May
of 2018, President Trump and the Secretary of the Department of Health and Human Services released a “blueprint” to lower
prescription drug prices and out-of-pocket costs. Certain proposals in the blueprint, and related drug pricing measures
proposed since the blueprint, could cause significant operational and reimbursement changes for the pharmaceutical industry.
As another example, legislation passed in 2019 revised how certain prices reported by manufacturers under the Medicaid
Drug Rebate Program are calculated, a revision that the Congressional Budget Office has estimated will save the Medicaid
program approximately $3 billion in the next ten years.
There have also been efforts by federal and state government officials or legislators to implement measures to regulate prices
or payment for pharmaceutical products, including legislation on drug importation. Recently, there has been considerable
public and government scrutiny of pharmaceutical pricing and proposals to address the perceived high cost
21
Table of Contents
of pharmaceuticals. There have also been recent state legislative efforts to address drug costs, which generally have focused
on increasing transparency around drug costs or limiting drug prices.
Data privacy and security
We may be subject to privacy and security laws in the various jurisdictions in which we operate, obtain or store personally
identifiable information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and
there has been an increasing focus on privacy and data protection issues with the potential to affect our business.
Within the United States, our operations may be affected by the Health Insurance Portability and Accountability Act of 1996
as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations,
collectively, HIPAA, which impose obligations on certain “covered entities” (healthcare providers, health plans and
healthcare clearinghouses) and certain of their “business associate” contractors with respect to safeguarding the privacy,
security and transmission of individually identifiable health information. Although we believe that we currently are neither a
“covered entity” nor a “business associate” under the legislation, HIPAA may affect our interactions with customers who are
covered entities or their business associates because HIPAA affects the ability of these entities to disclose patient health
information to us. Various states also have laws that regulate the privacy and security of patient information and so may
affect our business operations. For example, we are subject to the California Consumer Privacy Act, or CCPA, that became
effective on January 1, 2020. The CCPA gives California consumers (defined to include all California residents) certain
rights, including the right to ask companies to disclose the types of personal information collected, specific pieces of
information collected by a company, the categories of sources from which such information was collected, the business
purpose for collecting or selling the consumer’s personal information, and the categories of third parties with whom a
company shares personal information. The CCPA also imposes several obligations on companies to provide notice to
California consumers regarding a company’s data processing activities. Additionally, the CCPA gives California consumers
the right to ask companies to delete a consumer’s personal information and it places limitations on a company’s ability to sell
personal information, including providing consumers a right to opt out of sales of their personal information.
Outside the United States, other data privacy and security regulations may apply. For example, the processing of personal
data in the European Economic Area, or the EEA, is subject to the General Data Protection Regulation, or the GDPR, which
took effect in May 2018. The GDPR increases obligations with respect to clinical trials conducted in the EEA, such as in
relation to the provision of fair processing notices, exercising data subject rights and reporting certain data breaches to
regulators and affected individuals, as well as how we document our relationships with third parties that process GDPR-
covered personal data on our behalf. The GDPR also increases the scrutiny applied to transfers of personal data from the
EEA (including from clinical trial sites in the EEA) to countries that are considered by the European Commission to lack an
adequate level of data protection, such as the United States.
Compliance with data privacy and security regulation can require allocation of resources as well as changes in operations and
non-compliance can result in substantial penalties. For example, the GDPR and the CCPA impose substantial fines and other
regulatory penalties for breaches of data protection requirements, and they confer a private right of action on data subjects (in
the case of the GDPR) and consumers (in the case of the CCPA) and their representatives for breaches of certain data
protection requirements.
Additional regulation
In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including
the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act,
affect our business. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive
substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or
expose individuals to hazardous substances, we could be liable for damages and governmental fines. Equivalent laws have
been adopted in foreign countries that impose similar obligations.
22
Table of Contents
Intellectual property
We actively seek to protect the proprietary technology that we consider important to our business, including pursuing patents
that cover our ADC platform, proprietary composition of matter, ADC product candidates and methods of using and
manufacturing the same, as well as any other relevant inventions and improvements that are considered commercially
important to the development of our business. We also rely on trade secrets, know how and continuing technological
innovation to develop and maintain our proprietary and intellectual property position.
Our commercial success will depend significantly on our ability to obtain and maintain patents and other proprietary
protection for the technology, inventions and improvements we consider important to our business, and to defend our patents,
preserve the confidentiality of our trade secrets and operate without infringing the patents and proprietary rights of third
parties. Our policy is to seek to protect our proprietary and intellectual property position by, among other methods, filing
U.S., international (under Patent Cooperation Treaty, or PCT) and foreign patent applications related to our proprietary
technology, inventions and improvements that we consider to be important to the development and implementation of our
business.
The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most
countries, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent
application. In the United States, a patent’s term may be lengthened by patent term adjustment, which compensates a patentee
for administrative delays by the USPTO in examining and granting a patent or may be shortened if a patent is terminally
disclaimed over an earlier filed patent. The term of a patent that covers a drug or biological product may also be eligible for
patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. In the future, if
and when our drug candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent
term extensions on issued patents covering those drugs, depending upon the length of the clinical studies for each drug and
other factors. There can be no assurance that any of our pending patent applications will issue or that we will benefit from
any patent term extension or favorable adjustments to the terms of any of our patents.
As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and
intellectual property position for our drug candidates and technologies will depend on our success in obtaining effective
patent claims and enforcing those claims if granted. However, our pending patent applications, and any patent applications
that we may in the future file or license from third parties, may not result in the issuance of patents. We also cannot predict
the breadth of claims that may be allowed or enforced in our patents. Any issued patents that we may currently own or
license or may receive in the future may be challenged, invalidated, circumvented or have the scope of their claims narrowed.
For example, we cannot be certain of the priority of inventions covered by pending third party patent applications. If third
parties prepare and file patent applications in the United States that also claim technology or therapeutics to which we have
rights, we may have to participate in interference proceedings in the USPTO to determine priority of invention, which could
result in substantial costs to us, even if the eventual outcome is favorable to us, which is highly unpredictable. In addition,
because of the extensive time required for clinical development and regulatory review of a drug candidate we may develop, it
is possible that, before any of our drug candidates can be commercialized, any related patent may expire or remain in force
for only a short period following commercialization, thereby limiting the protection such patent would afford the respective
product and any competitive advantage such patent may provide. For more information regarding the risks related to our
intellectual property, please see “Risk factors—Risks related to our intellectual property.”
As of January 31, 2020, we owned, in all of our patent portfolios, 18 issued U.S. patents, 12 pending non-provisional U.S.
patent applications (including two allowed U.S. patent applications), 7 pending provisional U.S. patent applications, 81
issued foreign patents, five pending PCT patent applications and 88 pending foreign patent applications (including 6 allowed
foreign patent applications) in a number of jurisdictions, including, but being not limited to, Australia, Brazil, Canada, China,
Europe, Eurasia, Gulf Cooperation Council, Hong Kong, Israel, India, Indonesia, Iran, Japan, Mexico, Macau, New Zealand,
Russia, South Korea, South Africa, and Taiwan. Our nine issued U.S. patents covering our Fleximer ADC platform are
projected to expire in 2032, excluding any additional term for patent term adjustments or patent term extensions; our one
issued U.S. patent covering our Dolaflexin ADC platform is projected to expire in 2034, excluding any additional term for
patent term adjustments or patent term extensions; our additional eight issued U.S. patents are projected to expire in 2030 and
2037, excluding any additional term for patent term adjustments or patent term extensions;
23
Table of Contents
and any patent that may issue from our pending U.S. applications is projected to expire between 2032 and 2041, in each case,
excluding any additional term for patent term adjustments or patent term extensions. In addition, we have exclusively in
licensed four issued U.S. patents and one issued European patent for the NaPi2b antibody from Recepta. These in licensed
issued U.S. and foreign patents are projected to expire in 2029, excluding any additional term for patent term adjustments or
patent term extensions. We have so far not filed for patent protection in all national and regional jurisdictions where such
protection may be available. In addition, we may decide to abandon national and regional patent applications before they are
granted. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to
situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted
by others. It is also quite common that depending on the country, various scopes of patent protection may be granted on the
same product candidate or technology.
The intellectual property portfolio of our ADC platform, our ADC product candidates and components thereof and
companion diagnostics are summarized below. Some of these portfolios are in very early stages and prosecution has yet to
commence on most of the pending patent applications. Prosecution is a lengthy process, during which the scope of the claims
initially submitted for examination by the USPTO may be narrowed (sometimes significantly) by the time they issue, if they
issue at all. We expect this to be the case with respect to our pending patent applications referred to below.
Fleximer ADC platform
The intellectual property portfolio for our Fleximer ADC platform is directed to compositions of matter for the Fleximer
ADCs, as well as methods of using and making these novel conjugates, compositions of matter for Fleximer drug conjugates
prior to conjugation with the antibody or antibody fragment and methods of making the same, and compositions of matter for
our proprietary auristatin compounds (and by extension our proprietary DolaLock feature) and conjugates thereof (e.g., to
Fleximer and/or an antibody or antibody fragment). As of January 31, 2020, we owned nine issued U.S. patents, two pending
U.S. patent applications (including one allowed application), 41 issued foreign patents, and 9 pending foreign patent
applications (including three allowed applications) in a number of jurisdictions, including Australia, Brazil, Canada, China,
Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, Russia, South Korea, and Taiwan. Any U.S. or foreign patent
issuing from the pending applications covering the Fleximer ADC platform is projected to expire in 2032, excluding any
additional term for patent term adjustments or patent term extensions.
Dolaflexin ADC platform
The intellectual property portfolio for our Dolaflexin ADC platform is directed to compositions of matter for the Dolaflexin
ADCs, as well as methods of using and making these novel conjugates, compositions of matter for Dolaflexin drug
conjugates prior to conjugation with the antibody or antibody fragment and methods of making the same. As of January 31,
2020, we owned one issued U.S. patent, and two pending U.S. patent applications, 27 issued foreign patent, and 16 pending
foreign patent applications (including three allowed applications) in a number of jurisdictions, including Australia, Brazil,
Canada, China, Eurasia, Europe, Israel, India, Japan, South Korea, Mexico and South Africa. Any U.S. or foreign patent
issuing from the pending applications covering Dolaflexin ADC platform is projected to expire in October 2034, and any
U.S. or foreign patent issuing from the pending applications covering the method of making the Dolaflexin ADC is projected
to expire in 2038, excluding any additional term for patent term adjustments or patent term extensions.
XMT-1536 ADC
The intellectual property portfolio for our NaPi2b ADC product candidate, XMT-1536, is directed to compositions of matter
for our novel ADC based on exclusively in licensed NaPi2b antibody and our Dolaflexin platform, as well as methods of
using, making these novel conjugates, methods of administration and companion diagnostics. As of January 31, 2020, we
owned six pending U.S. patent applications (including three pending provisional U.S. patent applications), 21 pending
foreign patent applications, and two pending PCT applications directed to the composition of matter for XMT-1536, methods
of using and making same, companion diagnostics for XMT-1536 ADC and XMT-1536 dosing regimens. We also intend to
enter the national/regional phase of the pending PCT patent application in foreign jurisdictions, including Australia, Brazil,
Canada, China, Eurasia, Europe, Israel, India, Japan, South Korea, Mexico and South Africa. Any U.S. or foreign patent
issuing from the pending applications covering XMT-1536 is projected to expire in 2037, and any U.S. or foreign patent
issuing from the pending applications covering XMT-1536 companion diagnostics is projected to expire
24
Table of Contents
in 2038, excluding any additional term for patent term adjustments or patent term extensions, and any U.S. or foreign patent
issuing from the pending applications covering the XMT-1536 dosing regimens is projected to expire in 2039 or 2041.
In addition, we have exclusively in licensed four issued U.S. patents and one issued European patent for the novel NaPi2b
antibody from Recepta, which Recepta licensed from Ludwig Institute for Cancer Research. These in licensed issued U.S.
and European patents are projected to expire in 2029, excluding any additional term for patent term adjustments or patent
term extensions. Recepta still owns one pending Brazilian patent application for the NaPi2b antibody, which is not licensed
to us. A patent issuing from this Brazilian patent application is projected to expire in 2029.
Dolasynthen ADC platform
The intellectual property portfolio for our novel Dolasynthen platform is directed to compositions of matter for the novel
scaffold and ADCs thereof, as well as methods of using and making these novel conjugates and scaffolds. As of January 31,
2020, we owned one pending U.S. patent application, 15 pending foreign patent applications, and one pending PCT patent
application. We intend to enter the national/regional phase of the PCT patent applications in a number of jurisdictions,
including Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, Russia, South Korea,
and Taiwan. Any U.S. or foreign patent issuing from the pending applications covering the novel DNA alkylators and novel
scaffold platforms is projected to expire between 2037 and 2039, excluding any additional term for patent term adjustments
or patent term extensions.
XMT-1592 ADC
The intellectual property portfolio for our site specific NaPi2b ADC product candidate, XMT-1592, is directed to
compositions of matter for our novel ADC based on exclusively in licensed NaPi2b antibody and our Dolasynthen platform,
as well as methods of using, making these novel conjugates and administration of these novel conjugates. As of January 31,
2020, we owned one pending provisional U.S. patent application related to XMT-1592. Any U.S. or foreign patent issuing
from the pending applications covering XMT-1592 is projected to expire in 2041, excluding any additional term for patent
term adjustments or patent term extensions.
Immunosynthen ADC platform
The intellectual property portfolio for our novel Immunosynthen platform is directed to compositions of matter for the novel
STING agonists, as well as methods of using and methods of making these novel payloads. As of January 31, 2020, we
owned three pending provisional U.S. patent applications related to Immunosynthen. Any U.S. or foreign patent issuing from
the pending applications is projected to expire in 2040, excluding any additional term for patent term adjustments or patent
term extensions.
In addition to patents, we rely upon unpatented trade secrets and know-how and continuing technological innovation to
develop and maintain our competitive position. We seek to protect our proprietary information, in part, by executing
confidentiality agreements with our collaborators and scientific advisors and non-competition, non-solicitation,
confidentiality and invention assignment agreements with our employees and consultants. We have also executed agreements
requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements we
enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of
inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the
respective counterparty. We cannot guarantee, however, that we will have executed such agreements with all applicable
employees and contractors, or that these agreements will afford us adequate protection of our intellectual property and
proprietary information rights. With respect to the building of our proprietary compound library, we consider trade secrets
and know-how to be our primary intellectual property. Trade secrets and know-how can be difficult to protect. In particular,
we anticipate that with respect to this technology platform, these trade secrets and know-how will over time be disseminated
within the industry through independent development and public presentations describing the methodology. For more
information regarding the risks associated with our trade secrets, please see “Risk factors—Risks related to our intellectual
property—Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade
secrets and other proprietary information.”
25
Table of Contents
Competition
The biotechnology and biopharmaceutical industries, and the oncology subsector, are characterized by rapid evolution of
technologies, fierce competition and strong defense of intellectual property. Any product candidates that we successfully
develop and commercialize will have to compete with existing therapies and new therapies that may become available in the
future. While we believe that our proprietary ADC platforms and scientific expertise provide us with competitive advantages,
a wide variety of institutions, including large biopharmaceutical companies, specialty biotechnology companies, academic
research departments and public and private research institutions, are actively developing potentially competitive products
and technologies. These competitors generally fall within the following categories:
New cancer treatments: Many global pharmaceutical companies, as well as medium and small biotechnology companies,
are pursuing new cancer treatments whether small molecules, biologics or ADCs. Any of these treatments could prove to be
superior clinically to our products.
ADC platforms: Although Dolaflexin, Dolasynthen and the new platform initiatives we have underway are highly
differentiated and proprietary, many companies continue to invest in innovation in the ADC field including new payload
classes, new conjugation approaches and new targeting moieties. Any of these initiatives could lead to a platform that has
superior properties to ours. We are also aware of multiple companies with ADC technologies that may be competitive to our
platforms, including Astellas, AstraZeneca, Daiichi Sankyo, ImmunoGen, Immunomedics, Pfizer and Seattle Genetics. These
companies or their partners, including AbbVie, Genentech and Takeda, may develop product candidates which compete in
the same indications as our current and future product candidates. We expect to compete on improved efficacy, safety and
tolerability compared to other product candidates and if our products are not demonstrably superior in these respects
compared to other approved therapeutics, we may not be able to compete effectively.
Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical and human
resources than we do. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and
achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Accelerated merger and
acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being
concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining
qualified scientific and management personnel, establishing clinical study sites and patient registration for clinical studies
and acquiring technologies complementary to, or necessary for, our programs. Smaller or early stage companies may also
prove to be significant competitors, particularly through collaborative arrangements with large and established companies.
Our commercial opportunity could be substantially limited in the event that our competitors develop and commercialize
products that are more effective, safer, less toxic, more convenient or less expensive than our comparable products. In
geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting
in our competitors building a strong market position in advance of our products’ entry. We believe the factors determining the
success of our programs will be the efficacy, safety and tolerability of our product candidates.
Employees
As of January 31, 2020, we had 83 full time employees, including 63 with M.D., Ph.D. or other advanced degrees. Of these
full time employees, 66 are engaged in research and development and 17 are engaged in general and administrative activities.
None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our
relationship with our employees to be good.
Facilities
Our corporate headquarters are located in Cambridge, Massachusetts. We occupy approximately 34,000 square feet of office
and laboratory space that we lease in the multi-tenant building in which our corporate headquarters are located. We have an
option to extend the lease term for an additional five years thereafter. We believe that this office and laboratory space is
sufficient to meet our current needs and that suitable additional space will be available as and when needed.
26
Table of Contents
Corporate Information
We were incorporated in 2001 as a Delaware corporation. Our principal executive offices are located at 840 Memorial Drive,
Cambridge, MA 02139, and our telephone number is 617-498-0020. Our internet site is www.mersana.com. We routinely
make available important information free of charge, including copies of our Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section
13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after such reports are electronically filed with, or
furnished to, the SEC. We recognize our website as a key channel of distribution to reach public investors and as a means of
disclosing material non-public information to comply with our disclosure obligations under SEC Regulation FD. Information
contained on our website shall not be deemed incorporated into, or to be part of this Annual Report on Form 10-K, and any
website references are not intended to be made through active hyperlinks.
ITEM 1A. RISK FACTORS
The following risk factors and other information included in this Annual Report on Form 10-K should be carefully
considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not
presently known to us or that we currently believe to be immaterial may also adversely affect our business. If any of the
following risks occur, our business, financial condition, results of operations and future growth prospects could be materially
and adversely affected.
Risks related to our financial position and need for additional capital
We have incurred net losses since our inception, we have no products approved for commercial sale and we anticipate that
we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or sustain
profitability.
We have incurred net losses since our inception. Our net loss was $28.2 million for the year ended December 31, 2019. As of
December 31, 2019, we had an accumulated deficit of $192.4 million. We do not know when or whether we will become
profitable. To date, we have not commercialized any products and therefore have never generated any revenues from the sale
of products, and we do not expect to generate any product revenues in the foreseeable future. Our losses have resulted
principally from costs incurred in our discovery and development activities. Our net losses may fluctuate significantly from
quarter to quarter and year to year.
We have devoted most of our financial resources to research and development, including our clinical and preclinical
development activities. To date, we have financed our operations primarily through the sale of equity securities, the receipt of
funds through strategic partnerships with third parties and our credit facility. The amount of our future net losses will depend,
in part, on the rate of our future expenditures. We have not completed pivotal clinical studies for any product candidate and
only have one product candidate in a clinical study. It will be several years, if ever, before we have a product candidate ready
for commercialization. Even if we obtain regulatory approval to market a product candidate, our future revenues would
depend upon the size of the market or markets in which our product candidates received such approval and our ability to
achieve sufficient market acceptance, reimbursement from third‑party payors and adequate market share for our product
candidates in those markets.
We expect to continue to incur significant expenses and increasing net losses for at least the next several years. We expect our
expenses will increase substantially in connection with our ongoing activities, as we:
·
·
·
conduct clinical development of XMT-1536, our lead product candidate, and any other current or future product
candidates;
seek regulatory approval for XMT‑1536, and any other current or future product candidates, if our development
efforts are successful;
add personnel to support our product development efforts;
27
Table of Contents
·
·
continue our research and development efforts for new product opportunities; and
continue to operate as a public company.
If we are required by the United States Food and Drug Administration, or FDA, or any equivalent foreign regulatory
authority to perform clinical studies or preclinical studies in addition to those we currently expect to conduct, or if there are
any delays in completing the clinical studies of XMT‑1536 or any other current or future product candidates, our expenses
could increase.
To become and remain profitable, we must succeed in developing our product candidates, obtaining regulatory approval for
them, and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We may not
succeed in these activities, and we may never generate revenue from product sales or strategic partnerships in an amount
sufficient to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in
subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability
to raise capital, expand our business, discover or develop other product candidates or continue our operations.
We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when
needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.
Our cash, cash equivalents and short-term marketable securities were $99.8 million as of December 31, 2019. We have
utilized substantial amounts of cash since our inception and expect that we will continue to expend substantial resources for
the foreseeable future developing XMT‑1536, our lead product candidate, and any other current or future product candidates.
These expenditures may include costs associated with research and development, conducting preclinical studies and clinical
studies, potentially obtaining regulatory approvals and manufacturing products, as well as marketing and selling products
approved for sale, if any, and potentially acquiring new technologies. In addition, other unanticipated costs may arise.
Because the outcome of our planned and anticipated clinical studies is highly uncertain, we cannot reasonably estimate the
actual amounts necessary to successfully complete the development and commercialization of our product candidates. Our
costs will increase if we experience any delays in our clinical studies for XMT‑1536 or any other current or future product
candidates, including delays in enrollment of patients. We also incur costs associated with operating as a public company,
hiring additional personnel and expanding our facilities.
Our future capital requirements depend on many factors, including:
·
·
·
·
·
·
the scope, progress, results and costs of researching and developing XMT‑1536 and any other current or future
product candidates and conducting preclinical studies and clinical studies;
the timing of, and the costs involved in, obtaining regulatory approvals for XMT‑1536 and any other current or
future product candidates if preclinical studies and clinical studies are successful;
the cost of manufacturing XMT‑1536 and any other current or future product candidates for clinical studies in
preparation for regulatory approval and in preparation for commercialization;
the cost of commercialization activities for XMT‑1536 and any other current or future product candidates, if any
product candidates are approved for sale, including manufacturing, marketing, sales and distribution costs;
our ability to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of
such agreements;
the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including
litigation costs and the outcome of such litigation; and
28
Table of Contents
·
the timing, receipt and amount of sales of, or royalties on, our future products, if any, or products developed by our
partners.
As further explained in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operation of
this Form 10-K, based on our current operating plan, we estimate that our existing cash, cash equivalents and marketable
securities will be sufficient to fund our projected operating requirements through at least the next twelve months following
the filing of our Annual Report on Form 10-K, including our Phase 1 clinical study for XMT‑1536 and our planned dose
escalation study for XMT-1592. Our operating plan, however, may change as a result of many factors currently unknown to
us and we may need additional funds sooner than planned. Additional funds may not be available when we need them on
terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to
delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for one or more of our
product candidates or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities
that may be necessary to commercialize our product candidates. In addition, we may seek additional capital due to favorable
market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans.
Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to
relinquish rights to our technologies or ADC product candidates on unfavorable terms to us.
We may seek additional capital through a variety of means, including through private and public equity offerings and debt
financings. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the
ownership interests of our common stockholders will be diluted, and the terms of such equity or convertible debt securities
may include liquidation or other preferences that are senior to or otherwise adversely affect the rights of our common
stockholders. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting
our ability to take certain actions, such as incurring future debt, making capital expenditures, declaring dividends or
encumbering our assets to secure future indebtedness, each of which could adversely impact our ability to conduct our
business and execute our operating plan. If we raise additional funds through strategic partnerships with third parties, we may
have to relinquish valuable rights to our technologies, including our platforms, or product candidates, or grant licenses on
terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when needed,
we may be required to delay, limit, reduce or terminate our product development or commercialization efforts for
XMT‑1536, our lead product candidate, or any other current or future product candidates, or grant rights to third parties to
develop and market product candidates that we would otherwise prefer to develop and market ourselves.
We have a credit facility that requires us to meet certain operating and financial covenants and place restrictions on our
operating and financial flexibility.
On May 8, 2019, we entered into a loan and security agreement, or the Credit Facility, with Silicon Valley Bank, or SVB,
pursuant to which we may borrow, at our option, up to $20.0 million, through August 31, 2020. The Credit Facility is
secured by substantially all of our assets, except for our intellectual property, which is subject to a negative pledge, and
certain other customary exclusions, which ensures that SVB’s rights to repayment would be senior to the rights of the holders
of our common stock in the event of liquidation.
The Credit Facility includes customary covenants including covenants requiring us to maintain our corporate existence and
governmental approvals, deliver certain financial reports, maintain insurance coverage and maintain a liquidity ratio.
Additionally, we are restricted in our ability to transfer collateral, incur additional indebtedness, engage in mergers or
acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets and agree to a change in
control. Upon the occurrence of an event of default, which includes our failure to satisfy our payment obligations under the
Credit Facility, the breach of certain of the covenants under the Credit Facility, or the occurrence of a material adverse change
in our business, SVB is entitled to increase the applicable interest rate, accelerate amounts due under the Credit Facility and
dispose the collateral as permitted under applicable law. Any declaration by SVB of an event of default could significantly
harm our business and prospects and could cause the price of our common stock to decline.
29
Table of Contents
We may expend our resources to pursue a particular product candidate and fail to capitalize on product candidates that
may be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and managerial resources, we focus on specific product candidates. As a result, we may
forgo or delay pursuit of opportunities with other product candidates that later prove to have greater commercial potential.
Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market
opportunities. Failure to properly assess potential product candidates could result in our focus on product candidates with low
market potential, which would harm our business and financial condition. Our spending on current and future research and
development programs and product candidates for specific indications may not yield any commercially viable product
candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we
may relinquish valuable rights to that product candidate through partnering, licensing or other royalty arrangements in cases
in which it would have been more advantageous for us to retain sole development and commercialization rights to such
product candidate.
Risks related to development and approval of our ADC product candidates
Failure of a discovery program or product candidate may occur at any stage of preclinical or clinical development, and,
because our and our partner’s discovery programs and our product candidates are in early stages of preclinical or clinical
development, there is a relatively higher risk of failure and we or our partners may never succeed in generating revenue
from such discovery programs or product candidates.
Our early encouraging preclinical results for XMT‑1536, our lead product candidate, or any other current or future product
candidates, are not necessarily predictive of the results of our ongoing or future discovery programs or clinical studies.
Promising results in preclinical studies of a drug candidate may not be predictive of similar results in later‑stage preclinical
studies or in humans during clinical studies. Many companies in the pharmaceutical and biotechnology industries have
suffered significant setbacks in late‑stage clinical studies after achieving positive results in early‑stage development,
including early‑stage clinical studies, and we cannot be certain that we will not face similar setbacks. These companies’
setbacks have been caused by, among other things, preclinical findings made while clinical studies were underway or safety
or efficacy observations made in preclinical studies and clinical studies, including previously unreported adverse events.
Any clinical studies that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory
approval to market our product candidates. In addition, clinical trial results for one of our product candidates or for
competitor products utilizing similar technology, may raise concerns about the safety or efficacy of other products in our
pipeline. If the results of our ongoing or future clinical studies are inconclusive with respect to the efficacy of our product
candidates or if we do not meet the clinical endpoints with statistical significance or if there are safety concerns or adverse
events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our
product candidates. There can be significant variability in safety or efficacy results between different clinical studies of the
same product candidate due to numerous factors, including changes in study procedures set forth in protocols, differences in
the size and type of the patient populations, changes in and adherence to the clinical study protocols and the rate of dropout
among clinical study participants. Moreover, preclinical and clinical data are often susceptible to varying interpretations and
analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and
clinical studies nonetheless failed to obtain FDA approval.
Alternatively, even if we obtain regulatory approval, that approval may be for indications or patient populations that are not
as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety
warnings. We may also be required to perform additional or unanticipated clinical studies to obtain approval or be subject to
additional post‑marketing testing requirements to maintain regulatory approval. In addition, regulatory authorities may
withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a risk evaluation and
mitigation strategy (REMS) program. The failure to obtain timely regulatory approval of product candidates, any product
marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial
condition.
30
Table of Contents
Interim, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change
as more patient data become available and are subject to audit and verification procedures that could result in material
changes in the final data.
From time to time, we may publish interim, “top-line” or preliminary data from our clinical studies. Positive preliminary data
may not be predictive of such trial’s subsequent or overall results. Interim data from clinical trials that we may complete are
subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more
patient data become available. Preliminary or “top-line” data also remain subject to audit and verification procedures that
may result in the final data being materially different from the preliminary data we previously published. As a result, interim
and preliminary data should be viewed with caution until the final data are available. Adverse differences between
preliminary or interim data and final data could significantly harm our business prospects.
We currently have only one ADC product candidate, XMT-1536, in a clinical study. A failure of this product candidate in
clinical development would adversely affect our business and may require us to discontinue development of other ADC
product candidates based on the same technology.
XMT-1536 is currently our only clinical‑stage development product candidate. While we have certain other preclinical
programs in development and we intend to develop other product candidates, including XMT-1592, it will take additional
investment and time for such programs to reach the same stage of development as XMT-1536. In addition, we have other
product candidates in our current pipeline that are based on the same platform. If XMT-1536 fails in development as a result
of any underlying problem with our platform, then we may be required to discontinue development of the product candidates
that are based on the same technology. If we were required to discontinue development of XMT-1536 or if XMT-1536 were
to fail to receive regulatory approval or were to fail to achieve sufficient market acceptance, we could be prevented from or
significantly delayed in achieving profitability.
Events that may delay or prevent successful commencement, enrollment or completion of clinical studies of our product
candidates could result in increased costs to us as well as a delay in obtaining, or failure to obtain, regulatory approval, or
cause us to suspend or terminate a clinical trial, which could prevent us from commercializing our product candidates on
a timely basis, or at all.
We cannot guarantee that clinical studies, including our ongoing Phase 1b clinical study and anticipated additional clinical
studies for XMT-1536, our lead product candidate, will be conducted as planned or completed on schedule, if at all. A failure
of one or more clinical studies can occur at any stage of testing, and other events may cause us to temporarily or permanently
cease a clinical study. Events that may prevent successful or timely commencement, enrollment or completion of clinical
development include, among others:
·
·
·
·
·
·
·
delays by us in reaching a consensus with regulatory agencies on study design;
delays in reaching, or failing to reach, agreement on acceptable terms with prospective clinical research
organizations, or CROs, and clinical study sites;
difficulties in obtaining required Institutional Review Board, or IRB, approval at each clinical study site;
challenges in recruiting and enrolling suitable patients to participate in clinical studies that meet the criteria of the
protocol for the clinical study;
imposition of a clinical hold by regulatory agencies or IRBs for any reason, including safety concerns or after an
inspection of clinical operations or study sites;
failure by CROs, other third parties or us to adhere to clinical study requirements;
failure to perform in accordance with the FDA’s good clinical practices, or GCP, or applicable regulatory guidelines
in other countries;
31
Table of Contents
·
·
·
·
·
·
inadequate quantity or quality of a product candidate or other materials necessary to conduct clinical studies,
including, for example, delays in the testing, validation, manufacturing or delivery of the product candidates to the
clinical sites;
patients not completing participation in a study or not returning for post‑treatment follow‑up;
clinical study sites or patients dropping out of a study;
safety issues, including occurrence of serious adverse events, or SAEs, in clinical studies that are associated with the
product candidates that are viewed to outweigh their potential benefits or unforeseen safety issues in our ongoing
preclinical studies;
changes in regulatory requirements or guidance that require amending or submitting new clinical protocols; or
lack of adequate funding to continue the clinical study.
Delays, including delays caused by the above factors, can be costly and could negatively affect our ability to complete a
clinical study. If we or our partners are not able to successfully complete clinical studies, we or they will not be able to obtain
regulatory approval and will not be able to commercialize our product candidates or our partners’ product candidates based
on our technology.
An inability to enroll sufficient numbers of patients in our clinical studies could result in increased costs and longer
development periods for our product candidates.
Clinical studies require sufficient patient enrollment, which is a function of many factors, including:
·
·
·
·
·
·
·
·
the size and nature of the patient population;
the severity of the disease under investigation;
the nature and complexity of the study protocol, including eligibility criteria for the study;
the number of clinical study sites and the proximity of patients to those sites;
standard of care in the diseases under investigation;
the commitment of clinical investigators to identify eligible patients;
competing studies or trials; and
clinicians’ and patients’ perceptions as to the potential advantages and risks of the drug being studied in relation to
other available therapies, including any new drugs that may be approved for the indications we are investigating.
Challenges in recruiting and enrolling suitable patients to participate in clinical studies that meet the criteria of the protocol
for clinical studies could increase costs and result in delays to our current development plan for XMT‑1536, our lead product
candidate, or any other current or future product candidate.
32
Table of Contents
We may seek a Breakthrough Therapy Designation or Fast Track Designation by the FDA for any of our ADC product
candidates, and we may be unsuccessful. If we are successful, the designation may not actually lead to a faster
development or regulatory review or approval process, and it does not increase the likelihood that any ADC product
candidate would receive marketing approval.
We may seek a Breakthrough Therapy Designation or Fast Track Designation for any of our product candidates. A
breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a
serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate
substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as
substantial treatment effects observed early in clinical development. Fast Track Designation may be available if a product is
intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential
to address an unmet medical need for this condition. Drugs that receive Breakthrough Therapy Designation or Fast Track
Designation by the FDA may also be eligible for accelerated approval and/or priority review if they satisfy the criteria for
those programs.
The FDA has broad discretion whether or not to grant Breakthrough Therapy Designation or Fast Track Designation. Even if
we receive Breakthrough Therapy Designation or Fast Track Designation for a product candidate, such designation may not
result in a faster development process, review or approval compared to conventional FDA procedures and does not assure
ultimate approval by the FDA. In addition, even if any of our product candidates receives Breakthrough Therapy Designation
or Fast Track Designation, the FDA may later decide that the drugs no longer meet the conditions for qualification and
rescind the designation.
We may not be able to obtain orphan drug designation for our ADC product candidates, and even if we do, we may be
unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.
We may seek orphan drug designation status for one of our current or future product candidates, and we may be unsuccessful.
In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding
towards clinical trial costs, tax advantages and user-fee waivers. In Europe, orphan drug designation entitles a party to a
number of incentives, such as protocol assistance and scientific advice specifically for designated orphan medicines, and
potential fee reductions depending on the status of the sponsor. Generally, if a drug with an orphan drug designation
subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to
a period of marketing exclusivity, which precludes the European Medicines Agency or the FDA from approving another
marketing application for the same drug and indication for a set time period, except in limited circumstances. Even if we
obtain orphan drug exclusivity for a drug, that exclusivity may not effectively protect the drug from competition because
different drugs can be approved for the same condition, or the drug may be used off-label. Even after an orphan drug is
approved, the FDA can subsequently approve another drug for the same condition if the FDA concludes that the other drug is
clinically superior. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use
that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing
rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or
if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or
condition. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the
drug any advantage in the regulatory review or approval process. While we may seek orphan drug designation for applicable
indications for our current or future product candidates, we may never receive such designations. Even if we do receive such
designations, there is no guarantee that we will enjoy the benefits of those designations.
Clinical development, regulatory review and approval by the FDA and comparable foreign authorities are lengthy, time
consuming and inherently unpredictable. If we or our partners are ultimately unable to obtain regulatory approval for our
ADC product candidates, our business will be substantially harmed.
The preclinical studies and clinical studies of our product candidates are, and the manufacturing and marketing of our product
candidates will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United
States and in other countries where we intend to test and, if approved, market any such product candidate.
33
Table of Contents
These government regulations relate to, among other things, development, clinical studies, manufacturing and
commercialization. In order to obtain regulatory approval for the commercial sale of any product candidates, we or our
partners must demonstrate through extensive preclinical studies and clinical studies that the product candidate is safe and
effective for use in each target indication.
The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many
years following the commencement of clinical studies and depends upon numerous factors. Of the large number of drugs in
development in the United States, only a small percentage will successfully complete the FDA regulatory approval process
and will be commercialized. Accordingly, even if we are able to obtain the requisite financing to continue to fund our
development and preclinical studies and clinical studies, we cannot be assured that any of our product candidates will be
successfully developed or commercialized.
In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change
during the course of a product candidate’s clinical development and may vary among jurisdictions, which may cause delays
in the approval of or the decision not to approve an application. Regulatory approval has not been obtained for any product
candidate based on our technologies, and it is possible that none of our existing product candidates or any product candidates
we may seek to develop in the future will ever obtain regulatory approval. In addition, we may gain regulatory approval for
XMT‑1536, our lead product candidate, or any other current or future product candidates in some but not all of the territories
for which we seek approval or some but not all of the target indications, resulting in limited commercial opportunity for the
approved product candidates.
Applications for our or our partners’ product candidates could be delayed or could fail to receive regulatory approval for
many reasons, including, but not limited to the following:
·
·
·
·
·
·
·
·
·
the FDA or comparable foreign regulatory authorities may disagree with the number, design or implementation of
our clinical studies;
the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the
full population for which we seek approval;
the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical
studies or clinical studies;
the data collected from clinical studies of our product candidates may not meet the level of statistical or clinical
significance required by the FDA or comparable foreign regulatory authorities for marketing approval or may
otherwise not be sufficient to support the submission of a new drug application or biologics license application, or
other submission or to obtain regulatory approval in the United States or elsewhere;
the FDA may not accept data generated at our preclinical studies and clinical study sites;
the FDA may require us to conduct additional preclinical studies and clinical studies;
we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate’s
risk‑benefit ratio for its proposed indication is acceptable;
the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test
procedures and specifications or facilities of third‑party manufacturers with which we contract for clinical and
commercial supplies;
we or any third‑party service providers may be unable to demonstrate compliance with current Good Manufacturing
Practices, or cGMPs, to the satisfaction of the FDA or comparable foreign regulatory authorities, which could result
in delays in regulatory approval or require us to withdraw or recall products and interrupt commercial supply of our
products; or
34
Table of Contents
·
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval.
Any of these factors, many of which are beyond our control, may result in our failing to obtain regulatory approval to market
any of our product candidates, which would significantly harm our business, results of operations and prospects.
We may conduct clinical trials for ADC product candidates at sites outside the United States, and the FDA may not accept
data from trials conducted in such locations.
We may conduct clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted
outside the United States, acceptance of these data is subject to conditions imposed by the FDA. For example, the clinical
trial must be well designed and conducted and be performed by qualified investigators in accordance with ethical principles.
If the foreign data is the sole basis for a marketing application, then the data must be applicable to the U.S. population and
U.S. medical practice in ways that the FDA deems clinically meaningful and the FDA must be able to validate the data
through an on-site inspection, if necessary. In addition, while these clinical trials are subject to the applicable local laws, FDA
acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and
regulations. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely
result in the need for additional trials, which would be costly, time-consuming and could delay or permanently halt our
development of the applicable product candidates.
If we fail to obtain regulatory approval in jurisdictions outside the United States, we will not be able to market our
products in those jurisdictions.
We intend to market our product candidates, including XMT‑1536, our lead product candidate, if approved, in international
markets either directly or through partnerships. Such marketing will require separate regulatory approvals in each market and
compliance with numerous and varying regulatory requirements. The approval procedures vary from country to country and
may require additional testing that we are not required to perform to obtain regulatory approval in the United States.
Moreover, the time required to obtain approval in countries outside the United States may differ from that required to obtain
FDA approval. In addition, in many countries outside the United States, a drug must be approved for reimbursement before it
can be approved for sale in that country. Approval by the FDA does not ensure approval by regulatory authorities in other
countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities
in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with
obtaining FDA approval. We or our partners may not obtain foreign regulatory approvals on a timely basis, if at all. We or
our partners may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our
products in any market. If we or any existing or future partner are unable to obtain regulatory approval for XMT‑1536 or any
of our other current or future product candidates in one or more significant foreign jurisdictions, then the commercial
opportunity for such product candidate and our financial condition will be adversely affected.
Even if we receive regulatory approval for our ADC product candidates, such products will be subject to ongoing
regulatory review, which may result in significant additional expense. Additionally, our ADC product candidates, if
approved, could be subject to labeling and other restrictions, and we may be subject to penalties if we fail to comply with
regulatory requirements or experience unanticipated problems with our products.
Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved
indicated uses for which the product may be marketed or to conditions of approval, or contain requirements for potentially
costly post‑marketing testing and surveillance to monitor safety and efficacy. In addition, if the FDA or any other governing
regulatory body approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution,
adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and
ongoing regulatory requirements. These requirements include submissions of safety and other post‑marketing information
and reports, registration, as well as continued compliance with cGMP and GCP, for any clinical studies that we conduct
post‑approval.
35
Table of Contents
Later discovery of previously unknown problems with an approved drug, including adverse events of unanticipated severity
or frequency, or with manufacturing operations or processes, or failure to comply with regulatory requirements, may result in,
among other things:
·
·
·
·
·
restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or
voluntary or mandatory product recalls;
fines, warning letters or holds on clinical studies;
refusal by the FDA or any other governing regulatory body to approve pending applications or supplements to
approved applications filed by us, or suspension or revocation of product license approvals;
product seizure or detention, or refusal to permit the import or export of products; and
injunctions or the imposition of civil or criminal penalties.
The policies of the FDA or any other governing regulatory body may change and additional government regulations may be
enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative action, either in the United
States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or
policies, or not able to maintain regulatory compliance, we may lose any marketing approval that may have been obtained
and we may not achieve or sustain profitability, which would adversely affect our business.
Our ADC product candidates or ADCs developed or commercialized by our competitors may cause undesirable side effects
or have other properties that delay or prevent regulatory approval of our ADC product candidates or limit their
commercial potential.
Undesirable side effects caused by our product candidates or ADCs being developed or commercialized by our partners or
competitors could cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in a more
restrictive label or the denial of regulatory approval by the FDA or other regulatory authorities and potential product liability
claims. Further, clinical studies by their nature utilize a sample of the potential patient population. With a limited number of
subjects and limited duration of exposure, rare and severe side effects of our product candidates or those of our competitors
may only be uncovered with a significantly larger number of patients exposed to the drug. SAEs deemed to be caused by our
product candidates or those of our competitors, either before or after receipt of marketing approval, could have a material
adverse effect on the development of our product candidates and our business as a whole.
If we or others identify undesirable side effects caused by our product candidates or those of our competitors either before or
after receipt of marketing approval, a number of potentially significant negative consequences could result, including:
·
·
·
·
·
·
our clinical studies may be put on hold;
we may be unable to obtain regulatory approval for our product candidates;
regulatory authorities may withdraw or limit their approvals of our product candidates;
regulatory authorities may require the addition of labeling statements, such as a contraindication, black box
warnings or additional warnings;
the FDA may require development of a REMS with Elements to Assure Safe Use as a condition of approval or
post‑approval;
we may decide to remove such product candidates from the marketplace;
36
Table of Contents
·
·
·
we may be subject to regulatory investigations and government enforcement actions;
we could be sued and held liable for harm caused to patients; and
our reputation may suffer.
Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could
substantially increase commercialization costs.
If we or our third‑party collaborators are unable to successfully develop and commercialize any required companion
diagnostics for our product candidates or engage a third party to do so, or we or they experience significant delays in
doing so, we may not realize the full potential of our ADC product candidates.
If a companion diagnostic is required for the label for XMT‑1536, our lead product candidate, or any of our other current or
future product candidates, therefore conditioning our ability to market such product candidates on the commercial availability
of an approved companion diagnostic, we may seek approval for our validated assay as a companion diagnostic or we may
contract with third parties to create and obtain approval for a companion diagnostic. To be successful in developing and
commercializing such a companion diagnostic, we need to address a number of scientific, technical and logistical challenges.
We have little experience in the development and commercialization of diagnostics and may not be successful in developing
and commercializing appropriate diagnostics to pair with XMT‑1536 or any of our other current or future product candidates.
Companion diagnostics are subject to regulation by the FDA and equivalent foreign regulatory authorities as medical devices
and require separate regulatory approval prior to commercialization. Given our limited experience in developing and
commercializing diagnostics, we may rely in part or in whole on third parties for their design, manufacture and
commercialization. We, our collaborators or such third parties may encounter difficulties in developing and obtaining
approval for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation,
reproducibility or clinical validation. Any delay or failure by us, our collaborators or such third parties to develop or obtain
regulatory approval of the companion diagnostics could delay or prevent approval of our product candidates. If we, or any
third parties that we may contract with to assist us, are unable to successfully develop and commercialize companion
diagnostics for our product candidates, or experience delays in doing so:
·
·
·
the development of XMT‑1536 and our other current or future product candidates, may be adversely affected if we
are unable to appropriately select patients for enrollment in our clinical trials;
our product candidates may not receive marketing approval if safe and effective use of a therapeutic product
candidate depends on the availability of an in vitro diagnostic; and
we may not realize the full commercial potential of any product candidates that receive marketing approval if,
among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our
products.
As a result, our business would be harmed, possibly materially.
In addition, third‑party collaborators may encounter production difficulties that could constrain the supply of the companion
diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics in the
clinical community. If such companion diagnostics fail to gain market acceptance, it would have an adverse effect on our
ability to derive revenues from sales of our product candidates, if approved. In addition, any diagnostic company with whom
we contract may decide to discontinue selling or manufacturing the companion diagnostic that we anticipate using in
connection with development and commercialization of our product candidates or our relationship with such diagnostic
company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain
supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product
candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or
commercialization of our product candidates.
37
Table of Contents
We or our partners may fail to discover and develop additional potential product candidates.
Our and our partners’ research programs to identify new product candidates will require substantial technical, financial and
human resources, and we or our partners may be unsuccessful in our or their efforts to identify new product candidates. If we
or our partners are unable to identify suitable additional product candidates for preclinical and clinical development, our or
their ability to develop product candidates and our ability to obtain revenues from commercializing our products or to receive
royalties from our partners’ sales of their products in future periods could be compromised, which could result in significant
harm to our financial position and adversely impact our stock price.
Risks related to our reliance on third parties
Because we rely on third‑party manufacturing and supply partners, our supply of research and development, preclinical
and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.
We rely on third‑party contract manufacturers to manufacture our preclinical and clinical study product supplies, and we lack
the internal resources and the capability to manufacture any product candidates on a clinical or commercial scale. The
facilities used by our contract manufacturers to manufacture the active pharmaceutical ingredient and final drug product must
be acceptable to the FDA and other comparable foreign regulatory agencies pursuant to inspections that would be conducted
after we submit our marketing application or relevant foreign regulatory submission to the applicable regulatory agency.
There can be no assurance that our preclinical and clinical development product supplies will be sufficient, uninterrupted or
of satisfactory quality or continue to be available at acceptable prices. If our contract manufacturers cannot successfully
manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or applicable
foreign regulatory agencies, they will not be able to secure or maintain regulatory approval for their manufacturing facilities.
Any replacement of our manufacturers could require significant effort and expertise because there may be a limited number
of qualified replacements.
The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and
manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests
required by regulatory authorities in order to comply with regulatory standards, such as cGMP. We have no direct control
over our contract manufacturers’ ability to maintain adequate quality control, quality assurance and qualified personnel. In
the event that any of our manufacturers fails to comply with regulatory requirements or to perform its obligations to us in
relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for
other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities
or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at
all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or
proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third
party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to
obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are
required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities
and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated
with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely
manner or within budget. Our reliance on contract manufacturers also exposes us to the possibility that they, or third parties
with access to their facilities, will have access to and may appropriate our trade secrets or other proprietary information.
We expect to continue to rely on third‑party manufacturers if we receive regulatory approval for any product candidate. To
the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these
third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements,
including those related to quality control and assurance. If we are unable to obtain or maintain third‑party manufacturing for
product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our
product candidates successfully. Our or a third party’s failure to execute on our manufacturing requirements and comply with
cGMP could adversely affect our business in a number of ways, including:
·
an inability to initiate or continue clinical studies of product candidates under development;
38
Table of Contents
·
·
·
·
·
delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;
loss of the cooperation of an existing or future strategic partner;
subjecting third‑party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory
authorities;
a requirement to cease distribution or to recall batches of our product candidates; and
in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands
for our products.
We, or our third‑party manufacturers, may be unable to successfully scale‑up manufacturing of our ADC product
candidates in sufficient quality and quantity, which would delay or prevent us from developing our ADC product
candidates and commercializing approved products, if any.
In order to conduct clinical studies of our product candidates and commercialize any approved product candidates, we, or our
manufacturing partners, will need to manufacture them in large quantities. We, or our manufacturing partners, may be unable
to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost‑effective manner, or
at all. In addition, quality issues may arise during scale‑up activities. If we, or any manufacturing partners, are unable to
successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing
and clinical studies of that product candidates may be delayed or infeasible, and regulatory approval or commercial launch of
any resulting product may be delayed or not obtained, which could significantly harm our business. We have evaluated which
third‑party manufactures to engage for scale‑up to commercial supply of our product candidates, including XMT‑1536, our
lead product candidate, and we have begun transfer and scale-up of certain manufacturing activities. If we are unable to
obtain or maintain third‑party manufacturing for commercial supply of product candidates, or to do so on commercially
reasonable terms, we may not be able to develop and commercialize our product candidates successfully.
We rely on third parties to conduct preclinical studies and clinical studies for our product candidates, including
XMT‑1536, our lead product candidate, and if such third parties do not properly and successfully perform their
obligations to us, we may not be able to obtain regulatory approvals for XMT‑1536 or any other current or future ADC
product candidates.
We have designed the Phase 1 clinical study for XMT-1536, our lead product candidate, and intend to design any future
clinical study for any future unpartnered product candidates that we may develop if preclinical studies are successful.
However, we rely on CROs and other third parties to assist in managing, monitoring and otherwise carrying out many of
these studies. As a result, we have less direct control over the conduct, timing and completion of these clinical studies and the
management of data developed through clinical studies than would be the case if we were relying entirely upon our own staff.
These CROs and other third parties are not our employees and we have limited control over the amount of time and resources
that they dedicate to our programs. We compete with many other companies for the resources of these third parties. These
third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw
time and resources from our programs. The third parties with whom we contract might not be diligent, careful or timely in
conducting our preclinical studies or clinical studies, resulting in the preclinical studies or clinical studies being delayed or
unsuccessful.
The third parties on whom we rely generally may terminate their engagements at any time, and having to enter into
alternative arrangements would delay development and commercialization of our product candidates. Communicating with
outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities.
Outside parties may:
·
have staffing difficulties;
39
Table of Contents
·
·
·
·
fail to comply with contractual obligations;
experience regulatory compliance issues;
undergo changes in priorities or become financially distressed; or
form relationships with other entities, some of which may be our competitors.
The FDA and comparable foreign regulatory authorities require compliance with regulations and standards, including GCP,
for designing, conducting, monitoring, recording, analyzing and reporting the results of clinical studies to assure that the data
and results are credible and accurate and that the rights, integrity and confidentiality of study participants are protected.
Although we rely, and intend to continue to rely, on third parties to conduct our clinical studies, they are not our employees,
and we are responsible for ensuring that each of these clinical studies is conducted in accordance with its general
investigational plan, protocol and other requirements. Our reliance on these third parties for research and development
activities will reduce our control over these activities but will not relieve us of our responsibilities.
If these third parties do not successfully carry out their duties under their agreements, if the quality or accuracy of the data
they obtain is compromised due to their failure to adhere to clinical study protocols or to regulatory requirements, or if they
otherwise fail to comply with clinical study protocols or meet expected deadlines, the clinical studies of our product
candidates may not meet regulatory requirements. The FDA enforces GCP regulations through periodic inspections of
clinical study sponsors, principal investigators and study sites. If we or our CROs fail to comply with applicable GCPs or
other regulatory requirements, the clinical data generated in our clinical studies may be deemed unreliable, third parties may
need to be replaced and preclinical development activities or clinical studies may be extended, delayed, suspended or
terminated. If any of these events occur, we may not be able to obtain regulatory approval of our product candidates on a
timely basis or at all.
We depend on strategic partnerships with other companies to assist in the research, development and commercialization of
our ADC platforms and ADC product candidates. If our existing partners do not perform as expected, this may negatively
affect our ability to commercialize our ADC product candidates, generate revenues through technology licensing, or
otherwise negatively affect our business.
We have established strategic partnerships and intend to continue to establish strategic partnerships with third parties to
research, develop and commercialize our platforms and existing and future product candidates. We entered into a
collaboration agreement with Merck KGaA for the development and commercialization of other product candidates. For
certain of these programs, we will depend on our partners to design and conduct their clinical studies. As a result, we may not
be able to conduct these programs in the manner or on the time schedule we currently contemplate, which may negatively
impact our business operations. In addition, if any of these partners withdraw support for these programs or proposed
products or otherwise impair their development or experience negative results, our business and our product candidates could
be negatively affected.
Our partners may terminate their agreements with us for cause under certain circumstances or at will in certain cases and
discontinue use of our technologies. In addition, we cannot control the amount and timing of resources our partners may
devote to products utilizing or incorporating our technology. Moreover, our relationships with our partners may divert
significant time and effort of our scientific staff and management team and require effective allocation of our resources to
multiple internal and collaborative projects. Our partners may fail to perform their obligations under the collaboration
agreements or may not perform their obligations in a timely manner. If conflicts arise between our partners and us, the other
party may act in a manner adverse to us and could limit our ability to implement our strategies. If any of our partners
terminate or breach our agreements with them, or otherwise fail to complete their obligations in a timely manner, it may have
a detrimental effect on our financial position by reducing or eliminating the potential for us to receive technology access and
license fees, milestones and royalties, reimbursement of development costs, as well as possibly requiring us to devote
additional efforts and incur costs associated with pursuing internal development of product candidates. Furthermore, if our
partners do not prioritize and commit sufficient resources to programs associated with our product candidates or
collaboration product candidates, we or our partners may be unable to commercialize these product candidates, which would
limit our ability to generate revenue and become profitable.
40
Table of Contents
Our partners may separately pursue competing products, therapeutic approaches or technologies to develop treatments for the
diseases targeted by us or our partners. Competing products, either developed by the partners or to which the partners have
rights, may result in the withdrawal of partner support for our product candidates. Even if our partners continue their
contributions to the strategic partnerships, they may nevertheless determine not to actively pursue the development or
commercialization of any resulting products. Additionally, if our partners pursue different clinical or regulatory strategies
with their product candidates based on our platforms or technologies, adverse events with their product candidates could
negatively affect our product candidates utilizing similar technologies. Any of these developments could harm our product
development efforts.
To date, we have depended on a small number of partners for a substantial portion of our revenue. The loss of any one of
these partners could result in a material decline in our revenue.
We have strategic partnerships with a limited number of companies. To date, a substantial portion of our revenue has resulted
from payments made under agreements with our strategic partners, and we expect that a portion of our revenue will continue
to come from strategic partnerships. The loss of any of our partners, or the failure of our partners to perform their obligations
under their agreements with us, including paying license or technology fees, milestone payments, royalties or
reimbursements, could have a material adverse effect on our financial performance. Payments under our existing and future
strategic partnerships are also subject to significant fluctuations in both timing and amount, which could cause our revenue to
fall below the expectations of securities analysts and investors and cause a decrease in our stock price.
We may not be successful in establishing and maintaining additional strategic partnerships, which could adversely affect
our ability to develop and commercialize products, negatively impacting our operating results.
We continue to strategically evaluate our partnerships and, as appropriate, we expect to enter into additional strategic
partnerships in the future, including potentially with major biotechnology or biopharmaceutical companies. We face
significant competition in seeking appropriate partners for our product candidates, and the negotiation process is
time‑consuming and complex. In order for us to successfully partner our product candidates, potential partners must view
these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are
seeking and other available products for licensing by other companies. Even if we are successful in our efforts to establish
strategic partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such
strategic partnerships if, for example, development or approval of a product candidate is delayed or sales of an approved
product are disappointing. Any delay in entering into strategic partnership agreements related to our product candidates could
delay the development and commercialization of such candidates and reduce their competitiveness even if they reach the
market. If we are not able to generate revenue under our strategic partnerships when and in accordance with our expectations
or the expectations of industry analysts, this failure could harm our business and have an immediate adverse effect on the
trading price of our common stock.
If we fail to establish and maintain additional strategic partnerships related to our unpartnered product candidates, we will
bear all of the risk and costs related to the development of any such product candidate, and we may need to seek additional
financing, hire additional employees and otherwise develop expertise, such as regulatory expertise, for which we have not
budgeted. If we were not successful in seeking additional financing, hiring additional employees or developing additional
expertise, our cash burn rate would increase or we would need to take steps to reduce our rate of product candidate
development. This could negatively affect the development of any unpartnered product candidate.
Risks related to commercialization of our ADC product candidates
Our future commercial success depends upon attaining significant market acceptance of our ADC product candidates, if
approved, among physicians, patients and health care payors.
Even if we obtain regulatory approval for XMT‑1536, our lead product candidate, or any other current or future product
candidates that we may develop or acquire in the future, the product candidate may not gain market acceptance among
41
Table of Contents
physicians, health care payors, patients and the medical community. Market acceptance of any approved products depends on
a number of factors, including:
·
·
·
·
·
·
·
·
the efficacy and safety of the product, as demonstrated in clinical studies;
the indications for which the product is approved and the label approved by regulatory authorities for use with the
product, including any warnings that may be required on the label;
acceptance by physicians and patients of the product as a safe and effective treatment;
the cost, safety and efficacy of treatment in relation to alternative treatments;
the availability of adequate reimbursement and pricing by third‑party payors and government authorities;
relative convenience and ease of administration;
the prevalence and severity of adverse side effects; and
the effectiveness of our sales and marketing efforts.
Perceptions of any product are influenced by perceptions of competitors’ products that are in the same class of drugs or have
a similar mechanism of action. As a result, adverse public perception of our competitors’ products may negatively impact the
market acceptance of our product candidates. Market acceptance is critical to our ability to generate significant revenue and
become profitable. Any therapeutic candidate, if approved and commercialized, may be accepted in only limited capacities or
not at all. If any approved products are not accepted by the market to the extent that we expect, we may not be able to
generate significant revenue and our business would suffer.
The incidence and prevalence for target patient populations of our drug candidates have not been established with
precision. If the market opportunities for our drug candidates are smaller than we estimate or if any approval that we
obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be
adversely affected, possibly materially.
The precise incidence and prevalence of epithelial ovarian cancer and non‑squamous NSCLC with NaPi2b expression are
unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these
diseases who have the potential to benefit from treatment with our drug candidates, are based on estimates. The total
addressable market opportunity for XMT‑1536 or XMT-1592 for the treatment of epithelial ovarian cancer and
non‑squamous NSCLC with NaPi2b expression will ultimately depend upon, among other things, the diagnosis criteria
included in the final label for XMT‑1536 or XMT-1592, if our drug candidates are approved for sale for these indications,
acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients who can
be treated with our drug candidates may turn out to be lower than expected, patients may not be otherwise amenable to
treatment with our drugs, or new patients may become increasingly difficult to identify or gain access to, all of which would
adversely affect our results of operations and our business.
If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in commercializing
our product candidates if and when they are approved.
We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of products.
To achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a
sales and marketing organization.
In the future, we expect to build a focused sales and marketing infrastructure to market XMT‑1536, our lead product
candidate, and any other current or future product candidates in the United States and certain foreign jurisdictions, if and
when they are approved. There are risks involved with establishing our own sales, marketing and distribution capabilities.
42
Table of Contents
For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the
commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or
does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This
may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.
Factors that may inhibit our efforts to commercialize our products on our own include:
·
·
·
·
·
our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
the inability of sales personnel to obtain access to physicians;
the lack of adequate numbers of physicians to prescribe any future products;
the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and
unforeseen costs and expenses associated with creating an independent sales and marketing organization.
If we are unable to establish our own sales, marketing and distribution capabilities and enter into arrangements with third
parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to
market, sell and distribute any products that we develop ourselves.
In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute certain of
our product candidates outside of the United States or may be unable to do so on terms that are favorable to us. We likely will
have limited control over such third parties, and any of them may fail to devote the necessary resources and attention to sell
and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either
on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.
Reimbursement may be limited or unavailable in certain market segments for our ADC product candidates, which could
make it difficult for us to sell our products profitably.
In both domestic and foreign markets, sales of any of our product candidates, if approved, will depend, in part, on the extent
to which the costs of our products will be covered by third‑party payors, such as government health programs, commercial
insurance and managed health care organizations. These third-party payors decide which drugs will be covered and establish
reimbursement levels for those drugs. The containment of health care costs has become a priority of foreign and domestic
governments as well as private third-party payors. The prices of drugs have been a focus in this effort. Governments and
private third‑party payors have attempted to control costs by limiting coverage and the amount of reimbursement for
particular medications, which could affect our ability to sell our product candidates profitably. Cost‑control initiatives could
cause us to decrease the price we might establish for products, which could result in lower than anticipated product revenues.
Reimbursement by a third‑party payor may depend upon a number of factors, including the third‑party payor’s determination
that use of a product is:
·
·
·
·
a covered benefit under its health plan;
safe, effective and medically necessary;
appropriate for the specific patient;
cost‑effective; and
43
Table of Contents
·
neither experimental nor investigational.
Adverse pricing limitations may hinder our ability to recoup our investment in XMT‑1536, our lead product candidate or any
other current or future product candidates, even if such product candidates obtain marketing approval.
Obtaining coverage and reimbursement approval for a product from a government or other third‑party payor is a time
consuming and costly process that could require us to provide supporting scientific, clinical and cost‑effectiveness data for
the use of our products to the payor. Further, there is significant uncertainty related to third‑party payor coverage and
reimbursement of newly approved drugs. We may not be able to provide data sufficient to gain acceptance with respect to
coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement will be available for any of our
product candidates. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our
products. If reimbursement is not available or is available only to limited levels, we may not be able to commercialize certain
of our products. In addition, in the United States, third‑party payors are increasingly attempting to contain health care costs
by limiting both coverage and the level of reimbursement of new drugs. As a result, significant uncertainty exists as to
whether and how much third‑party payors will reimburse patients for their use of newly approved drugs, which in turn will
put pressure on the pricing of drugs.
Price controls may be imposed in foreign markets, which may adversely affect our future profitability.
In some countries, including member states of the European Union, the pricing of prescription drugs is subject to
governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In such
countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval
for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and
reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may
further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained.
Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low‑priced
and high‑priced member states, can further reduce prices. In some countries, we may be required to conduct a clinical study
or other studies that compare the cost‑effectiveness of our product candidates to other available therapies in order to obtain or
maintain reimbursement or pricing approval. We cannot be sure that such prices and reimbursement will be acceptable to us
or our strategic partners. Publication of discounts by third‑party payors or authorities may lead to further pressure on the
prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels
or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our
strategic partners and the potential profitability of our product candidates in those countries would be negatively affected.
The impact of health care reform legislation and other changes in the health care industry and in health care spending on
us is currently unknown and may adversely affect our business model.
Our revenue prospects could be affected by changes in health care spending and policy in the United States and abroad. We
operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws,
regulations or decisions, related to health care availability, the method of delivery or payment for health care products and
services could negatively impact our business, operations and financial condition.
Within the United States, there have been ongoing government efforts at the federal and state levels to reform the provision
or control the cost of health care. There have been a number of legislative and regulatory changes to the healthcare system,
such as the enactment and subsequent modification of the Health Care Reform Act, that could affect our future results of
operations or the commercial success of our products, if approved. See “BUSINESS-Government regulation - Healthcare
reform”. We continue to evaluate the effect that healthcare reform efforts may have on our business, but expect that
healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally
and on our ability to successfully commercialize our product candidates, if approved. Healthcare reform efforts to contain or
reduce costs of health care may adversely affect:
·
the demand for any products for which we may obtain regulatory approval;
44
Table of Contents
·
·
·
·
our ability to set a price that we believe is fair for our products;
our ability to obtain coverage and reimbursement approval for a product;
our ability to generate revenues and achieve or maintain profitability; and
the level of taxes that we are required to pay.
We cannot predict the ultimate content, timing or effect of any such reforms.
In addition, other legislative changes have been proposed and adopted that affect health care spending. The Budget Control
Act of 2011, includes provisions to reduce the federal deficit. The Budget Control Act, as amended, resulted in the imposition
of 2% reductions in Medicare payments to providers which began in April 2013, and will remain in effect through 2029
unless additional Congressional action is taken. Any significant spending reductions affecting Medicare, Medicaid or other
publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be
imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act,
could have an adverse impact on our results of operations.
We face substantial competition, which may result in others discovering, developing or commercializing products before,
or more successfully than, we do.
The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense
competition and a strong emphasis on proprietary products. Many third parties compete with us in developing various
approaches to cancer therapy. They include pharmaceutical companies, biotechnology companies, academic institutions and
other research organizations. Any treatments developed by our competitors could be superior to our product candidates. It is
possible that these competitors will succeed in developing technologies that are more effective than our platforms or product
candidates or that would render our platforms obsolete or noncompetitive. We anticipate that we will face increased
competition in the future as additional companies enter our market and scientific developments surrounding other cancer
therapies continue to accelerate.
We are also aware of multiple companies with ADC technologies that may be competitive to our platforms, including
Astellas, AstraZeneca, Daiichi Sankyo, ImmunoGen, Immunomedics, Pfizer and Seattle Genetics. These companies or their
partners, including AbbVie, Genentech and Takeda, may develop product candidates which compete in the same indications
as our current and future product candidates. We expect to compete on improved efficacy, safety and tolerability compared to
other product candidates and if our products are not demonstrably superior in these respects compared to other approved
therapeutics, we may not be able to compete effectively.
Many of our competitors have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical studies, conducting clinical studies, obtaining regulatory approval and marketing than we do. In
addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of
collecting royalties for use of technology that they have developed. Smaller or early‑stage companies may also prove to be
significant competitors, particularly through strategic partnerships with large and established companies. These third parties
compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring
technologies complementary to our programs.
In addition, if our product candidates are approved and commercialized, we may face competition from biosimilars. The
route to market for biosimilars was established with the passage of the Health Care Reform Act in March 2010. The Health
Care Reform Act establishes a pathway for the FDA approval of follow‑on biologics and provides twelve years data
exclusivity for reference products and an additional six months exclusivity period if pediatric studies are conducted. In
December 2018, however, a federal district court judge, in a challenge brought by a number of state attorneys general, found
the Health Care Reform Act unconstitutional in its entirety. Given the court’s decision struck down the Health Care Reform
Act in its entirety, the decision means numerous reforms enacted as part of the Health Care Reform Act, but not specifically
related to health insurance, such as the BPCIA, are invalid as well. While the Trump administration and CMS have both
stated that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, if any,
45
Table of Contents
and other efforts to repeal and replace the Health Care Reform Act will impact the biosimilar framework created by the
Health Care Reform Act and our Business.
In Europe, the European Medicines Agency has issued guidelines for approving products through an abbreviated pathway,
and biosimilars have been approved in Europe. If a biosimilar version of one of our potential products were approved in the
United States or Europe, it could have a negative effect on sales and gross profits of the potential product and our financial
condition.
With respect to our current and potential future product candidates, we believe that our ability to compete effectively and
develop products that can be manufactured cost‑effectively and marketed successfully will depend on our ability to:
·
·
·
·
·
·
·
·
advance our technology platforms;
obtain and maintain intellectual property protection for our technologies and products;
obtain required government and other public and private approvals on a timely basis;
attract and retain key personnel;
commercialize effectively;
obtain reimbursement for our products in approved indications;
comply with applicable laws, regulations and regulatory requirements and restrictions with respect to the
commercialization of our products, including with respect to any changed or increased regulatory restrictions; and
enter into additional strategic partnerships to advance the development and commercialization of our product
candidates.
Risks related to our intellectual property
If we are unable to obtain or protect intellectual property rights related to our technology and ADC product candidates, or
if our intellectual property rights are inadequate, we may not be able to compete effectively.
Our success depends in large part on our ability to obtain and maintain protection with respect to our intellectual property and
proprietary technology. We rely upon a combination of patents, trade secret protection and confidentiality agreements to
protect the intellectual property related to our platforms and our product candidates, including our lead product candidate,
XMT‑1536. The patent position of biopharmaceutical companies is generally uncertain because it involves complex legal
and factual considerations and has, in recent years, been the subject of much litigation. As a result, the issuance, scope,
validity, enforceability and commercial value of our patent rights is highly uncertain. The standards applied by the United
States Patent and Trademark Office, or USPTO, and foreign patent offices in granting patents are not always applied
uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope
of claims allowable in patents. In addition, changes in either the patent laws or interpretation of the patent laws in the United
States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The patent
prosecution process is expensive, complex and time‑consuming, and we may not be able to file, prosecute, maintain, enforce
or license all necessary or desirable patents and patent applications at a reasonable cost or in a timely manner. It is also
possible that we fail to identify patentable aspects of our research and development output before it is too late to obtain patent
protection. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been
found. We may be unaware of prior art that could be used to invalidate an issued patent or prevent our pending patent
applications from issuing as patents.
46
Table of Contents
The patent applications that we own or in‑license may fail to result in issued patents, and even if they do issue as patents,
such patents may not cover our platforms and product candidates in the United States or in other countries. The issuance of a
patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the
courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims
being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or
commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology
and product candidates. For example, even if patent applications we license or own do successfully issue as patents and even
if such patents cover our platforms and product candidates, third parties may challenge their validity, enforceability or scope,
which may result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and
patent applications may not provide adequate protection or exclusivity for our ADC platform or product candidates, prevent
others from designing around our claims or otherwise provide us with a competitive advantage. Any of these outcomes could
impair our ability to prevent competition from third parties, which may have an adverse impact on our business.
If patent applications we own or have in‑licensed with respect to our platforms or our product candidates fail to issue as
patents, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity, it could
dissuade companies from collaborating with us. We cannot offer any assurances about which, if any, patents will issue, the
breadth of any such patents or whether any issued patents will be found invalid and unenforceable or will be threatened by
third parties. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of
rights necessary for the successful development and commercialization of any product candidate. Since patent applications in
the United States and most other countries are confidential for a period of time after filing, and some remain so until issued,
we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, if third
parties have filed such patent applications, an interference proceeding in the United States can be initiated by the USPTO or a
third‑party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.
In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it
is filed. Various extensions may be available; however, the life of a patent and the protection it affords is limited. Given the
amount of time required for the development, testing and regulatory review of new product candidates, our owned or
in‑licensed patents protecting such candidates might expire before or shortly after such candidates are commercialized. If we
encounter delays in obtaining regulatory approvals, the period of time during which we could market a drug under patent
protection could be further reduced. Even if patents covering our product candidates are obtained, once the patent life has
expired for a product, we may be open to competition from similar or generic products. The launch of a generic version of
one of our products in particular would be likely to result in an immediate and substantial reduction in the demand for our
product, which could have a material adverse effect on our business, financial condition, results of operations and prospects.
On September 16, 2011, the Leahy‑Smith America Invents Act, or the Leahy‑Smith Act, was signed into law, which could
increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of
our issued patents. The Leahy‑Smith Act includes a number of significant changes to U.S. patent law. These include
provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switch the
U.S. patent system from a “first‑to‑invent” system to a “first‑to‑file” system. Under a first‑to‑file system, assuming the other
requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on
an invention regardless of whether another inventor had made the invention earlier. These provisions also allow third‑party
submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a
patent by the USPTO administered post grant proceedings. The USPTO developed additional regulations and procedures to
govern administration of the Leahy‑Smith Act, and many of the substantive changes to patent law associated with the
Leahy‑Smith Act, and, in particular, the first‑to‑file provisions, only became effective on March 16, 2013. Accordingly, it is
not clear what, if any, impact the Leahy‑Smith Act will have on the operation of our business. The Leahy‑Smith Act and its
implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial
condition, results of operations and prospects.
Any loss of patent protection could have a material adverse impact on our business. We may be unable to prevent competitors
from entering the market with a product that is similar to or the same as our product candidates.
47
Table of Contents
Issued patents covering XMT‑1536, our lead product candidate, and any other current or future ADC product candidates
could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign authority.
If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering XMT‑1536,
our lead product candidate, or any other current or future product candidates, the defendant could counterclaim that the patent
covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert
invalidity or unenforceability of a patent. Grounds for a validity challenge could be, among other things, an alleged failure to
meet any of several statutory requirements, including lack of novelty, obviousness, lack of written description or
non‑enablement. Grounds for an unenforceability assertion could be, among other things, an allegation that someone
connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement,
during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad,
even outside the context of litigation. Such mechanisms include re‑examination, inter partes review, post‑grant review,
interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition
proceedings). Such proceedings could result in revocation, cancellation or amendment to our patents in such a way that they
no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability
is unpredictable. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating
prior art of which we, our licensors, our patent counsel and the patent examiner were unaware during prosecution. If a third
party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the
patent protection on one or more of our product candidates. Any such loss of patent protection could have a material adverse
impact on our business, financial condition, results of operations and prospects.
If we fail to comply with our obligations under any license, strategic partnership or other agreements, we may be required
to pay damages and could lose intellectual property rights that are necessary for developing and protecting our ADC
product candidates.
We rely, in part, on license, collaboration and other agreements. We may need to obtain additional licenses from others to
advance our research or allow commercialization of our product candidates and it is possible that we may be unable to obtain
additional licenses at a reasonable cost or on reasonable terms, if at all. The licensing or acquisition of third party intellectual
property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third
party intellectual property rights that we may consider attractive. These established companies may have a competitive
advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In
addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to use. We also may be
unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return
on our investment.
In addition, our existing licenses and collaboration agreements, including our license with Recepta Biopharma S.A., or
Recepta, for intellectual property covering the NaPi2b antibody in XMT‑1536 and XMT-1592, impose, and any future
licenses, collaborations or other agreements we enter into are likely to impose, various development, commercialization,
funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us.
If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be
required to pay damages and the licensor may have the right to terminate the license, including, in the case of our agreement
with Recepta, the license for the rights covering the NaPi2b antibody in XMT‑1536 and XMT-1592. Any of the foregoing
could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or
enable a competitor to gain access to the licensed technology. Disputes may arise regarding intellectual property subject to a
licensing, collaboration or other agreements, including:
·
·
the scope of rights granted under the license agreement and other interpretation related issues;
the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject
to the licensing agreement;
48
Table of Contents
·
·
·
·
the sublicensing of patent and other rights under our collaborative development relationships;
our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
the inventorship and ownership of inventions and know how resulting from the joint creation or use of intellectual
property by our licensors and us and our partners; and
the priority of invention of patented technology.
In addition, the agreements under which we currently license intellectual property or technology to or from third parties are
complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any
contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant
intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant
agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and
prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our
current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and
commercialize the affected product candidates.
In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or
to maintain the patents, covering the technology that we license from third parties. For example, pursuant to our license
agreement with Recepta, Ludwig Institute for Cancer Research Ltd., a co‑owner of the intellectual property, retains control of
such activities. Therefore, we cannot be certain that these patents and applications will be prosecuted, maintained and
enforced in a manner consistent with the best interests of our business. If our licensors fail to obtain or maintain such
intellectual property, or lose rights to such intellectual property, the rights we have licensed and our exclusivity may be
reduced or eliminated and our right to develop and commercialize any of our products that are subject to such licensed rights
could be adversely affected.
Moreover, our rights to our in‑licensed patents and patent applications are dependent, in part, on inter‑institutional or other
operating agreements between the joint owners of such in‑licensed patents and patent applications. If one or more of such
joint owners breaches such inter‑institutional or operating agreements, our rights to such in‑licensed patents and patent
applications may be adversely affected. In addition, while we cannot currently determine the amount of the royalty
obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of
our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully
develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be
unable to achieve or maintain profitability. Any of the foregoing could have a material adverse effect on our competitive
position, business, financial conditions, results of operations and prospects.
If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing
intellectual property rights we have, we may have to abandon development of the relevant program or product candidate and
our business, financial condition, results of operations and prospects could suffer.
We may become involved in lawsuits to protect or enforce our intellectual property or to defend against intellectual
property claims, which could be expensive, time consuming and unsuccessful.
Competitors and other third parties may infringe our patents or misappropriate or otherwise violate our owned and
in‑licensed intellectual property rights. To counter infringement or unauthorized use, litigation or other intellectual property
proceedings may be necessary to enforce or defend our owned and in‑licensed intellectual property rights, to protect our trade
secrets or to determine the validity and scope of our own intellectual property rights or the proprietary rights of others. Such
litigation or proceedings can be expensive and time consuming, and any such claims could provoke defendants to assert
counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. We may
not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Many of our current and
potential competitors have the ability to dedicate substantially greater resources to litigate intellectual property rights than we
can and have more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be
able to prevent third parties from infringing upon or misappropriating our
49
Table of Contents
intellectual property. Even if resolved in our favor, litigation or other intellectual property proceedings could result in
substantial costs and diversion of management attention and resources, which could harm our business and financial results.
In addition, in a litigation or other proceeding, a court or administrative judge may decide that a patent owned by or licensed
to us is invalid or unenforceable, or a court may refuse to stop the other party from using the technology at issue on the
grounds that our patents do not cover the technology in question. An adverse result in any litigation or other proceeding could
put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because
of the substantial amount of discovery required in connection with intellectual property litigation and other proceedings, there
is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. During
the course of any patent or other intellectual property litigation or other proceeding, there could be public announcements of
the results of hearings, rulings on motions and other interim proceedings or developments and if securities analysts or
investors regard these announcements as negative, the perceived value of our product candidates, programs or intellectual
property could be diminished. Accordingly, the market price of our common stock may decline. Any of the foregoing could
have a material adverse effect on our business, financial conditions, results of operations and prospects.
Third‑party claims of intellectual property infringement or misappropriation may prevent or delay our development and
commercialization efforts.
Our commercial success depends in part on our ability and the ability of our strategic partners to develop, manufacture,
market and sell product candidates and use our proprietary technologies without infringing, misappropriating or otherwise
violating the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside
the United States, involving patent and other intellectual property rights in the biopharmaceutical industries, including patent
infringement lawsuits, interferences, oppositions, reexamination, inter partes review, derivation and post grant review
proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and
pending patent applications owned by third parties exist in the fields in which we are developing and may develop our
product candidates. As the biopharmaceutical industries expand and more patents are issued, the risk increases that our
product candidates may be subject to claims of infringement of the patent rights of third parties.
Third parties may assert that we, our customers, licensees or parties indemnified by us are employing their proprietary
technology without authorization or have infringed upon, misappropriated or otherwise violated their intellectual property or
other rights, regardless of their merit. For example, we may be subject to claims that we are infringing the patent, trademark
or copyright rights of third parties, or that our employees have misappropriated or divulged their former employers’ trade
secrets or confidential information. There may be third‑party patents or patent applications with claims to materials,
formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates,
that we failed to identify. For example, applications filed before November 29, 2000 and certain applications filed after that
date that will not be filed outside the United States remain confidential until issued as patents. Except for certain exceptions,
including the preceding exceptions, patent applications in the United States and elsewhere are generally published only after
a waiting period of approximately 18 months after the earliest filing, and sometimes not at all. Therefore, patent applications
covering our platforms or our product candidates could have been filed by others without our knowledge. Additionally,
pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that
could cover our platforms, our product candidates or the use or manufacture of our product candidates.
Even if we believe a third party’s claims against us are without merit, a court of competent jurisdiction could hold that such
third party’s patent is valid, enforceable and cover aspects of our product candidates, including the materials, formulations,
methods of manufacture, methods of analysis, or methods for treatment, in which case, such third party would be able to
block our ability to develop and commercialize the applicable technology or product candidate until such patent expired or
unless we obtain a license and we may be required to pay such third-party monetary damages, which could be substantial.
Such licenses may not be available on acceptable terms, if at all. Even if we were able to obtain a license, the rights may be
nonexclusive, which could result in our competitors gaining access to the same intellectual property and it could require us to
make substantial licensing and royalty payments. Ultimately, we could be prevented
50
Table of Contents
from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or
threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.
Parties making claims against us may also obtain injunctive or other equitable relief, which could effectively block our ability
to further develop and commercialize our technologies or one or more of our product candidates. Defending against claims of
patent infringement, misappropriation of trade secrets or other violations of intellectual property could be costly and time
consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle at an early stage, such
litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in
significant demands on the time and attention of our management team, distracting them from the pursuit of other company
business. In the event of a successful claim of infringement against us, in addition to potential injunctive relief, we may have
to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our
infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time
and monetary expenditure.
We may face a claim of misappropriation if a third party believes that we inappropriately obtained and used trade secrets of
such third party. If we are found to have misappropriated a third party’s trade secrets, we may be prevented from further
using such trade secrets, limiting our ability to develop our product candidates, we may be required to obtain a license to such
trade secrets which may not be available on commercially reasonable terms or at all and may be non‑exclusive, and we may
be required to pay damages, which could be substantial. Any of the foregoing could have a material adverse effect on our
business, financial condition, results of operations and prospects.
We may not be able to protect our intellectual property and proprietary rights throughout the world.
Filing, prosecuting and defending patents on product candidates in all countries throughout the world where we expect there
to be significant markets for our products could be prohibitively expensive, and the laws of foreign countries may not protect
our rights to the same extent as the laws of the United States. In addition, our intellectual property license agreements may
not always include worldwide rights. For example, certain U.S. and foreign issued patents and patent applications are
licensed to us by Recepta on a worldwide basis, except that Recepta retains exclusive rights in such patents and patent
applications in Brazil. Consequently, we may not be able to prevent third parties from practicing our inventions in all
countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent
protection to develop their own products and, further, may export otherwise infringing products to territories where we have
patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with
our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from
competing.
Additionally, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of
the United States, and many companies have encountered significant problems in protecting and defending such rights in
foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the
enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could
make it difficult for us to stop the infringement of our licensed and owned patents or marketing of competing products in
violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and
proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other
aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent
applications at risk of not issuing as patents, and could provoke third parties to assert claims against us. We may not prevail
in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.
Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to
obtain a significant commercial advantage from the intellectual property that we develop or license.
Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third
parties. In addition, many countries limit the enforceability of patents against government agencies or government
contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of
such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our
business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects
may be adversely affected.
51
Table of Contents
Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and
other proprietary information.
In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect
proprietary know‑how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce
and any other elements of our platform technology and discovery and development processes that involve proprietary
know‑how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We
seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our
employees, consultants and outside scientific advisors, contractors and partners. We cannot guarantee that we have entered
into such agreement with each party that may have or have had access to our trade secrets or proprietary technology and
processes. Additionally, our confidentiality agreements and other contractual protections may not be adequate to protect our
intellectual property from unauthorized disclosure, third‑party infringement or misappropriation. We may not have adequate
remedies in the case of a breach of any such agreements, and our trade secrets and other proprietary information could be
disclosed to our competitors or others may independently develop substantially equivalent or superior proprietary
information and techniques or otherwise gain access to our trade secrets or disclose such technologies.
Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming,
and the outcome is unpredictable. In addition, some courts outside and within the United States sometimes are less willing to
protect trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position
and may have a material adverse effect on our business.
We may be subject to claims by third parties asserting that our licensors, employees, consultants, advisors or we have
misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
Many of our and our licensors’ employees, including our senior management, consultants or advisors are currently, or
previously were, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or
potential competitors. Some of these employees, including members of our senior management, executed proprietary rights,
non‑disclosure and non‑competition agreements, or similar agreements, in connection with such previous employment.
Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know‑how
of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual
property, including trade secrets or other proprietary information, of any such individual’s current or former employer.
Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying
monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual
property rights could be awarded to a third party, and we could be required to obtain a license from such third party to
commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to
management. Any of the foregoing may have a material adverse effect on our business, financial condition, results of
operations and prospects.
In addition, while it is our policy to require our employees and contractors who may be involved in the conception or
development of intellectual property to execute agreements assigning such intellectual property to us, we may be
unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we
regard as our own. The assignment of intellectual property rights may not be self‑executing or the assignment agreements
may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us,
to determine the ownership of what we regard as our intellectual property.
If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business
may be materially harmed.
Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may
develop, one or more of our owned or in‑licensed U.S. patents may be eligible for limited patent term extension under the
Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch‑Waxman Amendments. The Hatch‑Waxman
Amendments permit a patent term extension of up to five years as compensation for the patent term lost during the FDA
52
Table of Contents
regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years
from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a
method for using it or a method for manufacturing it may be extended. However, we may not be granted an extension
because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to
apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy
applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than
we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our
competitors may obtain approval of competing products following our patent expiration, and our business, financial
condition, results of operations and prospects could be materially harmed.
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission,
fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced
or eliminated for non‑compliance with these requirements.
Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and patent applications
will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of
our owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees
due to U.S. and non‑U.S. patent agencies. The USPTO and various non‑U.S. government agencies require compliance with
several procedural, documentary, fee payment and other similar provisions during the patent application process. We are also
dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed
intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in
accordance with the applicable rules. There are situations, however, in which non‑compliance can result in abandonment or
lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In
such an event, potential competitors might be able to enter the market with similar or identical products or technology, which
could have a material adverse effect on our business, financial condition, results of operations and prospects.
Intellectual property rights do not necessarily address all potential threats.
The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights
have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For
example:
·
·
·
·
·
·
others may be able to make ADC products that are similar to any product candidates we may develop or utilize
similar ADC‑related technology but that are not covered by the claims of the patents that we license or may own in
the future;
we, or our license partners or current or future strategic partners, might not have been the first to make the
inventions covered by the issued patent or pending patent application that we license or may own in the future;
we, or our license partners or current or future strategic partners, might not have been the first to file patent
applications covering certain of our or their inventions;
others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our owned or licensed intellectual property rights;
it is possible that our pending licensed patent applications or those that we may own in the future will not lead to
issued patents;
issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges
by our competitors;
53
Table of Contents
·
·
·
·
our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major
commercial markets;
we may not develop additional proprietary technologies that are patentable;
the patents of others may harm our business; and
we may choose not to file a patent in order to maintain certain trade secrets or know how, and a third party may
subsequently file a patent covering such intellectual property.
Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of
operations and prospects.
Risks related to our business and industry
If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop
our ADC product candidates, conduct our clinical studies and commercialize our ADC product candidates.
Our ability to compete in the highly competitive biotechnology and biopharmaceutical industries depends upon our ability to
attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on
members of our senior management, including Anna Protopapas, our President and Chief Executive Officer. The loss of the
services of any of our senior management could impede the achievement of our research, development and
commercialization objectives. Also, each of these persons may terminate their employment with us at any time. We do not
maintain “key person” insurance for any of our executives or other employees.
Recruiting and retaining qualified scientific, clinical, sales and marketing personnel will also be critical to our success. We
conduct our operations at our facility in Cambridge, Massachusetts, in a region that is headquarters to many other
biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and
the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or
at all. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous
pharmaceutical and biotechnology companies for similar personnel. In addition, we rely on consultants and advisors,
including scientific and clinical advisors, to assist us in formulating our research and development and commercialization
strategy. Our consultants and advisors, may be employed or have commitments under consulting or advisory contracts with
other entities that may limit their availability to us.
We may encounter difficulties in managing our growth and expanding our operations successfully.
As we seek to advance our product candidates through clinical studies and commercialization, we will need to expand our
development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these
capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various
strategic partners, suppliers and other third parties. Future growth will impose significant added responsibilities on members
of management. Our future financial performance and our ability to commercialize our product candidates and to compete
effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to
manage our development efforts and clinical studies effectively and hire, train and integrate additional management,
administrative and, if necessary, sales and marketing personnel. Due to our limited financial resources and the limited
experience of our management team in managing a company with such anticipated growth, we may not be able to accomplish
these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company or disrupt
our operations.
54
Table of Contents
As a pharmaceutical manufacturer, our activities, including our interactions with healthcare providers, third party payors,
patients and government officials, are, and will continue to be, subject to extensive regulation involving health care, anti-
corruption, data privacy and security and consumer protection laws. Failure to comply with applicable laws could result
in substantial penalties, contractual damages, reputational harm, diminished revenues and curtailment or restructuring of
our operations.
Our activities may now or in the future be directly or indirectly subject to various federal and state laws related to health care,
anti-corruption, data privacy and security consumer protection. If we obtain FDA approval for any of our product candidates
and begin commercializing those products in the United States, our potential exposure under such laws will increase
significantly, and our costs associated with compliance with such laws are also likely to increase. These laws include, but are
not limited to:
·
·
·
·
·
·
·
·
·
·
federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person
from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly
making, or causing to be made, a false statement to get a false claim paid;
the federal anti‑kickback law, which prohibits, among other things, persons from offering, soliciting, receiving or
providing any remuneration, directly or indirectly, to induce, either the referral of an individual, for an item or
service or the purchasing or ordering of a good or service, for which payment may be made under federal health care
programs such as the Medicare and Medicaid;
the federal anti-kickback prohibition known as Eliminating Kickbacks in Recovery Act or EKRA, enacted in 2018,
which prohibits certain payments related to referrals of patients to certain providers (recovery homes, clinical
treatment facilities and laboratories) and applies to services reimbursed by private health plans as well as
government health care programs;
the federal law known as HIPAA, which, in addition to privacy protections to healthcare providers and other entities,
prohibits executing a scheme to defraud any healthcare benefit program (which may include private health plans) or
making false statements relating to healthcare matters;
the FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing
such products for off-label use and regulates the distribution of samples;
federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government
or provide certain discounts or rebates to government authorities or private entities, often as a condition of
reimbursement under government healthcare programs;
the so-called “federal sunshine” law, which requires pharmaceutical and medical device companies to monitor and
report certain financial interactions with certain healthcare providers to the federal government for re-disclosure to
the public (the scope of which reportable interactions will increase for interactions occurring on or after 2021);
the privacy, security and breach provisions of HIPAA, which impose obligations on certain “covered entities”
(healthcare providers, health plans and healthcare clearinghouses) and certain of their “business associate”
contractors with respect to safeguarding the privacy, security and transmission of individually identifiable health
information;
federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers;
the Foreign Corrupt Practices Act, a United States law which regulates certain financial relationships with foreign
government officials (which could include, for example, certain medical professionals); and
55
Table of Contents
·
state law analogues of each of the above federal laws, such as anti‑kickback and false claims laws which may apply
to items or services reimbursed by any third‑party payor, including private health plans, state privacy laws, state
consumer protection laws, and state laws regulating interactions between pharmaceutical manufacturers and
healthcare providers, many of which differ from each other in significant ways and often are not preempted by
federal laws, thus complicating compliance efforts.
In addition, the regulatory approval and commercialization of any of our product candidates outside the United States will
also likely subject us to foreign equivalents of the health care laws mentioned above, among other foreign laws.
Efforts to ensure that our business arrangements will comply with applicable health care laws may involve substantial costs.
It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with
current or future statutes, regulations or case law interpreting applicable fraud and abuse or other health care laws and
regulations. If our operations are found to be in violation of any of the laws described above or any other governmental
regulations that apply to us, we may be subject to penalties, including, without limitation, civil, criminal and administrative
penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other
federal health care programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment
or restructuring of our operations.
Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory
standards and requirements and insider trading.
We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional
failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing
standards we have established, to comply with federal and state health care fraud and abuse laws and regulations, to report
financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and
business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud,
kickbacks, self‑dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of
pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical
studies, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and
deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling
unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits
stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and
we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our
business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement,
possible exclusion from participation in Medicare, Medicaid and other federal health care programs, contractual damages,
reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which
could adversely affect our ability to operate our business and our results of operations.
If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit
commercialization of our ADC product candidates.
We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even
greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes
injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product
liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in
the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer
protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial
liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require
significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:
·
injury to our reputation;
56
Table of Contents
·
·
·
·
·
·
·
·
·
decreased demand for our product candidates or products that we may develop;
withdrawal of clinical study participants;
costs to defend the related litigations;
a diversion of management’s time and our resources;
substantial monetary awards to study participants or patients;
product recalls, withdrawals or labeling, marketing or promotional restrictions;
loss of revenue;
the inability to commercialize our product candidates; and
a decline in our stock price.
Failure to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product
liability claims could prevent or inhibit the commercialization of products we develop. We currently carry product liability
insurance covering our clinical studies in the amount of $10 million in the aggregate. Although we maintain such insurance,
any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in
whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have
various exclusions, and we may be subject to a product liability claim for which we have no coverage. In such instance, we
might have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that
are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. If we are
unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential
product liability claims, it could prevent or inhibit the development and commercial production and sale of our product
candidates, which could adversely affect our business, financial condition, results of operations and prospects.
We and our third‑party contract manufacturers must comply with environmental, health and safety laws and regulations,
and failure to comply with these laws and regulations could expose us to significant costs or liabilities.
We and our third‑party manufacturers are subject to numerous environmental, health and safety laws and regulations,
including those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling,
treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and
biological materials, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or
contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous
materials and wastes. In the event of contamination or injury, or failure to comply with environmental, health and safety laws
and regulations, we could be held liable for any resulting damages and any such liability could exceed our assets and
resources. We could also incur significant costs associated with civil or criminal fines and penalties for failure to comply with
such laws and regulations.
Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to
our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against
potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against
us in connection with our storage or disposal of biological, hazardous or radioactive materials.
Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial
costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future
laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and
regulations also may result in substantial fines, penalties or other sanctions.
57
Table of Contents
Further, with respect to the operations of our third‑party contract manufacturers, it is possible that if they fail to operate in
compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated
with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in
the manufacture and supply of our product candidates or products.
We may acquire assets or form strategic alliances in the future, and we may not realize the benefits of such acquisitions.
We may acquire additional technologies and assets, form strategic alliances or create joint ventures with third parties that we
believe will complement or augment our existing business. If we acquire assets with promising markets or technologies, we
may not be able to realize the benefit of acquiring such assets if we are unable to successfully integrate them with our
existing technologies. We may encounter numerous difficulties in developing, manufacturing and marketing any new
products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or
enhancing our business. We cannot be assured that, following any such acquisition, we will achieve the expected synergies to
justify the transaction.
Our internal computer systems, or those of our strategic partners, third‑party collaborators or other contractors or
consultants, may fail or suffer security breaches, which could adversely affect our business, including through material
disruptions of our programs or business operations.
ransomware, malware, unauthorized access, natural disasters,
Our internal information technology systems and those of our current or future strategic partners, third party collaborators
and other contractors and consultants are vulnerable to service interruptions or security breaches, including from cyber-
terrorism, war and
attacks, computer viruses,
telecommunication and electrical failures. If a failure, accident or security breach were to occur and cause interruptions in our
operations or the operations of those third parties with which we contract, it could result in a material disruption of our
programs and our business operations. We could lose access to our trade secrets or other proprietary information or
experience other disruptions, which could require a substantial expenditure of resources to remedy. For example, the loss of
clinical study data for our product candidates could result in delays in our regulatory approval efforts and significantly
increase our costs to recover or reproduce the data.
We could also be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental
release or loss of information maintained in our information systems and networks, including personal information of our
employees or others. Outside parties may attempt to penetrate our systems or those of the third parties with which we
contract or to coerce or fraudulently induce our employees or employees of such third parties to disclose sensitive
information to gain access to our data. The number and complexity of these threats continue to increase over time. Although
we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process to
identify and mitigate threats, such risks cannot be eliminated. Furthermore, there can be no assurance that we, or those third
parties with which we contract, will promptly detect any such disruption or security breach, if at all. Additionally, the
development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and
updating as technologies change and efforts to overcome security measures become more sophisticated. To the extent that
any disruption or security breach results in a loss of or damage to our data or applications or other data or applications
relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we
could incur liabilities, our competitive position and the market perception of the effectiveness of our security measures could
be harmed, our credibility could be damaged and the further development of our product candidates could be delayed.
We, or the third parties upon whom we depend, may be adversely affected by serious disasters.
Any unplanned event, such as a flood, fire, explosion, earthquake, extreme weather condition, medical epidemic, power
shortage, telecommunication failure or other natural or human-made accidents or incidents that result in us being unable to
fully use our facilities, or the facilities of third-parties with which we contract, may have a material and adverse effect on our
ability to operate our business and have significant negative consequences on our financial and operating conditions. Loss of
access to these facilities may result in increased costs, delays in the development of our current or future product candidates
or the interruption of our business operations for a substantial period of time.
58
Table of Contents
There can be no assurance that the amounts of insurance that we maintain will be sufficient to satisfy any damages and losses
in the event a serious disaster or similar event occurs. If our facilities, or the manufacturing facilities of our third-party
contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short
period of time, any or all of our research and development programs and commercialization efforts may be harmed.
Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.
Our results of operations could be adversely affected by general conditions in the global economy and in the global financial
markets. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A
severe or prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business,
including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable
terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of
the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and
financial market conditions could adversely impact our business.
Risks related to our common stock
We are an “emerging growth company,” as defined in the JOBS Act, and we cannot be certain if the reduced disclosure
requirements applicable to emerging growth companies will make our common stock less attractive to investors.
We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth
company, we may take advantage of exemptions from various reporting requirements that are applicable to other public
companies that are not emerging growth companies, including, but not limited to, (1) not being required to comply with the
auditor attestation requirements of Section 404 of the Sarbanes‑Oxley Act, (2) reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy statements and (3) exemptions from the requirements of holding a
non‑binding advisory vote on executive compensation.
We could be an emerging growth company through 2022, although circumstances could cause us to lose that status earlier,
including if the market value of our common stock held by non‑affiliates exceeds $700.0 million as of any June 30 before
that time or if we have total annual gross revenue of $1.07 billion or more during any fiscal year before that time, in which
cases we would no longer be an emerging growth company as of the following December 31 or, if we issue more than
$1.00 billion in non‑convertible debt during any three‑year period before that time, we would cease to be an emerging
growth company immediately. Even after we no longer qualify as an emerging growth company, we may still qualify as a
“smaller reporting company” which would allow us to take advantage of many of the same exemptions from disclosure
requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the
Sarbanes‑Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy
statements. We cannot predict if investors will find our common stock less attractive because we may rely on these
exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for
our common stock and our stock price may be more volatile. When these exemptions cease to apply, we expect to incur
additional expenses and devote increased management effort toward ensuring compliance with them, and we cannot predict
or estimate the amount or timing of such additional costs.
Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such
time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from
new or revised accounting standards and, therefore, are subject to the same new or revised accounting standards as other
public companies that are not emerging growth companies.
59
Table of Contents
If our stock price is volatile, our stockholders could incur substantial losses.
Our stock price has been and may continue to be volatile. The market price of shares of our common stock could be subject
to wide fluctuations in response to many risk factors listed in this “Risk Factors” section, and others beyond our control,
including:
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
results and timing of preclinical studies and clinical studies of our current or future product candidates, including
XMT‑1536 and XMT-1592;
results of clinical studies of our competitors’ products;
failure to adequately protect our trade secrets;
the terms on which we raise additional capital or our ability to raise it;
commencement or termination of any strategic partnership or licensing arrangement;
regulatory developments, including actions with respect to our products or our competitors’ products;
actual or anticipated fluctuations in our financial condition and operating results;
publication of research reports by securities analysts about us or our competitors or our industry;
our failure or the failure of our competitors to meet analysts’ projections or guidance that we or our competitors may
give to the market;
additions and departures of key personnel;
strategic decisions by us or our competitors, such as acquisitions, divestitures, spin‑offs, joint ventures, strategic
investments or changes in business strategy;
the passage of legislation or other regulatory developments affecting us or our industry;
fluctuations in the valuation of companies perceived by investors to be comparable to us;
sales of our common stock by us (including pursuant to the pre-funded warrants described below), our insiders or
our other stockholders;
speculation in the press or investment community;
announcement or expectation of additional financing efforts;
changes in market conditions for biopharmaceutical stocks; and
changes in general market and economic conditions.
In addition, the stock market has historically experienced significant volatility, particularly with respect to pharmaceutical,
biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences
company stocks often does not relate to the operating performance of the companies represented by the stock. As a result of
this volatility, stockholders may not be able to sell their common stock at or above the price for which they paid for their
shares. As we operate in a single industry, we are especially vulnerable to these factors to the extent that they affect our
industry or our products, or to a lesser extent our markets. Furthermore, as a result of this volatility, we may not
60
Table of Contents
be able to maintain compliance with listing requirements of the Nasdaq Stock Market. In the past, securities class action
litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation
could result in substantial costs and divert our management’s attention and resources, and could also require us to make
substantial payments to satisfy judgments or to settle litigation.
Our principal stockholders and management own a significant percentage of our stock and are able to exercise significant
influence over matters subject to stockholder approval.
As of December 31, 2019, our executive officers, directors and stockholders who own more than 5% of our outstanding
common stock, together with their respective affiliates, beneficially owned a significant amount of our common stock,
including shares subject to outstanding options and warrants that are exercisable within 60 days after such date. Accordingly,
these stockholders are able to exert a significant degree of influence over our management and affairs and over matters
requiring stockholder approval, including the election of our board of directors and approval of significant corporate
transactions. This concentration of ownership could have the effect of entrenching our management or board of directors,
delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain
control of us, which in turn could have a material and adverse effect on the fair market value of our common stock.
We are incurring and will continue to incur significant increased costs as a result of operating as a public company, and
our management is required to devote substantial time to compliance requirements and initiatives.
As a public company, we are incurring and will continue to incur significant legal, insurance, accounting and other expenses
that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules of the SEC and The Nasdaq Stock
Market have imposed various requirements on public companies, including requiring establishment and maintenance of
effective disclosure and financial controls. Our management and other personnel need to devote a substantial amount of time
to these compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase our legal
and financial compliance costs and will make some activities more time-consuming and costly.
We do not expect to pay any cash dividends for the foreseeable future.
We do not anticipate that we will pay any cash dividends to holders of our common stock in the foreseeable future. Instead,
we plan to retain any earnings to maintain and expand our operations. In addition, our credit facility contains terms and any
future debt financing arrangement may contain additional terms prohibiting or limiting the amount of dividends that may be
declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price
appreciation, which may never occur, as the only way to realize any return on their investment.
Provisions in our amended and restated certificate of incorporation, our amended and restated by‑laws and Delaware law
may have anti‑takeover effects that could discourage an acquisition of us by others, even if an acquisition would be
beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current
management.
Our amended and restated certificate of incorporation, amended and restated by‑laws and Delaware law contain provisions
that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that
stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium
for their shares. Our amended and restated certificate of incorporation and by‑laws include provisions that:
·
·
·
authorize “blank check” preferred stock, which could be issued by our board of directors without stockholder
approval and may contain voting, liquidation, dividend and other rights superior to our common stock;
create a classified board of directors whose members serve staggered three‑year terms;
specify that special meetings of our stockholders can be called only by our board of directors;
61
Table of Contents
·
·
·
·
·
·
·
prohibit stockholder action by written consent;
establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our
stockholders, including proposed nominations of persons for election to our board of directors;
provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even
though less than a quorum;
provide that our directors may be removed only for cause;
specify that no stockholder is permitted to cumulate votes at any election of directors;
expressly authorize our board of directors to have discretion to modify, alter or repeal our amended and restated
by‑laws; and
require supermajority votes of the holders of our common stock to amend specified provisions of our amended and
restated certificate of incorporation and amended and restated by‑laws.
These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our
management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our
common stock, thereby depressing the market price of our common stock.
In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section 203 of the
General Corporation Law of the State of Delaware, or the DGCL, which prohibits a person who owns in excess of 15% of
our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in
which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in
a prescribed manner.
Any provision of our amended and restated certificate of incorporation, amended and restated by‑laws or Delaware law that
has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a
premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our
common stock.
The 2017 Tax Act could adversely affect our business and financial condition.
On December 22, 2017, the U.S. President signed into law legislation commonly called the “Tax Cuts and Jobs Act” (the
2017 Tax Act) that significantly revises the Internal Revenue Code of 1986, as amended (the Code). The 2017 Tax Act,
among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a
top marginal rate of 35% to a rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings
(except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable
income in respect of net operating losses generated during or after 2018 and elimination of net operating loss carrybacks,
immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying
or repealing many business deductions and credits. Notwithstanding the reduction in the corporate income tax rate, the
overall impact of the 2017 Tax Act is uncertain and our business and financial condition could be adversely affected. In
addition, it is uncertain if and to what extent various states will conform to the federal tax law. The impact of this tax reform
on holders of our common stock is also uncertain and could be adverse. We urge you to consult with your legal and tax
advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock.
62
Table of Contents
Our ability to use net operating losses and certain tax credit carryforwards may be subject to certain limitations.
For the years ended December 31, 2019, 2018 and 2017, the Company recorded no income tax benefit for the net operating
losses incurred in each year, due to the uncertainty of realizing a benefit from those items. The Company has incurred net
operating losses (NOLs) since its inception. As of December 31, 2019, the Company had federal NOLs of approximately
$163.5 million and state NOLs of approximately $98.5 million. Of the $163.5 million of federal NOLs, $34.1 million expire
at various dates through 2037. The remaining $129.3 million of federal NOLs do not expire. The state NOLs will expire at
various dates through 2039. As of December 31, 2019, the Company had Federal and State research and development tax
credit carryforwards of approximately $2.0 million and $0.7 million, respectively, which expire at various dates through
2039. Under the 2017 Tax Act, federal NOLs incurred in 2019 and in future years may be carried forward indefinitely, but the
deductibility of such federal NOLs is limited. It is uncertain if and to what extent various states will conform to the 2017 Tax
Act. In addition, under Section 382 of the Internal Revenue Code, and corresponding provisions of state law, if a corporation
undergoes an “ownership change,” which is generally defined as a greater than 50% change, by value, in its equity ownership
over a three-year period, the corporation’s ability to use its pre-change NOLs and other pre-change tax attributes to offset its
post-change income or taxes may be limited. Our past issuances of stock and other changes in our stock ownership may have
resulted in ownership changes within the meaning of Section 382 of the Code; accordingly, our pre-change NOLs may be
subject to limitation under Section 382. If we determine that we have not undergone an ownership change, the Internal
Revenue Service could challenge our analysis, and our ability to use our NOLs to offset taxable income could be limited by
Section 382 of the Code. Future changes in our stock ownership, some of which are outside of our control, could result in
ownership changes under Section 382 of the Code further limiting our ability to utilize our NOLs. Our NOLs may also be
impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs. The Company has
determined that ownership changes have occurred since our inception and that certain NOLs and research and development
tax credit carryforwards will be subject to limitation. We may also have incurred subsequent ownership changes.
Furthermore, our ability to utilize our NOLs is conditioned upon our attaining profitability and generating U.S. federal
taxable income. We have incurred net losses since our inception and anticipate that we will continue to incur significant
losses for the foreseeable future; thus, we do not know whether or when we will generate the U.S. federal taxable income
necessary to utilize our NOLs. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets
due to the uncertainty of the ultimate realization of the future benefits of those assets.
Our amended and restated certificate of incorporation designates the state or federal courts within the State of Delaware
as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could
limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or
employees.
Our amended and restated certificate of incorporation provides that, subject to limited exceptions, the state or federal courts
within the State of Delaware will be exclusive forums for (1) any derivative action or proceeding brought on our behalf,
(2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us
or our stockholders, (3) any action asserting a claim against us arising pursuant to any provision of the DGCL, our amended
and restated certificate of incorporation or our amended and restated by‑laws or (4) any other action asserting a claim against
us that is governed by the internal affairs doctrine. Any person or entity that purchases or otherwise acquires any interest in
shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and
restated certificate of incorporation described above. This choice of forum provision may limit a stockholder’s ability to
bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees,
which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to
find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of,
one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such
matters in other jurisdictions, which could adversely affect our business and financial condition.
ITEM 1B. UNRESOLVED STAFF COMMENTS.
None.
63
Table of Contents
ITEM 2. PROPERTIES.
Our corporate headquarters are located in Cambridge, Massachusetts. We occupy approximately 34,000 square feet of office
and laboratory space that we lease in a multi-tenant building in which our corporate headquarters are located. We have an
option to extend the lease term for an additional five years thereafter. We believe that this office and laboratory space is
sufficient to meet our current needs, and that suitable additional space will be available as and when needed.
ITEM 3. LEGAL PROCEEDINGS.
From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our
business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this
Annual Report on Form 10-K, we do not believe we are party to any claim or litigation, the outcome of which, if determined
adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our
business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs,
diversion of management resources and other factors.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
64
Table of Contents
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS
AND ISSUER PURCHASES OF EQUITY SECURITIES
Certain Information Regarding the Trading of Our Common Stock
Our common stock trades under the symbol “MRSN” on the Nasdaq Global Select Market. As of February 25, 2020, there
were approximately 36 holders of record of shares of our common stock.
Dividend Policy
We have never declared nor paid cash dividends on our common stock. We currently intend to retain all of our future
earnings, if any, to finance the growth and development of our business. We do not intend to pay cash dividends in respect of
our common stock in the foreseeable future. Any future determination to pay cash dividends will be made at the discretion of
our board of directors and will depend on restrictions and other factors our board of directors may deem relevant. Investors
should not purchase our common stock with the expectation of receiving cash dividends.
Stock Performance Graph
The following performance graph and related information shall not be deemed to be “soliciting material” or to be “filed” with
the Securities and Exchange Commission, or SEC, for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or the Exchange Act, nor shall such information be incorporated by reference into any future filing under the
Exchange Act or Securities Act of 1933, as amended, or the Securities Act, except to the extent that we specifically
incorporate it by reference into such filing.
The following graph compares the performance of our common stock to the Nasdaq Composite Index and to the Nasdaq
Biotechnology Index from June 28, 2017 (the first date that shares of our common stock were publicly traded) through
December 31, 2019, which was the last trading day of the year. The comparison assumes $100 was invested in our common
stock and in each of the foregoing indices after the market closed on June 28, 2017, and it assumes reinvestment of
dividends, if any. The stock price performance included in this graph is not necessarily indicative of future stock price
performance.
65
Table of Contents
ITEM 6. SELECTED FINANCIAL DATA
You should read the following selected financial data together with our financial statements and the related notes appearing
elsewhere in this Annual Report on Form 10-K and the information under the heading “Management’s Discussion and
Analysis of Financial Condition and Results of Operations.” We have derived the statement of operations data for the years
ended December 31, 2019, 2018 and 2017 and the balance sheet data as of December 31, 2019 and 2018 from our audited
financial statements included elsewhere in this Annual Report on Form 10-K. The historical statement of operations data for the
years ended December 31, 2016 and 2015 and the historical balance sheet data as of December 31, 2017, 2016 and 2015 have been
derived from audited financial statements not included in this Annual Report on Form 10-K. All financial information presented has
been consolidated and reflects the operations of Mersana Therapeutics Inc. and its wholly-owned subsidiaries. Our historical results
are not necessarily indicative of results expected in any future period. The selected historical financial information in this section is
not intended to replace our consolidated financial statements and the related notes thereto.
Statements of Operations Data:
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Other income (expense):
Interest income
Interest expense
Total other income (expense), net
Net loss
Net loss attributable to common stockholders —
basic and diluted(1)
Net loss per share attributable to common
stockholders — basic and diluted(1)
Weighted-average number of shares of common
stock used in net loss per share attributable to
common stockholders — basic and diluted(1)
Balance Sheet Data:
Cash, cash equivalents and marketable securities
Working capital(2)
Total assets
Long-term debt, net of discount
Convertible preferred stock
Total stockholders’ equity (deficit)
2019
2018
Year ended
December 31,
2017
(in thousands, except
share and per share data)
2016
2015
$
42,123 $
10,594 $
17,545 $
25,171 $
10,359
55,040
17,283
72,323
59,915
16,334
76,249
46,700
10,462
57,162
32,008
6,984
38,992
21,353
5,347
26,700
2,226
(234)
1,992
(28,208) $
1,398
—
1,398
(64,257) $
910
—
910
(38,707) $
121
—
121
(13,700) $
2
(89)
(87)
(16,428)
$
$
(28,208) $
(64,257) $
(38,707) $
(13,700) $
(16,428)
$
(0.65) $
(2.79) $
(3.22) $
(10.82) $
(13.43)
43,492,113
23,032,250 12,022,733 1,266,758 1,223,457
2019
2018
Year ended
December 31,
2017
(in thousands)
2016
2015
$ 99,790 $ 70,131 $125,216 $100,297 $ 11,534
2,019
14,409
—
36,296
(42,692)
73,787
105,087
—
94,450
(55,619)
77,256
107,541
4,201
—
78,318
85,662
130,715
—
—
69,994
4,880
78,502
—
—
8,795
(1)
(2)
See Note 2 to our financial statements appearing elsewhere in this Annual report on Form 10-K for further details on
the calculation of basic and diluted net loss per share applicable to common stockholders.
We define working capital as current assets less current liabilities.
66
Table of Contents
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with
our audited financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K.
Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or
indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future
performance and that our actual results of operations, financial condition and liquidity, and the development of the industry
in which we operate may differ materially from the forward-looking statements contained in this Annual Report. In addition,
even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate
are consistent with the forward-looking statements contained in this Annual Report, they may not be predictive of results or
developments in future periods.
The following information and any forward-looking statements should be considered in light of factors discussed elsewhere
in the Annual Report on Form 10-K, including those risks identified under Part II, Item 1A. Risk Factors.
We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the
date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly
update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on
which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in
the forward-looking statements.
Overview
We are a clinical-stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a
clinically meaningful benefit for cancer patients with significant unmet need. We have leveraged 20 years of industry
learning in the ADC field to develop proprietary and differentiated technology platforms that enable us to design ADCs to
have improved efficacy, safety and tolerability relative to existing ADC therapies.
We believe that our innovative platforms which include Dolaflexin and Dolasynthen, delivering our DolaLock payload, as
well as Immunosynthen, delivering a novel stimulator of interferon genes, or STING, agonist, compose a highly efficient
product engine that has enabled a robust discovery pipeline for us and our partners. Our ADCs in preclinical and clinical
studies are first-in-class molecules that target multiple tumor types with high unmet medical need and have exhibited
improved safety and efficacy compared to ADCs developed using first-generation technology.
Our goal is to become a leading oncology company by leveraging the potential of our innovative and differentiated ADC
technologies and the experience and competencies of our management team to identify, acquire and develop promising ADC
product candidates and to commercialize cancer therapeutics that are improvements over existing treatments.
XMT-1536, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin
platform to deliver an average of 10-12 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed
in NSCLC adenocarcinoma and ovarian cancer with limited expression in normal tissue. We are actively recruiting and
dosing patients with ovarian cancer and NSCLC adenocarcinoma, where a majority of patients express NaPi2b in a Phase 1
clinical trial.
We have selected our next clinical product candidate, XMT-1592. XMT-1592 uses one of our new platforms, Dolasynthen,
and also targets NaPi2b. XMT-1592 comprises the same proprietary NaPi2b antibody and potent auristatin DolaLock
payload with controlled bystander effect as XMT-1536, with the additional features of homogeneous, site-specific
bioconjugation and precise DAR.
67
Table of Contents
Our early stage programs include a potentially first-in-class B7-H4-targeted DolaLock ADC addressing areas of high unmet
medical need. Our objective is to rapidly progress through IND-enabling studies and scale up manufacturing activities with
third parties. B7-H4 provides significant opportunities for development in areas of high unmet need such as breast cancer,
NSCLC and ovarian cancer.
In addition, we have established strategic research and development partnerships with Merck KGaA and Asana Biosciences
for the development and commercialization of additional ADC product candidates against a limited number of targets
selected by our partners based on our Fleximer platform. We believe the potential of our ADC technologies, supported by our
world class management team and protected by our robust intellectual property portfolio, will allow us to develop targeted
and highly tailored therapies to help cancer patients become cancer survivors.
Since inception, our operations have focused on building our platforms, identifying potential product candidates, producing
drug substance and drug product material for use in preclinical studies, conducting preclinical and toxicology studies,
manufacturing clinical study material and conducting clinical studies, establishing and protecting our intellectual property,
staffing our company and raising capital. We do not have any products approved for sale and have not generated any revenue
from product sales. We have funded our operations primarily through our strategic partnerships, private placements of our
convertible preferred stock and public offerings of our common stock.
Since inception, we have incurred significant cumulative operating losses. Our net losses were $28.2 million, $64.3 million
and $38.7 million for the years ended December 31, 2019, 2018 and 2017, respectively. As of December 31, 2019, we had an
accumulated deficit of $192.4 million. We expect to continue to incur significant expenses and operating losses over the next
several years. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:
·
·
·
·
continue clinical development activities for our lead product candidate XMT-1536 and anticipate initiating clinical
development activities for XMT-1592;
initiate first-in-human studies for our next clinical candidate XMT-1592;
develop a research assay and companion diagnostic for the NaPi2b biomarker;
continue activities to discover, validate and develop additional product candidates;
· maintain, expand and protect our intellectual property portfolio; and
·
hire additional research, development and general and administrative personnel.
Financial Operations Overview
Revenue
To date, we have not generated any revenue from the sale of products. All of our revenue has been generated from strategic
partnerships.
In June 2014, we entered into an agreement with Merck KGaA for the development and commercialization of ADC product
candidates utilizing Fleximer for up to six target antigens. Merck KGaA is responsible for generating antibodies against the
target antigens and we are responsible for generating Fleximer and our proprietary payloads and conjugating this to the
antibody to create the ADC product candidates. Merck KGaA has the exclusive right to and is responsible for the further
development and commercialization of these ADC product candidates. In May 2018, we entered into a supply agreement
with Merck KGaA for the supply of materials that could be used for IND-enabling studies and clinical trials.
For the years ended December 31, 2019, 2018 and 2017, we recognized revenue of $2.1 million, $2.4 million and $3.6
million, respectively, related to the Merck KGaA agreements.
68
Table of Contents
In January 2016, we entered into collaboration agreements with Takeda for the development and commercialization of XMT-
1522, a HER2-targeted ADC, and up to seven ADC product candidates utilizing Fleximer. The Company’s collaboration
agreements with Takeda were terminated during the first quarter of 2019.
We recognized the remaining deferred revenue of $40.0 million related to the termination of the Takeda agreements in the
first quarter of 2019. We do not expect to have any further revenue related to these agreements.
We have provided limited services to Asana BioSciences. For the years ended December 31, 2019, 2018 and 2017, we
recorded an immaterial amount of revenue and revenue of $0.8 million and $0.1 million, respectively, related to those
services. In addition, we recognized revenue of $1.5 million related to a milestone achieved during the third quarter of 2018.
For the foreseeable future, we expect substantially all of our revenue to be generated from our collaboration agreements with
Merck KGaA and Asana BioSciences. Given the uncertain nature and timing of clinical development, we cannot predict
when or whether we will receive further milestone payments or any royalty payments under these collaborations.
For information about our revenue recognition policy, see the notes to consolidated financial statements included in this
Annual Report on Form 10-K.
Expenses
Research and Development Expenses
Research and development expenses consist primarily of costs incurred for our research and development activities,
including our drug discovery efforts, and the development of our product candidates, which include:
·
·
·
·
·
employee-related expenses, including salaries, benefits, and stock-based compensation expense;
costs of funding research and development performed by third parties that conduct research, preclinical activities,
manufacturing and clinical studies on our behalf;
laboratory supplies;
facility costs, including rent, depreciation and maintenance expenses; and
upfront and milestone payments under our third-party licensing agreements.
Research and development costs are expensed as incurred. Costs of certain activities, such as manufacturing, preclinical and
clinical studies, are generally recognized based on an evaluation of the progress to completion of specific tasks. Costs for
certain development activities, such as clinical studies, are recognized based on an evaluation of the progress to completion
of specific tasks using data such as patient enrollment, clinical site activations and information provided to us by the third
parties with whom we contract.
Research and development activities are central to our business model. Product candidates in later stages of clinical
development generally have higher development costs than those in earlier stages of clinical development, primarily due to
the increased size and duration of later-stage clinical trials and manufacturing costs. We expect that our total future research
and development costs will continue to increase over current levels, depending on the progress of our clinical development
programs. There are numerous factors associated with the successful development and commercialization of any of our
product candidates, including future trial design and various regulatory requirements, many of which cannot be determined
with accuracy at our current stage of development. Additionally, future commercial and regulatory factors beyond our control
may impact our clinical development programs and plans.
69
Table of Contents
A significant portion of our research and development costs have been external costs, which we track on a program-by-
program basis following nomination as a product candidate. We have not historically tracked all of our internal research and
development expenses on a program-by-program basis as they are deployed across multiple projects under development. The
following table summarizes our external research and development expenses, by program, following nomination as a
development candidate for the years ended December 31, 2019, 2018 and 2017. All external research and development
expenses not attributable to the XMT-1536 and XMT-1522 programs are captured within preclinical and discovery costs.
These costs relate to our next ADC clinical candidate, XMT-1592, as well as additional earlier discovery stage programs and
certain unallocated costs. We terminated the development of XMT-1522 in the first quarter of 2019. Our internal research and
development costs are primarily personnel-related costs, stock-based compensation costs, facility costs, including
depreciation, and lab consumables. Pre-development candidate expenses, unallocated costs and internal research and
development costs have been stated separately.
(in thousands)
XMT-1536 external costs
XMT-1522 external costs
Preclinical and discovery costs
Internal research and development costs
Total research and development costs
2019
9,461
1,936
16,980
26,663
55,040
$
$
$
Year ended
December 31,
2018
15,922 $
15,562
4,517
23,914
59,915 $
$
2017
8,647
14,661
3,093
20,299
46,700
The successful development of our product candidates is highly uncertain. As such, we cannot reasonably estimate or know
the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of
our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from the
development efforts associated with our product candidates. This is due to the numerous risks and uncertainties associated
with developing drugs, including the uncertainty of:
·
·
·
·
·
·
·
successful completion of preclinical studies and IND-enabling studies;
successful enrollment in and completion of clinical studies;
receipt of marketing approvals from applicable regulatory authorities;
establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;
commercializing the product candidates, if and when approved, whether alone or in collaboration with others; and
continued acceptable safety profile of the drugs following approval.
A change in the outcome of any of these variables with respect to the development, manufacture or commercialization of any
of our product candidates would significantly change the costs, timing and viability associated with the development of that
product candidate.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and other employee-related costs, including stock-based
compensation, for personnel in executive, finance, accounting, business development, legal operations, information
technology and human resources functions. Other significant costs include facility costs not otherwise included in research
70
Table of Contents
and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting
services.
We anticipate that our general and administrative expenses will increase in the future to support continued research and
development activities, including increased costs related to the hiring of additional personnel, fees to outside consultants and
patent costs, among other expenses.
Other Income (Expense)
Other income (expense) consists primarily of interest income earned on cash equivalents and marketable securities. Interest
expense is related to the credit facility that we entered into on May 9, 2019, with Silicon Valley Bank. It bears a floating per
annum rate interest, as well as a final payment of 5% of the amounts drawn, that is being recorded as interest expense over
the term through the maturity date using the effective-interest method. Also included in interest expense is the amortization
of the deferred financing costs and the accretion of debt discount relating to the credit facility.
Results of Operations
Comparison of Years Ended December 31, 2019 and 2018
The following table summarizes our results of operations for the years ended December 31, 2019 and 2018, together with the
changes in those items:
(in thousands)
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Other income (expense):
Interest income
Interest expense
Total other income (expense), net
Net loss
Collaboration Revenue
Year ended
December 31,
2019
42,123 $
2018
10,594 $
Dollar Change
31,529
$
55,040
17,283
72,323
2,226
(234)
1,992
59,915
16,334
76,249
1,398
—
1,398
$ (28,208) $ (64,257) $
(4,875)
949
(3,926)
828
(234)
594
36,049
Collaboration revenue was $42.1 million during the year ended December 31, 2019, compared to $10.6 million during
the year ended December 31, 2018, an increase of $31.5 million, primarily as a result of the termination of the Takeda
agreements and the recognition of the remaining deferred revenue of $40.0 million in early 2019. Additionally, revenue of
$2.1 million was recognized in connection with the Merck KGaA Agreement and Merck KGaA Supply Agreement in the
year ended December 31, 2019. This compares to the revenue recognized during the year ended December 31, 2018 for
support of partner programs with Takeda, Merck KGaA and Asana BioSciences of $9.1 million and recognition of a
milestone of $1.5 million achieved upon completion of a GLP toxicology study by Asana BioSciences.
71
Table of Contents
Research and Development Expense
Research and development expense was $55.0 million for the year ended December 31, 2019, compared to $59.9 million for
the year ended December 31, 2018. The overall decrease of $4.9 million was primarily attributable to the following:
·
·
decrease of $13.5 million related to the development and manufacturing activities for XMT-1522; and
decrease of $9.0 million related to manufacturing activities for XMT-1536.
These decreased costs were partially offset by the following:
·
·
·
·
·
·
increase of approximately $8.3 million related to preclinical development and manufacturing activities for XMT-
1592;
increase of approximately $3.0 million related to XMT-1536 clinical and regulatory expenses;
increase of approximately $3.0 million related to research efforts to further platform development and evaluate
potential product candidates;
increase of $1.8 million related to employee compensation, including stock-based compensation expense;
increase of $0.8 million related to advancement of companion diagnostic development efforts for the NaPi2B
biomarker; and
increase of $0.6 million related to a milestone paid upon dosing of the first patient in the expansion cohort of the
XMT-1536 clinical trial.
We expect our research and development expenses to increase as we continue our clinical development XMT-1536 and
XMT-1592 and continue to advance our preclinical product candidate pipeline and invest in improvements in our ADC
technologies.
General and Administrative Expense
General and administrative expense was $17.3 million for the year ended December 31, 2019, compared to $16.3 million for
the year ended December 31, 2018. The overall increase of $0.9 million was primarily attributable to the increase in stock-
based compensation expense.
We expect that our general and administrative expense will increase in the future to support continued research and
development activities. These increases will likely include legal, auditing and filing fees, additional insurance premiums and
general compliance and consulting expenses.
Total Other Income (Expense), Net
Total other income (expense), net was $2.0 million and $1.4 million for the years ended December 31, 2019 and 2018,
respectively. Other income consists primarily of interest income on cash equivalents and short-term marketable securities,
which increased $0.8 million due to higher investable balances for the year ended December 31, 2019. Interest expense of
$0.2 million was related to our outstanding borrowings under the credit facility.
72
Table of Contents
Comparison of Years Ended December 31, 2018 and 2017
The following table summarizes our results of operations for the years ended December 31, 2018 and 2017, together with the
changes in those items:
(in thousands)
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Other income (expense):
Interest income
Interest expense
Total other income (expense), net
Net loss
Collaboration Revenue
Year ended
December 31,
2018
10,594 $
2017
17,545 $
Dollar Change
(6,951)
$
59,915
16,334
76,249
1,398
—
1,398
46,700
10,462
57,162
910
—
910
$ (64,257) $ (38,707) $
13,215
5,872
19,087
488
—
488
(25,550)
The decrease in collaboration revenue from $17.5 million during the year ended December 31, 2017 to $10.6 million for the
year ended December 31, 2018 was primarily the result of a decrease in efforts to support partner programs and a third
quarter 2018 increase in total projected efforts associated with longer anticipated timelines, as a result of partial clinical hold,
used to recognize XMT-1522 revenue. In addition, the year ended December 31, 2017 included a $4.0 million increase in
revenue relating to changes in estimates of the costs to complete services under the Takeda agreements.
Research and Development Expense
Research and development expense increased by $13.2 million from $46.7 million for the year ended December 31, 2017 to
$59.9 million for the year ended December 31, 2018, an increase of 28%.
The increase in research and development expense was primarily attributable to the following:
·
·
·
·
·
approximately $2.3 million in increased employee compensation and $0.7 million in increased lab consumables both
primarily due to an increase in headcount as our programs progressed in clinical and preclinical studies;
approximately $9.3 million in increased external research and development expenses for manufacturing activities
for XMT-1536 and XMT-1522, as well as research efforts to further platform development and evaluate potential
product candidates;
approximately $2.9 million in increased external clinical and regulatory expenses due primarily to the
commencement of our first in-human trials for XMT-1536; and
approximately $1.5 million in increased lab consumables and facilities costs;
partially offset by a reduction of approximately $2.8 million related to milestone payments in 2017 in connection
with the XMT-1522 and XMT-1536 clinical trials, which were non-recurring events.
We expect our research and development expenses to increase as we continue our clinical development of XMT-1536 and
continue to advance our preclinical product candidate pipeline and invest in improvements in our ADC technologies.
73
Table of Contents
General and Administrative Expense
General and administrative expense increased by $5.9 million from $10.5 million during the year ended December 31, 2017
to $16.3 million for the year ended December 31, 2018, an increase of 56%.
The increase in general and administrative expense was primarily attributable to the following:
·
·
·
approximately $3.0 million in increased personnel costs primarily due to additional headcount as we built the
infrastructure to support the growth of the research and development organization;
approximately $1.7 million in increased professional fees, including external legal fees, corporate communications
and public relations costs to support operations as a growing public company; and
approximately $1.0 million in increased other costs, including insurance, software and franchise taxes.
We expect that our general and administrative expense will increase in future periods as we expand our operations and incur
additional costs in connection with being a public company. These increases will likely include legal, auditing and filing fees,
additional insurance premiums and general compliance and consulting expenses.
Other Income
Other income increased by $0.5 million from $0.9 million for the year ended December 31, 2017 to $1.4 million for the year
ended December 31, 2018. The change in other income was primarily due to increased interest income in the year ended
December 31, 2018.
Liquidity and Capital Resources
Sources of Liquidity
Since the closing of our initial public offering in July 2017, we have financed our operations primarily with the proceeds
from that offering and our 2019 follow-on public offering. The follow-on public offering was completed on March 5, 2019
and resulted in net proceeds of $92.2 million. On May 8, 2019, the Company entered into a term-loan agreement for up to
$20.0 million, of which $5.0 million was funded in connection with the execution of the agreement. No additional amounts
have been drawn since the initial $5.0 million. As of December 31, 2019, we had cash, cash equivalents and short-term
marketable securities of $99.8 million.
On July 2, 2018, we established an ATM pursuant to which we are able to offer and sell up to $75.0 million of our common
stock from time to time at prevailing market prices. As of December 31, 2019, we had not sold any shares under the ATM
and had $75.0 million of potential availability under the program.
Cash Flows
The following table provides information regarding our cash flows for the years ended December 31, 2019, 2018 and 2017:
(in thousands)
Net cash used in operating activities
Net cash provided by (used in) investing activities
Net cash provided by financing activities
Increase (decrease) in cash, cash equivalents and restricted cash
74
2019
Year ended
December 31,
2018
$ (67,744) $ (55,216) $ (42,679)
(99,624)
87,195
1,064
68,597
33,043 $ (73,706)
(27,293)
97,704
2,667 $
$
2017
Table of Contents
Net Cash Used in Operating Activities
Net cash used in operating activities was $67.7 million for the year ended December 31, 2019 and primarily consisted of a
net loss of $28.2 million adjusted for non-cash items including stock-based compensation of $4.9 million and depreciation of
$1.2 million, as well as change in our net working capital and the decrease in deferred revenue of $41.4 million primarily
related to Takeda agreements. Net cash used in operating activities was $55.2 million for the year ended December 31, 2018
and primarily consisted of a net loss of $64.3 million adjusted for non-cash items including stock-based compensation of $3.9
million and depreciation of $1.3 million, as well as change in our net working capital and the decrease in deferred revenue of
$6.2 million. Net cash used in operating activities was $42.7 million for the year ended December 31, 2017 and primarily
consisted of a net loss of $38.7 million adjusted for non-cash items including stock-based compensation of $1.4 million and
depreciation of $0.9 million, as well as change in our net working capital and the decrease in deferred revenue of $9.9
million.
Net Cash Provided by (Used in) Investing Activities
Net cash used in investing activities was $27.3 million during the year ended December 31, 2019 compared to net cash
provided by investing activities of $87.2 million during the year ended December 31, 2018. Net cash used in investing
activities for the year ended December 31, 2019 consisted primarily of purchases of marketable securities, partially offset by
maturities of marketable securities. Net cash provided by investing activities for the year ended December 31, 2018 consisted
primarily of maturities of marketable securities. Net cash used in investing activities for the year ended December 31, 2017
consisted primarily of purchases of marketable securities offset by maturities of marketable securities.
Net Cash Provided by Financing Activities
Net cash provided by financing activities was $97.7 million during the year ended December 31, 2019 compared to net cash
provided by financing activities of $1.1 million during the year ended December 31, 2018. During the year ended December
31, 2019 cash provided by financing activities consisted primarily of the proceeds from our follow-on public offering of our
common stock and issuance of debt. During the year ended December 31, 2018 cash provided by financing activities
consisted primarily of the proceeds from the exercise of stock options. During the year ended December 31, 2017 cash
provided by financing activities consisted primarily of the proceeds from our initial public offering.
Funding Requirements
We expect our cash expenditures to increase in connection with our ongoing activities, particularly as we continue the
research and development of, initiate clinical studies of, and seek marketing approval for our product candidates. In addition,
if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses
related to drug sales, marketing, manufacturing and distribution to the extent that such sales, marketing and distribution are
not the responsibility of potential collaborators.
Our future capital requirements will depend on many factors, including:
·
·
·
·
·
the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical
studies for our product candidates;
the scope, prioritization and number of our research and development programs;
the costs, timing and outcome of regulatory review of our product candidates;
our ability to establish and maintain collaborations on favorable terms, if at all;
the achievement of milestones or occurrence of other developments that trigger payments under any collaboration
agreements we obtain;
75
Table of Contents
·
·
·
·
·
the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical study costs under future
collaboration agreements, if any;
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property
rights and defending intellectual property‑related claims;
the extent to which we acquire or in‑license other product candidates and technologies;
the costs of securing manufacturing arrangements for clinical and commercial production; and
the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to
market our product candidates.
We plan to raise funds from collaborations, licensing agreements or other strategic partnerships or raise additional capital
through the issuance and sale of our common stock. There is inherent uncertainty associated with these fundraising
activities. In the absence of such funding, we plan to strategically manage uncommitted spend to execute our priorities and
implement cost-saving measures to reduce research and development and general and administrative expenditures which
could include limiting or delaying or terminating preclinical studies or other development activities for one or more of our
ADC product candidates. Therefore, we estimate that our cash, cash equivalents and marketable securities are sufficient to
fund our operating plan through at least the next twelve months following the filing of our Annual Report on Form 10-K,
including our Phase 1 clinical study for XMT-1536 and our planned dose escalation study for XMT-1592.
Identifying potential product candidates and conducting preclinical testing and clinical studies is a time‑consuming,
expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results
required to obtain marketing approval and achieve drug sales. In addition, our product candidates, if approved, may not
achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be
commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to
achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.
Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a
combination of equity offerings, debt financings, strategic partnerships and licensing arrangements. To the extent that we
raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common
stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect the rights of our common stockholders. We have access to an additional line of credit of $15.0 million under the Credit
Facility along with funds to be earned in connection with our agreements with Merck KGaA and Asana BioSciences, if
development activities are successful under those agreements. Future additional debt financing, if available, may involve
agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt,
making capital expenditures or declaring dividends.
If we raise funds through additional strategic partnerships or licensing arrangements with third parties, we may have to
relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant
licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings
when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization
efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market
ourselves.
76
Table of Contents
The following table summarizes our significant contractual obligations as of payment due date by period at December 31,
2019:
Contractual Obligations
(in thousands)
Lease commitments(1)
Long-term debt obligations(2)
Total
Total
Less than
1 Year
1 to 3
Years
3 to 5
Years
$ 3,489 $ 2,510 $
887 $
5,648
867
4,196
$ 9,137 $ 3,377 $ 5,083 $
More than
5 years
—
—
—
92 $
585
677 $
(1) Represents future minimum lease payments under our non‑cancelable operating and finance leases, which expire
through February 2024. The minimum lease payments above do not include any related common area maintenance
charges or real estate taxes.
(2) Represents future debt principal plus interest and final payments under our term-loan, which is payable in full on
February 1, 2023. Refer to footnote 8 in the Notes to the Consolidated Financial Statements.
We enter into agreements in the normal course of business with contract research organizations, contract manufacturing
organizations and institutions to license intellectual property. We have not included these payments in the table of contractual
obligations above since the contracts are cancelable at any time by us, generally upon 30 days prior written notice.
In July 2015, we entered into a license agreement with Recepta Biopharma S.A., or Recepta, as amended, for the NaPi2b
antibody. Under this agreement, we paid Recepta an upfront payment of $1.0 million and are obligated to pay Recepta up to
$65.5 million in development, regulatory and commercial milestones and tiered royalties in the low‑single digit percentages
on net sales of products outside of Brazil until the expiration of the royalty term. Upon the expiration of each royalty term in
each country for each applicable product, the exclusive licenses granted to each party under the agreement will become
fully‑paid up and royalty‑free. We have made $1.9 million in development milestone payments to date.
In January 2019, we entered into a license agreement with Synaffix B.V., or Synaffix, to develop, manufacture and
commercialize ADC targets using Synaffix’s proprietary technology for a total of six targets. At contract inception we
designated the first target and paid an upfront, non-refundable license fee of $0.8 million. We are required to make milestone
payments to Synaffix of up to an aggregate of $24.8 million in development and regulatory milestones, up to $20.0 million in
one-time sales milestones based on the achievement of annual sales objectives for the first target. In addition, upon
designation of additional targets, we will be obligated to pay in the range of $44.8 million to $62.8 million for issuance,
development, regulatory and one time sales milestones. Finally, pursuant to the terms this license agreement, upon
commencement of commercial sales of a product, if any, we are required to pay to Synaffix tiered royalties in the low‑single
digit percentages on net sales of the respective products. We have not made any milestone payments to Synaffix to date.
We did not have, during the periods presented, and we do not currently have, any off‑balance sheet arrangements, as defined
under applicable Securities and Exchange Commission rules.
Off‑Balance Sheet Arrangements
JOBS Act
In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act
provides that an “emerging growth company,” or an EGC, can take advantage of the extended transition period provided in
Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised
accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would
otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition
77
Table of Contents
period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such
standards is required for other public companies.
We continue to evaluate the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act.
Subject to certain conditions, as an EGC, we intend to rely on certain of these exemptions, including without limitation,
(i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to
Section 404(b) of the Sarbanes‑Oxley Act and (ii) complying with any requirement that may be adopted by the Public
Company Accounting Oversight Board, or PCAOB, regarding mandatory audit firm rotation or a supplement to the auditor’s
report providing additional information about the audit and the financial statements, known as the auditor discussion and
analysis. We will remain an EGC until the earlier of (i) the last day of the fiscal year in which we have total annual gross
revenues of $1.07 billion or more; (ii) the last day of the fiscal year following the fifth anniversary of the date of the
completion of our IPO; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the
previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the Securities
and Exchange Commission.
Critical Accounting Policies and Significant Judgements and Estimates
Our management's discussion and analysis of our financial condition and results of operations are based on our financial
statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of
these financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities,
revenues, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our
estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable
under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an
ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The
effects of material revisions in estimates, if any, will be reflected in the financial statements prospectively from the date of
change in estimates.
We believe that our most critical accounting policies are those relating to revenue recognition, accrued research and
development expenses as discussed in the notes to consolidated financial statements included in this Annual Report on Form
10-K.
Revenue Recognition
We enter into collaboration agreements which are within the scope of Accounting Standards Update 2014-09, Revenue from
Contracts with Customers, or Topic 606, under which we license rights to our technology and certain of our product
candidates and perform research and development services for third parties. The terms of these arrangements typically
include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development
costs; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.
Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an
amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To
determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic
606, we perform the following five steps: (i) identification of the promised goods or services in the contract; (ii)
determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance
obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. We only apply the five-
step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods
or services it transfers to the customer.
The promised good or services in our arrangement typically consist of license rights to our intellectual property and research
and development services. We also have optional additional items in contracts, which are considered marketing offers and
are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides
a material right which would not be provided without entering into the contract. Performance obligations
78
Table of Contents
are promised goods or services in a contract to transfer a distinct good or service to the customer. Promised goods or services
are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily
available resources or (ii) the promised good or service is separately identifiable from other promises in the contract. In
assessing whether promised good or services are distinct, we consider factors such as the stage of development of the
underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether
the required expertise is readily available.
We estimate the transaction price based on the amount expected to be received for transferring the promised goods or
services in the contract. The consideration may include both fixed consideration or variable consideration. At the inception
of each arrangement that includes variable consideration and at each reporting period, we evaluate the amount of potential
payment and the likelihood that the payments will be received. We utilize either the most likely amount method or expected
amount method to estimate the amount expected to be received based on which method better predicts the amount expected
to be received. If it is probable that a significant revenue reversal would not occur, the variable consideration is included in
the transaction price.
Our contracts often include development and regulatory milestone payments. At contract inception and at each reporting
period, we evaluate whether the milestones are considered probable of being reached and estimates the amount to be included
in the transaction price using the most likely amount method. If it is not probable that a significant revenue reversal would
not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our
control or the licensee’s control, such as regulatory approvals, are not included in the transaction price. At the end of each
subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related
constraint, and if necessary, adjust our estimate of the overall transaction price.
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license
is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related
sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied
(or partially satisfied).
We allocate the transaction price based on the estimated standalone selling price of the underlying performance obligations or
in the case of certain variable consideration to one or more performance obligations. We must develop assumptions that
require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. We
utilize key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing
considered in negotiating the transaction and the estimated costs to complete the respective performance obligation. Certain
variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the
variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each
performance obligation are consistent with the amounts we would expect to receive for each performance obligation.
For performance obligations consisting of licenses and other promises, we utilize judgment to assess the nature of the
combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a
point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-
refundable, up-front fees. We evaluate the measure of progress each reporting period and, if necessary, adjusts the measure
of performance and related revenue recognition. If the license to our intellectual property is determined to be distinct from
the other performance obligations identified in the arrangement, we will recognize revenue from non-refundable, up-front
fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from
the license.
Collaborative Arrangements
We record the elements of our collaboration agreements that represent joint operating activities in accordance with ASC
Topic 808, Collaborative Arrangements (ASC 808). Accordingly, the elements of the collaboration agreements that represent
activities in which both parties are active participants and to which both parties are exposed to the significant risks and
rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. We
consider the guidance in ASC Topic 606 in determining the appropriate treatment for the transactions
79
Table of Contents
between us and our collaborative partners and the transactions between us and third parties. Generally, the classification of
transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement
along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, we will
recognize our share of the net sales on a gross basis if we are deemed to be the principal in the transactions with customers,
or on a net basis if we are instead deemed to be the agent in the transactions with customers, consistent with the guidance in
Topic 606.
Accrued Research and Development Expenses
As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each
balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel
to identify services that have been performed on our behalf and estimating the level of service performed and the associated
cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our
service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make
estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time.
We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The
significant estimates in our accrued research and development expenses include the costs incurred for services performed by
our vendors in connection with research and development activities for which we have not yet been invoiced.
We record our expenses related to research and development activities based upon our estimates of the services received and
efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The
financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven
payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided
and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period
over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be
expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate,
we adjust the accrued or prepaid expense balance accordingly. Although we do not expect our estimates to be materially
different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual
status and timing of services performed, we may report amounts that are too high or too low in any particular period. To
date, there have been no material differences from our estimates to the amounts actually incurred. Significant judgement is, at
times, involved in making the above estimates.
Recent accounting pronouncements
See Note 2, Recently Issued Accounting Pronouncements, in the Notes to Consolidated Financial Statements for a description
of recent accounting pronouncements applicable to our business.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to market risk-related to changes in interest rates. Our primary exposure to market risk is interest rate
sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments,
including cash equivalents and marketable securities are invested in U.S. Treasury obligations, commercial paper and
corporate bonds. However, we believe that due to the short-term duration of our investment portfolio and low-risk profile of
our investments, an immediate 100 basis points change in interest rates would not have a material effect on the fair market
value of our investments portfolio.
We are currently not exposed to market risk related to changes in foreign currency exchange rates, but we may contract with
vendors that are located Asia and Europe and may be subject to fluctuations in foreign currency rates at that time.
80
Table of Contents
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Mersana Therapeutics, Inc.
Index to Consolidated Financial Statements
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets
Consolidated Statements of Operations and Comprehensive Loss
Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
81
Page
82
83
84
85
86
87
Table of Contents
Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of Mersana Therapeutics, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Mersana Therapeutics, Inc. (the Company) as of
December 31, 2019 and 2018, the related consolidated statements of operations and comprehensive loss, convertible
preferred stock and stockholders' equity (deficit) and cash flows for each of the three years in the period ended December 31,
2019, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the
consolidated financial statements present fairly, in all material respects, the financial position of the Company at December
31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended
December 31, 2019, in conformity with U.S. generally accepted accounting principles.
Adoption of ASU No. 2016-02, “Leases”
As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for leases in
2019 due to the adoption of Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842), and the related
amendments.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion
on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether
due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control
over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial
reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over
financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test
basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of
the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2013.
Boston, Massachusetts
February 28, 2020
82
Table of Contents
Mersana Therapeutics, Inc.
Consolidated Balance Sheets
(in thousands, except share and per share data)
Assets
Current assets:
Cash and cash equivalents
Short-term marketable securities
Accounts receivable
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Other assets
Total assets
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
Accrued expenses
Deferred revenue
Operating lease liabilities
Short-term debt
Other liabilities
Total current liabilities
Operating lease liabilities
Long-term debt, net
Other liabilities
Total liabilities
Commitments (Note 15)
Stockholders' equity
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and
outstanding at December 31, 2019 and December 31, 2018, respectively
Common stock, $0.0001 par value; 175,000,000 shares authorized; 45,388,023 and
23,234,472 shares issued and outstanding at December 31, 2019 and December 31, 2018,
respectively
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
December 31,
December 31,
2019
2018
$
$
$
62,351 $
37,439
—
1,536
101,326
2,164
2,598
1,453
107,541 $
7,296 $
8,986
4,815
2,219
667
87
24,070
677
4,201
275
29,223
59,634
10,497
459
3,715
74,305
2,694
—
1,503
78,502
10,727
12,375
46,196
—
—
127
69,425
—
—
282
69,707
—
—
5
270,662
25
(192,374)
78,318
107,541 $
3
172,966
(8)
(164,166)
8,795
78,502
$
The accompanying notes are an integral part of these consolidated financial statements.
83
Table of Contents
Mersana Therapeutics, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Other income (expense):
Interest income
Interest expense
Total other income (expense), net
Net loss
Other comprehensive loss:
Unrealized gain (loss) on marketable securities
Comprehensive loss
Net loss attributable to common stockholders — basic and diluted
Net loss per share attributable to common stockholders — basic and diluted
Weighted-average number of shares of common stock used in net loss per
share attributable to common stockholders — basic and diluted
Year ended
December 31,
2018
2017
2019
$
42,123 $
10,594 $
17,545
55,040
17,283
72,323
59,915
16,334
76,249
2,226
(234)
1,992
(28,208) $
33
(28,175) $
(28,208) $
(0.65) $
1,398
—
1,398
(64,257) $
141
(64,116) $
(64,257) $
(2.79) $
46,700
10,462
57,162
910
—
910
(38,707)
(149)
(38,856)
(38,707)
(3.22)
$
$
$
$
43,492,113
23,032,250
12,022,733
The accompanying notes are an integral part of these consolidated financial statements.
84
Table of Contents
Mersana Therapeutics, Inc.
Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(in thousands, except share and per share data)
Series A-1
Convertible
Series B-1
Convertible
Series C-1
Convertible
Additional Accumulated
Other
Preferred Stock
Preferred Stock
Preferred Stock
Shares
Amount
Shares
Amount
Shares
Amount
Common Stock
Shares
Paid-in
Amount Capital
Comprehensive Accumulated Stockholders’
Deficit
Income (Loss)
Equity
Balance
December 31, 2016 25,085,153 $ 26,336 32,936,919 $ 35,232 14,674,062 $ 32,882 1,294,352 $
at
1 $
3,551 $
— $ (59,171) $ (55,619)
of
stock
partial
of
of
Issuance
stock
common
under
initial
public offering,
net of
issuance
costs of $7,580
Issuance
common
under
exercise
overallotment
option, net of
issuance costs of
$55
Conversion
preferred
into
stock
Exercise of stock
options
and
warrants
Stock-based
compensation
expense
Other
comprehensive
loss
Net loss
of
stock
common
Balance
at
December 31, 2017
of
stock
Cumulative
effect adjustment
for adoption of
ASC 606
Exercise of stock
options
Purchase
common
under ESPP
Stock-based
compensation
expense
Other
comprehensive
gain
Net loss
of
stock
Balance
at
December 31, 2018
of
Issuance
stock
common
under
public
offering, net of
issuance costs of
$5,587
Exercise of stock
options
and
warrants
Purchase
common
under ESPP
Retirement
of
common stock in
exchange
for
common
stock
warrant
Issuance
common
warrant
exchange
retirement
common stock
Stock-based
compensation
expense
Other
comprehensive
income
Net loss
of
stock
in
for
of
Balance
at
December 31, 2019
—
—
—
—
—
— 5,000,000
—
67,420
—
—
67,420
—
—
—
—
—
—
51,977
—
725
—
—
725
(25,085,153)
(26,336) (32,936,919)
(35,232) (14,674,062)
(32,882) 16,154,671
2
94,448
—
—
94,450
—
—
—
—
—
—
264,017
—
452
—
—
452
—
—
—
—
—
—
—
—
1,422
—
—
1,422
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
(149)
—
—
(38,707)
(149)
(38,707)
— 22,765,017 $
3 $168,018 $
(149) $ (97,878) $ 69,994
—
—
—
—
427,269
—
—
918
—
—
(2,031)
(2,031)
—
918
42,186
—
146
—
—
146
—
—
—
—
—
—
—
—
3,884
—
—
3,884
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
141
—
—
(64,257)
141
(64,257)
— 23,234,472 $
3 $172,966 $
(8) $(164,166) $
8,795
—
—
—
—
—
— 24,437,500
2
92,160
—
—
92,162
—
—
—
—
—
—
150,978
—
175
—
—
175
—
—
—
—
—
—
140,073
—
489
—
—
489
—
—
—
—
—
— (2,575,000)
—
(8,986)
—
—
(8,986)
—
—
—
—
—
—
—
—
8,986
—
—
8,986
—
—
—
—
—
—
—
—
4,872
—
—
4,872
—
—
— $
—
—
—
—
—
— $
—
—
—
—
—
—
—
—
—
—
—
—
—
33
—
—
(28,208)
33
(28,208)
— $
— 45,388,023 $
5 $270,662 $
25 $(192,374) $ 78,318
The accompanying notes are an integral part of these consolidated financial statements.
85
Table of Contents
Mersana Therapeutics, Inc.
Consolidated Statements of Cash Flows
(in thousands)
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Loss on disposal of fixed assets
Net amortization of premiums and discounts on investments
Stock-based compensation
Change in deferred rent
Other non-cash items
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses
Operating lease assets
Operating lease liabilities
Deferred revenue
Net cash used in operating activities
Cash flows from investing activities
Maturities of marketable securities
Purchase of marketable securities
Purchase of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities
Net proceeds from public offering of common stock
Net proceeds from initial public offering
Net proceeds from issuance of common stock upon partial exercise of overallotment
Proceeds from exercise of stock options
Proceeds from purchases of common stock under ESPP
Proceeds from issuance of debt, net of issuance costs
Payments under capital lease obligations
Net cash provided by financing activities
Increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental disclosures of non-cash activities:
Fair value of common stock retired in exchange for issuance of common stock warrant
Conversion of preferred stock to common stock upon closing of initial public offering
Purchases of property and equipment in accounts payable and accrued expenses
Debt financing costs in accrued expenses
Cash paid for interest
Right-of-use assets obtained in exchange for operating lease liabilities
Right-of-use assets obtained in exchange for financing lease liabilities
Adjustment to accumulated deficit and deferred revenue upon adoption of Topic 606
$
$
$
$
$
$
$
$
$
Year ended
December 31,
2018
2017
2019
$
(28,208)
$
(64,257)
$
(38,707)
1,245
—
(222)
4,872
—
103
459
2,179
—
(3,110)
(3,569)
1,771
(1,883)
(41,381)
(67,744)
27,000
(53,688)
(605)
(27,293)
92,162
—
—
175
489
4,965
(87)
97,704
2,667
60,005
62,672
8,986
—
—
180
132
4,369
429
—
$
$
$
$
$
$
$
$
$
1,257
20
(296)
3,884
110
—
325
(1,690)
(1,132)
7,375
5,431
—
—
(6,243)
(55,216)
88,565
—
(1,370)
87,195
—
—
—
918
146
—
—
1,064
33,043
26,962
60,005
—
—
317
—
—
—
—
2,031
$
$
$
$
$
$
$
$
$
928
—
(293)
1,422
(159)
—
267
(1,200)
60
1,335
3,562
—
—
(9,894)
(42,679)
47,220
(145,701)
(1,143)
(99,624)
—
67,420
725
452
—
—
—
68,597
(73,706)
100,668
26,962
—
94,450
35
—
—
—
—
—
The accompanying notes are an integral part of these consolidated financial statements.
86
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
1. Nature of Business and Basis of Presentation
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody drug conjugates
(ADCs) that offer a clinically meaningful benefit for cancer patients with significant unmet need. The Company leveraged
20 years of industry learning in the ADC field to develop proprietary and differentiated technology platforms that enable it to
design ADCs to have improved efficacy, safety and tolerability relative to existing ADC therapies. The Company’s
innovative platforms which include Dolaflexin and Dolasynthen, delivering its DolaLock payload, as well as
Immunosynthen, delivering a novel stimulator of interferon genes (STING) agonist, compose a highly efficient product
engine that has enabled a robust discovery pipeline for the Company and its partners. The Company’s product candidates
include XMT‑1536 and XMT-1592. XMT-1536, an ADC utilizing the Company’s Dolaflexin platform and targeting NaPi2b,
an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma is currently in a
Phase 1 study including both a dose escalation cohort and two expansion cohorts in ovarian cancer and NSCLC
adenocarcinoma. XMT-1592 uses one of the Company’s new platforms, Dolasynthen, and also targets NaPi2b. The Company
expects to file an Investigational New Drug (IND) application and initiate a Phase 1 dose escalation study of XMT-1592 in
patients with tumors likely to express NaPi2b in the first half of 2020.
The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, the need
for additional capital, risks of failure of preclinical and clinical studies, the need to obtain marketing approval and
reimbursement for any drug product candidate that it may identify and develop, the need to successfully commercialize and
gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology,
compliance with government regulations, development of technological innovations by competitors, reliance on third party
manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.
The Company has incurred net losses since inception. The Company’s net loss was $28,208, $64,257 and $38,707 for the
years ended December 31, 2019, 2018 and 2017, respectively. The Company expects to continue to incur operating losses for
at least the next several years. As of December 31, 2019, the Company had an accumulated deficit of $192,374. The future
success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its
ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to
research and development and general and administrative expense to support such research and development. Net losses and
negative cash flows have had, and will continue to have, an adverse effect on the Company’s stockholders’ equity and
working capital, and accordingly, its ability to execute its future operating plans.
The Company plans to obtain funding from collaborations, licensing agreements or other strategic partnerships or raise
additional capital through the issuance and sale of its common stock. There is inherent uncertainty associated with these
fundraising activities and they are not considered probable. In the absence of such funding, the Company plans to
strategically manage its uncommitted spend to execute its priorities and implement cost saving measures to reduce research
and development and general and administrative expenditures which could include limiting or delaying or terminating
preclinical studies or other development activities for one or more of the Company’s ADC product candidates. It is
considered probable that the Company can successfully implement efforts to manage uncommitted spending and carry out
necessary cost saving measures. Therefore, the Company expects its plans will enable its cash, cash equivalents and
marketable securities as of the filing of its Annual Report on Form 10-K to be sufficient to fund its projected operating plan
through at least the next twelve months, including the Phase 1 clinical study for XMT-1536 and the planned dose escalation
study for XMT-1592.
The funding requirements of the Company’s operating plan, however, are based on estimates that are subject to risks and
uncertainties and may change as a result of many factors currently unknown. Although management continues to pursue the
plans described above, there is no assurance that the Company will be successful in obtaining sufficient funding on terms
acceptable to the Company to fund continuing operations, if at all. Until such time as the Company can generate substantial
product revenues, if ever, the Company expects to finance its cash needs through a combination of equity
87
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
offerings, debt financings, strategic partnerships and licensing arrangements. The terms of any future financing may
adversely affect the holdings or the rights of the Company’s existing stockholders.
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC).
Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the
Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards
Board (FASB). All dollar amounts, except per share data in the text and tables herein, are stated in thousands unless
otherwise indicated.
2. Summary of Significant Accounting Policies
Principles of Consolidation
The accompanying consolidated financial statements include those of the Company and its wholly-owned subsidiary,
Mersana Securities Corp. All intercompany balances and transactions have been eliminated.
Use of Estimates
The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to
make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related
disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and
expenses during the reporting period. On an ongoing basis, the Company's management evaluates its estimates which
include, but are not limited to, management's judgments with respect to the separate units of accounting and best estimate of
selling price of those units of accounting within its revenue arrangements, accrued expenses, valuation of stock-based awards
and income taxes. Actual results could differ from those estimates.
Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for
evaluation by the chief operating decision-maker, or decision making group, in deciding how to allocate resources and assess
performance. The Company views its operations and manage its business as a single operating segment, which is the business
of discovering and developing ADCs.
Research and Development
Research and development costs are expensed as incurred and include:
·
·
·
·
employee-related expenses, including salaries, bonuses, benefits, travel and stock-based compensation expense;
fees and expenses incurred under agreements with contract research organizations, investigative sites and other
entities in connection with the conduct of preclinical and clinical studies and related services;
the cost of acquiring, developing and manufacturing ADC product candidates, clinical study materials and other
research and development materials;
fees and costs related to regulatory filings and activities;
88
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
·
·
·
costs associated with collaboration agreements and license fees and milestone payments related to license
agreements;
facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities,
maintenance of facilities, insurance and other supplies; and
other costs associated with clinical, preclinical, discovery and other research activities.
Costs for certain development activities, such as clinical studies and manufacturing development activities, are recognized
based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site
activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort
expended. Payments for these activities are based on the terms of the individual arrangements, which may differ from the
pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued research and development
expenses.
Revenue Recognition
The Company enters into collaboration agreements which are within the scope of Accounting Standards Update (ASU) No.
2014-09, Revenue from Contracts with Customers (Topic 606), under which the Company licenses rights to its technology
and certain of the Company’s product candidates and performs research and development services for third parties. The
terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees;
reimbursement of research and development costs; development, regulatory and commercial milestone payments; and
royalties on net sales of licensed products.
Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an
amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To
determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic
606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii)
determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance
obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company
only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in
exchange for the goods or services it transfers to the customer.
The promised good or services in the Company’s arrangement typically consist of license rights to the Company’s intellectual
property and research and development services. The Company also has optional additional items in contracts, which are
considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the
customer, unless the option provides a material right which would not be provided without entering into the
contract. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the
customer. Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on
its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from
other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors
such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the
intellectual property on their own or whether the required expertise is readily available.
The Company estimates the transaction price based on the amount expected to be received for transferring the promised
goods or services in the contract. The consideration may include both fixed consideration and variable consideration. At the
inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the
amount of potential payment and the likelihood that the payments will be received. The Company utilizes either the
89
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
most likely amount method or expected amount method to estimate the amount expected to be received based on which
method better predicts the amount expected to be received. If it is probable that a significant revenue reversal would not
occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating
arrangements in order to determine whether a significant financing component exists and concluded that a significant
financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the
cash selling price of the promised goods and services; and (b) timing of payment approximates the transfer of goods and
services and performance is over a relatively short period of time within the context of the entire term of the contract.
The Company’s contracts often include development and regulatory milestone payments. At contract inception and at each
reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the
amount to be included in the transaction price using the most likely amount method. If it is probable that a significant
revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company’s control or the licensee’s control, such as regulatory approvals, are not included in the
transaction price. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement
of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction
price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other
revenues and earnings in the period of adjustment.
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license
is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when
the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has
been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of the
Company’s collaboration arrangements.
The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance
obligations or in the case of certain variable consideration to one or more performance obligations. The Company must
develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation
identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may
include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete
the respective performance obligation. Certain variable consideration is allocated specifically to one or more performance
obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation
and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would
expect to receive for each performance obligation.
For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of
the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a
point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-
refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts
the measure of performance and related revenue recognition. If the license to the Company’s intellectual property is
determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize
revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the
customer is able to use and benefit from the license.
The Company receives payments from its customers based on billing schedules established in each contract. Such billings
generally have 30-day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the
Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to
consideration is unconditional.
Effective January 1, 2018, the Company adopted the provisions of Topic 606, using the modified retrospective transition
method. Under this method, the Company recorded the cumulative effect of initially applying the new standard to all
90
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
contracts in process as of the date of adoption. This standard applied to all contracts with customers, except for contracts that
are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The
adoption of the new revenue recognition guidance resulted in increases of $2,031 in deferred revenue and accumulated deficit
as of January 1, 2018. For the years ended December 31, 2019 and 2018, revenue was not materially impacted as compared
to the Company’s prior revenue recognition methodology under ASC 605 Revenue Recognition.
Collaborative Arrangements
The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with
ASC Topic 808, Collaborative Arrangements (ASC 808). Accordingly, the elements of the collaboration agreements that
represent activities in which both parties are active participants and to which both parties are exposed to the significant risks
and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The
Company considers the guidance in ASC Topic 606 in determining the appropriate treatment for the transactions between the
Company and its collaborative partners and the transactions between the Company and third parties. Generally, the
classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of
the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a
collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the
transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers,
consistent with the guidance in Topic 606.
Fair Value Measurements
Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market
participants at measurement dates. ASC Topic 820 Fair Value Measurement (ASC 820), establishes a three-level valuation
hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an
asset or liability as of the measurement date. The three levels are defined as follows:
Level 1—Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active
markets.
Level 2—Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and
inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
instrument.
Level 3—Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of
purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds,
commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These
91
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates
market value.
Cash and cash equivalents
Restricted cash included in other assets, noncurrent
Total cash, cash equivalents and restricted cash per statement of
cash flows
$
$
59,634
371
60,005
$
$
62,351 $
321
26,591
371
62,672 $
26,962
$
$
59,634
371
60,005
Year ended
Year ended
December 31, 2019
December 31, 2018
Beginning
of period
End
of period
Beginning
of period
End
of period
Marketable Securities
Short-term marketable securities consist of investments in debt securities with maturities greater than three months and less
than one year from the balance sheet date. The Company classifies all of its marketable securities as available-for-sale.
Accordingly, these investments are recorded at fair value. Amortization and accretion of discounts and premiums are
recorded as interest income within other income. Unrealized gains and losses on available-for-sale securities are included in
other accumulated comprehensive loss as a component of stockholders’ equity (deficit) until realized.
Other Assets
The Company recorded other assets of $1,453 and $1,503 as of December 31, 2019 and 2018, respectively. The December
31, 2019 and 2018 amounts are comprised of restricted cash of $321 and $371, respectively, held as security deposit for a
standby letter of credit related to a facility lease and $1,132 held by a service provider.
Accounting for Stock-based Compensation
The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation—Stock
Compensation (ASC 718). ASC 718 requires all stock-based payments to employees, directors and non-employees to be
recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the fair
value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires
inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of
expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of a public market for
the Company's common stock prior to completion of the initial public offering and a lack of company-specific historical and
implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of
similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate
with the expected term assumption. The historical volatility is calculated based on a period of time commensurate with the
expected term assumption. The computation of expected volatility is based on the historical volatility of a representative
group of companies with similar characteristics to the Company, including stage of product development and life science
industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107,
Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical
exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees,
the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free
interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The
expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so.
92
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
The Company determines the fair value of each restricted stock unit, or RSU, at its grant date based on the closing market
price of the Company’s common stock on that date. For stock-based compensation subject to service-based vesting
conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based
compensation on a straight-line basis over the requisite service period.
The Company records forfeitures as a cumulative adjustment in the period in which they occur.
Net Loss per Share
Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-
average number of common shares outstanding and 2,575,000 Exchange Warrants (as defined in footnote 10) outstanding
during the period, without further consideration for potentially dilutive securities. In accordance with Accounting Standards
Codification Topic 260, Earnings Per Share, the Exchange Warrants are included in the computation of basic net loss per
share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance
date. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-
average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury
stock method.
For purposes of the diluted net loss per share calculation, stock options, unvested restricted stock units (RSUs) and warrants
to purchase common stock and options to purchase common stock are considered to be potentially dilutive securities, but are
excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and
diluted net loss per share were the same for all periods presented.
The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of
diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):
Stock options
Unvested restricted stock units
Warrants
Property and Equipment
2019
Year ended
December 31,
2018
4,720,772 3,746,567 3,205,485
—
110,365
5,207,582 3,856,932 3,315,850
447,336
39,474
—
110,365
2017
Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line
method over the estimated useful life of each asset as follows:
Computer equipment, office equipment and software
Laboratory equipment
Leasehold improvements
3 years
5 years
Shorter of useful life or life of lease
Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the
balance sheet and related gains or losses are reflected in the statement of operations. There were no material sales of assets
during the years ended December 31, 2019, 2018 and 2017.
93
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate
that the carrying amount of the assets may not be fully recoverable. If an impairment review is performed to evaluate an asset
for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual
disposition of the asset to its carrying value. If the carrying amount of the asset exceeds its estimated undiscounted future net
cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair
value of the asset. The Company did not recognize impairment charges during the years ended December 31, 2019, 2018 and
2017.
Leases
Consistent with ASC 842, the Company determines if an arrangement is a lease at inception. Operating leases are included in
right-of-use lease assets (ROU assets), current portion of lease obligations and long-term lease obligations on the Company’s
consolidated balance sheets. Assets subject to finance leases are included in property and equipment, and the related lease
obligation is included in other current liabilities and other long-term liabilities on the Company’s consolidated balance sheets.
Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Lease expense for
operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing
leases is recognized as depreciation expense and interest expense using the effective interest method. The Company has
elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease
liabilities and ROU assets on the consolidated balance sheets for leases with an original term of twelve months or less.
ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease obligations represent the
Company’s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU
assets are initially recorded based on the present value of lease payments over the expected remaining lease term. When
determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that
the option will be exercised. Certain adjustments to the ROU asset may be required for items such as incentives received. The
interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company
could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar
economic environment. Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any
incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that
was in effect as of the lease commencement or transition date.
The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.
Patent Costs
The Company expenses patent application and related legal costs as incurred and classifies such costs as general and
administrative expenses in the accompanying consolidated statements of operations.
Income Taxes
The Company accounts for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes, which provides
for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the
expected future tax consequences of events that have been included in the financial statements or tax returns. The Company
determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and
liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to
reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that
some or all of the deferred tax assets will not be realized.
94
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained.
Recognized income tax positions are measured at the largest amount that is more likely than not to be realized. Changes in
recognition or measurement are reflected in the period in which the change in judgment occurs.
Comprehensive Income (Loss)
Comprehensive income (loss) comprises net loss and other comprehensive loss. For the years ended December 31, 2019,
2018 and 2017, other comprehensive income (loss) consisted of unrealized income and loss on marketable securities.
Concentration of Credit Risk and Off-balance Sheet Risk
The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts,
or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit
risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits
amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities
issued by the U.S. government. The Company is not exposed to any significant concentrations of credit risk from these
financial instruments.
Recently Issued Accounting Pronouncements
In February 2016, the FASB issued ASU No. 2016-02, Leases (ASC 842), which replaced the guidance in ASC 840, Leases.
The updated standard aims to increase transparency and comparability among organizations by requiring lessees to recognize
lease assets and lease liabilities on the balance sheet and requiring disclosure of key information about leasing arrangements.
This standard became effective for fiscal years beginning after December 15, 2018. The Company adopted the new standard
effective January 1, 2019 using the modified retrospective method as of the beginning of the period of adoption. The
Company has elected the package of practical expedients permitted in ASC Topic 842. Accordingly, the Company accounted
for its existing operating leases as operating leases under the new guidance, without reassessing (a) whether the contracts
contain a lease under ASC Topic 842, (b) whether classification of the operating leases would be different in accordance with
ASC Topic 842, or (c) whether the unamortized initial direct costs would have met the definition of initial direct costs in
ASC Topic 842 at lease commencement. The Company also elected not to include leases with an initial term of twelve
months or less in the recognized ROU asset and lease liabilities. As a result of the adoption of the new lease accounting
guidance, the Company recognized on January 1, 2019 (a) an operating lease liability of $4,778, and (b) an operating ROU
asset of $4,369 which represents the lease liability of $4,778 adjusted for deferred rent of $409. This standard had a material
impact on the Company’s balance sheets but had no impact on the Company’s results of operations and cash flows from
operations. The most significant impact was the recognition of ROU assets, lease obligations, and disclosures regarding the
amount, timing, and uncertainty of cash flows arising from leases.
In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting. This
guidance simplifies the accounting for share-based payments to non-employees by aligning it with the accounting for share-
based payments to employees, with certain exceptions. This guidance became effective for annual reporting periods
beginning after December 15, 2018, including interim periods within those annual reporting periods, and early adoption is
permitted. The guidance per ASU 2018-07 is to be adopted by using a modified retrospective approach with the cumulative
effect of initially applying the new standard at the date of initial application. The Company adopted the new standard
effective January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated
financial statements.
In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction
between Topic 808 and Topic 606. The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions
between collaborative arrangement participants should be accounted for as revenue when the collaborative
95
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions
with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. This
guidance will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within
those annual reporting periods, and early adoption is permitted. The guidance per ASU 2018-18 is to be adopted
retrospectively to the date of initial application of Topic 606. The Company does not anticipate a material impact to the
consolidated financial statements as a result of the adoption of this guidance.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit
Losses on Financial Instruments, which requires that financial assets measured at amortized cost be presented at the net
amount expected to be collected. Currently, U.S. GAAP delays recognition of the full amount of credit losses until the loss is
probable of occurring. Under this ASU, the income statement will reflect an entity’s current estimate of all expected credit
losses. The measurement of expected credit losses will be based upon historical experience, current conditions, and
reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-
for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down of the
security. This ASU is effective for annual periods beginning after December 15, 2019, including interim periods within those
annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that ASU
2016-13 may have on its financial position and results of operations.
3. Collaboration Agreements
Merck KGaA
In June 2014, the Company entered into a Collaboration and Commercial License Agreement with Merck KGaA (the Merck
KGaA Agreement). Upon the execution of the Merck KGaA Agreement, Merck KGaA paid the Company a nonrefundable
technology access fee of $12,000 for the right to develop ADCs directed to six exclusive targets over a specified period of
time. No additional fees are due when a target is designated and the commercial license to the target is granted. Merck KGaA
will be responsible for the product development and marketing of any products resulting from this collaboration. All six
targets were designated prior to 2018.
Under the terms of the Merck KGaA Agreement, the Company and Merck KGaA develop research plans to evaluate Merck
KGaA's antibodies as ADCs incorporating the Company's technology. The Company receives reimbursement for its efforts
under the research plans. The goal of the research plans is to provide Merck KGaA with sufficient information to formally
nominate a development candidate and begin IND-enabling studies or cease development on the designated target.
In addition to the payments received for research and development activities performed on behalf of Merck KGaA, the
Company is also eligible to receive up to a total of $780,000 in future milestones related to all targets under the Merck KGaA
Agreement, plus low to mid single digit royalties on the commercial sales of any resulting products during the applicable
royalty term. The total milestones are categorized as follows: development milestones $84,000; regulatory milestones
$264,000; and sales milestones $432,000. There are six individual development milestones per target, payable upon the
completion of various activities from the delivery of ADCs meeting defined specifications, through the dosing in a Phase 3
clinical trial. There are five regulatory milestones, which are payable upon regulatory approvals for a first indication in each
of the U.S., European Union and Japanese markets and regulatory approvals for both a second and a third indication in the
United States. There are three individual commercial milestones, which are payable upon the attainment of certain defined
thresholds for annual net sales.
Prior to 2018, the Company had received $3,000 related to development milestones under the Merck KGaA Agreement.
There have been no additional milestone payments in the years ended December 31, 2018 or 2019. The next potential
milestone payment the Company will be eligible to receive will be a development milestone of $500 on Merck KGaA's
96
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
designation of a preclinical development candidate for any target. Revenue will be recognized when achievement of the
milestone is considered probable.
Unless earlier terminated, the Merck KGaA Agreement will expire upon the expiration of the last royalty term for a product
under the Merck KGaA Agreement, after which time, Merck KGaA will have a perpetual, royalty-free license, or if Merck
KGaA does not designate any ADC product candidates produced by the Company under the Merck KGaA Agreement as
preclinical development candidates, upon the expiration of the last to expire research program. Merck KGaA may terminate
the Merck KGaA Agreement in its entirety or with respect to any target for convenience upon 60 days' prior written notice.
Each party may terminate the Merck KGaA Agreement in its entirety upon bankruptcy or similar proceedings of the other
party or upon an uncured material breach of the Merck KGaA Agreement by the other party. However, if such breach only
relates to one target, the agreement may only be terminated with respect to such target.
In May 2018, the Company entered into a Supply Agreement with Merck KGaA (the Merck KGaA Supply Agreement).
Under the terms of the Merck KGaA Supply Agreement, the Company will provide Merck KGaA preclinical non-GMP ADC
Drug Substance and clinical GMP Drug Substance for use in clinical trials associated with one of the antibodies designated
under the Merck KGaA Agreement. The Company receives fees for its efforts under the Merck KGaA Supply Agreement
and reimbursement equal to the supply cost. The Company may also enter into future supply agreements to provide clinical
supply material should Merck KGaA pursue clinical development of any other candidates nominated under the Merck KGaA
Agreement.
Accounting Analysis
The Company identified the following performance obligations under the Merck KGaA Agreement: (i) exclusive license and
research services for six designated targets, (ii) rights to future technological improvements and (iii) participation of project
team leaders and providing joint research committee services.
The Company has concluded that each license for a designated target is not distinct from the research services performed
related to the designated target as Merck KGaA cannot obtain the benefit of the license without the related research
services. Each license for a designated target and the related services performance obligation is considered distinct from
every other license for a designated target and related services performance obligation as each research plan is pursued
independent of every other research plans for other designated targets.
The Company utilizes the expected value approach to estimate the amount of consideration related to the payment of fees
associated with development and research services. The Company utilizes the most likely amount approach to estimate any
development and regulatory milestone payments to be received. As of the date of initial application of Topic 606, there were
no milestones payments that had not already been received, included in the estimated transaction price. The Company
considered the stage of development and the remaining risks associated with the remaining development required to achieve
the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Merck
KGaA. The milestone payment amounts were fully constrained, as a result of the uncertainty whether any of the associated
milestones would be achieved. The Company has determined that any commercial milestones and sales based royalties will
be recognized when the related sales occur as they were determined to relate predominantly to the license granted and
therefore have also been excluded from the transaction price.
The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of
each performance obligation or in the case of certain variable consideration to one or more performance obligations. The
estimated standalone selling prices for performance obligations, that include a license and research services, were developed
using the estimated selling price of the license and an estimate of the overall effort to perform the research service and an
estimated market rate for research services. The estimated standalone selling price of the licenses was established based on
comparable transactions. The estimated standalone selling price for the rights to future technological
97
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
improvements was developed based on the estimated selling prices of a license or rights received, as well as considering the
probability that additional technology would be made available or the probability the counterpart would utilize the
technology. The estimated standalone selling price for the joint research committee services was developed using an estimate
of the time and costs incurred to participate in the committees.
The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other
changes in circumstances occur. As of December 31, 2018, the total transaction price for the Merck KGaA Agreement was
$22,070. In the third quarter of 2019, the Company revised its estimate for fees associated with research and development
activities under the Merck KGaA Agreement to $6,500, a decrease of $570. The revised total transaction price for the Merck
KGaA Agreement is $21,500. The transaction price of $21,500 was allocated to the performance obligations as follows:
approximately $3,941 for each of the license and corresponding research and development services units of account for the
first and second designated targets; $3,439 for each of the license and corresponding research and development services units
of account for the third and sixth designated target; $3,152 for the license and corresponding research and development
services unit of account for the fourth designated target; $2,921 for the license and corresponding research and development
services unit of account for the fifth designated target; $425 for rights to future technological improvements; and $242 for
joint research committee services.
The Company is recognizing revenue related to the exclusive license and research and development services performance
obligation over the estimated period of the research and development services using a proportional performance model. The
Company measures proportional performance based on the costs incurred relative to the total costs expected to be
incurred. To the extent that the Company receives fees for the research services as they are preformed, these amounts are
recorded as deferred revenue. Revenue related to future technological improvements and joint research committee services
will be recognized ratably over the performance period (which in the case of the joint research committee services
approximate the time and cost incurred each period), which are 10 and 5 years, respectively. The Company is continuing to
reassess the estimated remaining term at each subsequent reporting period.
During the years ended December 31, 2019, 2018 and 2017, the Company recorded collaboration revenue of $853, $2,444
and $3,636, respectively, related to its efforts under the Merck KGaA Agreement. During the year ended December 31, 2019,
the Company recognized collaboration revenue and corresponding research and development expense of $1,280 related to the
Merck KGaA Supply Agreement. There were no amounts recognized during the years ended December 31, 2018 and 2017
related to the Merck KGaA Supply Agreement. Included in accounts receivable as of December 31, 2019 and 2018 was $0
and $450, respectively, related to the Merck KGaA Agreement and Merck KGaA Supply Agreement.
As of December 31, 2019 and 2018, the Company had recorded $4,815 and $5,462, respectively, in deferred revenue related
to the Merck KGaA Agreement and Merck KGaA Supply Agreement that will be recognized over the remaining performance
period.
Takeda XMT-1522 Strategic Partnership
In January 2016, the Company entered into a Development Collaboration and Commercial License Agreement with Takeda’s
wholly owned subsidiary, Millennium Pharmaceuticals, Inc. for the development and commercialization of XMT-1522 (the
XMT-1522 Agreement). Under the XMT-1522 Agreement, Takeda was granted the exclusive right to commercialize XMT-
1522 outside of the United States and Canada. Under the XMT-1522 Agreement, the Company was responsible for
conducting certain Phase 1 development activities for XMT-1522, including the ongoing Phase 1 clinical trial, at its own
expense. The parties agreed to collaborate on the further development of XMT-1522 in accordance with a global
development plan (Post-Phase 1 Development). On January 2, 2019, the Company received notice from Takeda stating that
Takeda was exercising its right to terminate the XMT-1522 Agreement upon 30 days’ prior written notice. The XMT-1522
Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the
XMT-1522 Agreement as of March 31, 2019. Under the XMT-1522 Agreement, the Company and Takeda
98
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
shared equally all agreed Post-Phase 1 Development costs through the date of termination and for a period of 30 days after
the effective termination date.
Takeda Strategic Research and Development Partnership
In March 2014, the Company entered into a Research Collaboration and Commercial License Agreement with Takeda’s
wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (the 2014 Agreement). The 2014 Agreement was amended in
January 2015 and amended and restated in January 2016 (the 2016 Restated Agreement). The agreements provided Takeda
with the right to develop ADCs directed to a total of seven exclusive targets, designated by Takeda, over a specified period of
time. On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate
the 2016 Restated Agreement upon 45 days’ prior written notice. The 2016 Restated Agreement terminated in accordance
with its provisions, and the Company and Takeda wound down activities related to the 2016 Restated Agreement as of March
31, 2019.
Accounting Analysis
The Company’s collaboration agreements with Takeda were terminated following receipt of written notices during the first
quarter of 2019. As there are no further performance obligation, the Company recognized the remaining deferred revenue of
$39,965 related to the termination of the Takeda agreements in the first quarter of 2019.
Prior to the termination of the agreements, the Company had identified 14 performance obligations in the agreements. The
Company concluded that the license related to each of the designated targets was not distinct from the research services
performed related to each of the designated targets as Takeda could not have obtain the benefit of the license without the
related research services. Each license to a designated target and the related service performance obligation was considered
distinct from every other license to a designated target and related services performance obligation as each research plan was
pursued independent of the any other research plans for other designated targets. Further, the material rights provided were
determined to be distinct from the other performance obligations in the arrangement as they were options in the contract
Takeda agreements and not required for Takeda to obtain the benefit of the other promised goods or services in the
arrangement. Similarly, the Company concluded that the XMT-1522 license and the related research and development
services, including the Phase 1 development and the transfer of certain materials and know-how related to the Company's
manufacturing processes, were one performance obligation. The license to the Company's intellectual property was not
determined to be distinct from the research and related development services that the Company was obligated to perform. For
the years ended December 31, 2019, 2018 and 2017, the Company recorded total revenue of $39,965, $5,868 and $13,784,
respectively, related to its efforts under the 2016 Restated Agreement and the XMT-1522 Agreement. Included in accounts
payable as of December 31, 2019 and 2018 was $2,310 and $2,749, respectively, related to the Takeda agreements. As of
December 31, 2019 and 2018, the Company had $0 and $39,965, respectively, of deferred revenue related to the Takeda
agreements.
The Company concluded that the Post-Phase 1 Development activities under the XMT-1522 Agreement represented joint
operating activities in which both parties were active participants and of which both parties were exposed to significant risks
and rewards that are dependent on the commercial success of the activities. Accordingly, the Company accounted for the
Post-Phase 1 Development activities in accordance with ASC 808. For the years ended December 31, 2019, 2018 and 2017,
the Company was billed approximately $200, $8,046 and $3,408, respectively, from Takeda representing Post-Phase 1
Development costs incurred by Takeda. These amounts have been reflected as research and development costs in the
consolidated statement of operations. The Company did not perform any Post-Phase 1 Development activities or incur any
associated costs prior to January 1, 2018. During the years ended December 31, 2019, 2018 and 2017, the Company billed
Takeda $195, $3,746 and $0, respectively, related to ASC 808 costs.
99
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Summary of Contract Assets and Liabilities
The following table presents changes in the balances of our contract assets and liabilities during the years ended December
31, 2019 and December 31, 2018:
Balance at
Beginning
of Period
Additions Deductions End of Period
Balance at
Year ended December 31, 2019
Contract assets
Contract liabilities:
Deferred revenue
Year ended December 31, 2018
Contract assets
Contract liabilities:
Deferred revenue
$
— $
— $
— $
—
$
46,196 $
210 $ 41,591 $
4,815
Balance at
Beginning
Balance at
of Period
Additions Deductions End of Period
$
— $
— $
— $
—
$
52,439 $
2,851 $ 9,094 $
46,196
During the year ended December 31, 2019, the Company recognized the following revenues as a result of changes in the
contract asset and the contract liability balances in the respective periods.
Revenue recognized in the period from:
Amounts included in the contract liability at the beginning of the period
Performance obligations satisfied in previous periods
Other Revenue
Year ended
December 31,
2019
2018
$
$
41,591 $
— $
8,704
—
The Company has provided limited services for a collaboration partner, Asana BioSciences. For the years ended December
31, 2019, 2018 and 2017, the Company recorded revenue of $25, $782 and $125, respectively, related to these services. In
addition, during the year ended December 31, 2018, the Company recognized revenue of $1,500 related to a milestone
achieved upon the completion of a GLP toxicology study by Asana BioSciences. The next potential milestone the Company
is eligible to receive is $2,500 upon dosing the fifth patient in a Phase 1 clinical study by Asana BioSciences. As of
December 31, 2019, the Company considered this next milestone to be fully constrained as there is considerable judgment
involved in determining whether it is probable that a significant revenue reversal would occur. As part of its evaluation of the
constraint, the Company considered numerous factors, including the fact that achievement of the milestone is outside the
control of the Company and there is a high level of uncertainty in achieving this milestone, as this would require initiation of
clinical trials by the collaboration partner. The Company reevaluates the probability of achievement of a milestone subject to
constraint at each reporting period and as uncertain events are resolved or other changes in circumstances occur.
100
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
4. Fair Value Measurements
The following table presents information about the Company’s assets and liabilities regularly measured and carried at a fair
value and indicates the level within fair value hierarchy of the valuation techniques utilized to determine such value as of
December 31, 2019 and 2018:
Quoted Prices
in Active
Markets
(Level 1)
Significant
Other
Significant
Observable Unobservable
Inputs
(Level 2)
Inputs
(Level 3)
Fair
Value
December 31, 2019
Marketable securities:
Commercial paper
Corporate bonds
U.S. Treasuries
December 31, 2018
Marketable securities:
U.S. Treasuries
$ 11,940 $
12,010
13,489
$ 37,439 $
— $ 11,940 $
—
13,489
13,489 $ 23,950 $
12,010
—
—
—
—
—
Quoted Prices
in Active
Markets
(Level 1)
Significant
Other
Significant
Observable Unobservable
Inputs
(Level 2)
Inputs
(Level 3)
Fair
Value
$ 10,497 $
$ 10,497 $
10,497 $
10,497 $
— $
— $
—
—
There were no changes in valuation techniques or transfers between fair value measurement levels during the years ended
December 31, 2019 and 2018.
The carrying amounts reflected in the consolidated balance sheets for prepaid expenses and other current assets, accounts
payable and accrued expenses approximate their fair values due to their short-term nature.
As of December 31, 2019, the carrying value of the Company’s outstanding borrowing under the Credit Facility
approximated fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. The
Credit Facility is discussed more detail in Note 8, “Debt”.
101
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
5. Marketable Securities
The following table summarizes marketable securities held at December 31, 2019 and 2018.
Gross
Amortized Unrealized Unrealized
Gross
Cost
Gains
Losses
Fair
Value
December 31, 2019
Commercial paper
Corporate bonds
U.S. Treasuries
December 31, 2018
U.S. Treasuries
$ 11,940 $
11,990
13,484
$ 37,414 $
— $
20
5
25 $
— $ 11,940
12,010
—
—
13,489
— $ 37,439
Gross
Amortized Unrealized Unrealized
Gross
Cost
Gains
Losses
Fair
Value
$ 10,505 $
$ 10,505 $
— $
— $
(8) $ 10,497
(8) $ 10,497
As of December 31, 2019, the Company did not hold any securities that were in an unrealized loss position. As of December
31, 2018, the Company held three securities that were in an unrealized loss position. The aggregate fair value of securities
held by the Company in an unrealized loss position at December 31, 2018 was $10,497. These securities were held by the
Company in an unrealized loss position for more than 12 months. The Company determined that there was no material
change in the credit risk of these securities. As a result, the Company determined it did not hold any investments with an
other-than-temporary impairment as of December 31, 2019 and 2018.
102
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
6. Property and Equipment
Property and equipment consists of the following as of December 31, 2019 and 2018:
Laboratory equipment
Computer equipment and office equipment
Leasehold improvements
Total property and equipment at cost
Less: Accumulated depreciation
December 31, December 31,
2019
2018
$
$
6,419 $
1,068
1,886
9,373
(7,209)
2,164 $
6,134
1,035
1,886
9,055
(6,361)
2,694
The Company recorded assets under finance leases of $429 as laboratory equipment during the year ended December 31,
2019. Financing leases are discussed in more detail in Note 12 “Leases”. Depreciation expense for the years ended
December 31, 2019, 2018 and 2017 was $1,245, $1,257 and $928, respectively.
7. Accrued Expenses
Accrued expenses consist of the following as of December 31, 2019 and 2018:
Accrued payroll and related expenses
Accrued preclinical, manufacturing and clinical expenses
Accrued professional fees
Accrued other
December 31, December 31,
2019
2018
$
$
4,037 $
4,230
675
44
8,986 $
3,042
8,314
567
452
12,375
8. Debt
On May 8, 2019, the Company entered into a loan and security agreement (the Credit Facility) with Silicon Valley Bank
(SVB) pursuant to which the Company can borrow, at its option, up to $20,000, in up to four principal advances of at least
$5,000 each (each, a Term Loan or collectively, the Term Loans) through August 31, 2020. The Company drew $5,000 on the
Term Loan upon execution of the Credit Facility.
The Term Loans bear interest at a floating per annum rate equal to the greater of (i) 4.0% and (ii) 1.50% below the Prime
Rate, as defined. The Company is obligated to make monthly interest only payments on each outstanding Term Loan
commencing on the first calendar day of the month following the funding date of such Term Loan and continuing on the first
calendar day of each month thereafter through August 31, 2020. Commencing on September 1, 2020 and continuing on the
first calendar day of each month thereafter, the Company is obligated to make 30 consecutive equal payments of principal,
together with applicable interest in arrears to SVB.
All outstanding principal and accrued and unpaid interest with respect to the Term Loans are due and payable in full on
February 1, 2023. Upon repayment of the Term Loans, the Company is also required to make a final payment to SVB equal
to 5.0% of the principal amount of the Term Loans then extended to the Company. This final payment is accreted under the
effective interest method over the life of each loan. The Term Loans are secured by substantially all of the
103
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Company’s assets, except for its intellectual property which is subject to a negative pledge, and certain other customary
exclusions.
At the Company’s option, it may prepay the outstanding principal balance of any Term Loans in whole but not in part, subject
to a prepayment fee of: (a) 3.0% of the Term Loans then extended to the Company if the prepayment occurs on or prior to
May 8, 2020, (b) 2.0% of the Term Loans then extended to the Company if the prepayment occurs after May 8, 2020 but on
or prior to May 8, 2021, or (c) 1.0% of the Term Loans then extended to the Company if the prepayment occurs after May 8,
2021 but before February 1, 2023. In the event the Company has not borrowed a total of $20,000 upon the earlier of August
21, 2020, acceleration of the Company’s payment obligations or Company’s prepayment of the then extended Term Loans,
the Company is required to pay an additional fee equal to 3.0% of any unborrowed portion of the committed funding (the
Unused Term Loan Commitment Fee).
financial, and
includes customary affirmative,
the
The Credit Facility
Company. Affirmative covenants include, among others, covenants requiring the Company to maintain its corporate
existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain
requirements regarding deposit accounts. Financial covenants include maintaining a liquidity ratio (as defined in the Credit
Facility) of 1.50 to 1.00. The restrictive covenants include, among others, requirements relating to the Company’s ability to
transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other
distributions, make investments, create liens, sell assets and agree to a change in control, in each case subject to certain
customary exceptions.
restrictive covenants applicable
to
The Company’s payment obligations under the Credit Facility are subject to acceleration upon the occurrence of specified
events of default, which include, but are not limited to, the occurrence of a material adverse change in the Company’s
business, operations, or financial or other condition. Amounts outstanding upon the occurrence of an event of default are
payable upon SVB’s demand and shall accrue interest at an additional rate of 5.0% per annum of the past due amount
outstanding. As of December 31, 2019, the Company was in compliance with all covenants under the Credit Facility. As
such, as of December 31, 2019, the classification of the loan balance as stated on the balance sheet was based on the timing
of defined future payment obligations.
The Company incurred $215 of debt issuance costs related to external legal and transaction fees. The Company recorded the
debt issuance costs as a direct deduction from the carrying value of the Term Loans which are amortized as interest expense
using the effective-interest method over the term of the Term Loans.
As of December 31, 2019, the Company had drawn a Term Loan of $5,000.
As of December 31, 2019, Debt consisted of the following:
Total debt
Less: Current portion of long-term-debt
Total debt, net of current portion
Debt financing costs, net of accretion
Accretion related to final payment
Long-term debt, net
104
December 31,
2019
5,000
(667)
4,333
(177)
45
4,201
$
$
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
As of December 31, 2019, the estimated future principal payments due are as follows:
2020
2021
2022
2023
Total debt
$
$
667
2,000
2,000
333
5,000
During the year ended December 31, 2019 the Company recognized $214 of interest expense related to the Credit Facility.
9. Preferred Stock
As of December 31, 2019, the Company has 25,000,000 shares of authorized preferred stock. No shares of preferred stock
have been issued.
10. Stockholders’ Equity (Deficit)
Common Stock
The holders of the common stock are entitled to one vote for each share held. Common stockholders are not entitled to
receive dividends, unless declared by the Board of Directors (the Board).
As of December 31, 2019 and 2018 there were 7,782,582 and 3,856,932, respectively, shares of common stock reserved for
the exercise of outstanding stock options and warrants.
Stock options
Restricted stock units
Exchange warrants
Warrants
Warrants
December 31, December 31,
2019
4,720,772
447,336
2,575,000
39,474
7,782,582
2018
3,746,567
—
—
110,365
3,856,932
In connection with a 2013 Series A‑1 Preferred Stock issuance, the Company granted to certain investors warrants to
purchase 129,491 shares of common stock. The warrants have a $0.05 per share exercise price and a contractual life of
10 years. The fair value of these warrants was recorded as a component of equity at the time of issuance. As of December 31,
2018, there were warrants to purchase 110,365 shares of common stock. During the year ended December 31, 2019, the
Company issued 69,680 shares of common stock upon the exercise of warrants.
Exchange Warrants
On November 26, 2019, the Company entered into an exchange agreement with entities affiliated with Biotechnology Value
Fund, L.P. (the “Exchanging Stockholders”), pursuant to which the Exchanging Stockholders exchanged an aggregate of
2,575,000 shares of common stock for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 2,575,000
shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, merger or
consolidation, change of control, reorganization or similar transaction, as described in the
105
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Exchange Warrants), with an exercise price of $0.0001 per share. The Exchange Warrants will expire ten years from the date
of issuance. The Exchange Warrants are exercisable at any time prior to expiration except that the Exchange Warrants cannot
be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially
own more than 9.99% of the Company’s common stock, subject to certain exceptions.
In accordance with Accounting Standards Codification Topic 505, Equity, the Company recorded the retirement of the
common stock exchanged as a reduction of common shares outstanding and a corresponding debit to additional paid-in-
capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity in
accordance with Accounting Standards Codification Topic 480, Distinguishing Liabilities from Equity, and fair value of the
Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company
determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the
issuance date due to the negligible exercise price for the Exchange Warrants. As of December 31, 2019, none of the
Exchange Warrants had been exercised.
11. Stock Options
Stock option plans
As of June 30, 2017, there were 3,141,625 options outstanding under the Company’s 2007 Stock Incentive Plan. The 2007
Plan expired in June 2017. Any cancellations under the 2007 Stock Incentive Plan will increase the options available under
the 2017 Stock Incentive Plan as described below.
In June 2017 the Company’s shareholders approved the 2017 Stock Incentive Plan (the 2017 Plan or the Plan). Under the
2017 Plan initially, up to 2,255,000 shares of common stock may be granted to the Company's employees, officers, directors,
consultants and advisors in the form of options, restricted stock units (RSUs) or other stock-based awards. The number of
shares of common stock issuable under the Plan will be cumulatively increased annually by 4% of the outstanding shares or
such lesser amount specified by the Board. The terms of the awards are determined by the Board, subject to the provisions of
the Plan. As of December 31, 2019 there were 1,511,587 shares available for future issuance under the Plan, including
929,378 shares automatically added to the plan on January 1, 2019.
With respect to incentive stock options, the exercise price per share will equal the fair market value of the common stock on
the date of grant, as determined by the Board, and the vesting period is generally four years. Nonqualified stock options will
be granted at an exercise price established by the Board at its sole discretion (which has not been less than fair market value
on the date of grant) and the vesting periods may vary. Options granted under the Plan expire no later than 10 years from the
date of grant. The Board may accelerate vesting or extend the expiration of granted options in the case of a merger,
consolidation, dissolution, or liquidation of the Company.
106
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Stock option activity
A summary of the activity under the Plan is as follows:
Number
of Shares
Weighted-
Average
Weighted Average
Remaining
Exercise Price Contractual Term Intrinsic Value
Aggregate
Outstanding at January 1, 2019
Granted
Exercised
Cancelled
Outstanding at December 31, 2019
3,746,567 $
1,698,383
(81,298)
(642,880)
4,720,772 $
6.58
3.74
2.15
9.42
5.24
7.6 $
3,897
7.3 $
9,836
Exercisable at December 31, 2019
2,684,095 $
4.49
6.3 $
7,064
The weighted-average grant date fair value of options granted during the years ended December 31, 2019, 2018 and 2017,
was $2.47, $8.78 and $5.53 per share, respectively.
Cash received from the exercise of stock options was $175, $918 and $452 for the years ended December 31, 2019, 2018 and
2017, respectively.
Restricted stock units
In July 2019, the Company issued RSUs with service conditions to employees. Vesting of these awards is contingent on the
fulfillment of the service conditions during the vesting term. The awards cliff-vest two years after the grant date.
Number
of Shares
Weighted-Average
Remaining
Contractual Term
Weighted-Average
Aggregate
Grant Date
Intrinsic Value
Fair Value
—
449,331
—
(1,995)
447,336
— $
—
—
—
1.5 $
— $
2,564 $
—
4.00
—
4.00
4.00
Unvested at January 1, 2019
Granted
Vested
Forfeited
Unvested at December 31, 2019
Stock-based compensation expense
The Company uses the provisions of ASC 718, Stock Compensation, to account for all stock-based awards to employees and
nonemployees.
The measurement date for employee awards is generally the date of grant. Stock-based compensation expense is recognized
over the requisite service period, which is generally the vesting period, using the straight-line method.
107
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
The following table presents stock-based compensation expense by award type included within the Company’s consolidated
statement of operations and comprehensive loss:
Stock options
Restricted stock units
Employee stock purchase plan
Stock-based compensation expense included in Total operating expenses $
$
Year ended
December 31,
2019
2018
2017
4,230 $
410
232
4,872 $
3,754 $
—
130
3,884 $
1,422
—
—
1,422
The following table presents stock-based compensation expense as reflected in the Company’s consolidated statements of
operations and comprehensive loss:
Research and development
General and administrative
Stock-based compensation expense included in Total operating expenses $
$
Year ended
December 31,
2019
2018
2017
2,245 $
2,627
4,872 $
1,788 $
2,096
3,884 $
770
652
1,422
As of December 31, 2019, there was $7,450 and $1,379 of unrecognized compensation expense related to unvested stock
options and unvested RSUs, respectively, that is expected to be recognized over a weighted average period of 2.5 and 1.5
years.
The fair value of each option award is estimated on the date of grant using the Black–Scholes option pricing model with the
following weighted average assumptions:
Risk-free interest rate
Expected dividend yield
Expected term (years)
Expected stock price volatility
December 31,
2018
2019
2017
2.3 %
— %
5.99
2.7 % 2.2 %
— % — %
6.07
6.21
74 %
73 % 67 %
Expected volatility for the Company’s common stock was determined based on the historical volatility of comparable
publicly traded companies. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the
expected term of the option. No dividend yield was assumed as the Company has not historically and does not expect to pay
dividends on its common stock. The expected term of the options granted is based on the use of the simplified method, in
which the expected term is presumed to be the mid-point between the vesting date and the end of the contractual term.
Prior to the Company’s initial public offering in June 2017, the fair value of the common stock had been determined by the
Board at each date of grant based on the variety of factors, including the Company’s financial position and historical
108
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
financial performance, the status of developments within the Company’s research and development activities, the
composition and ability of the current research and management team, an evaluation of the Company’s competition, the
current climate in the marketplace, the illiquid nature of the common stock, the effect of the rights and preferences of the
preferred shareholders, and the prospects of the liquidity event, among others.
The fair value of RSUs is determined based on the closing price of the Company’s common stock on the date of grant.
Employee Stock Purchase Plan
During the year ended December 31, 2017, the Board adopted and the Company's stockholders approved the 2017 employee
stock purchase plan (the 2017 ESPP). The Company initially reserved 225,000 shares of common stock for issuance under
the 2017 ESPP. During the years ended December 31, 2019 and 2018 the Company issued 140,073 and 42,186 shares,
respectively, under the 2017 ESPP. As of December 31, 2019, there were 275,085 available for issuance, including 232,344
shares automatically added to the 2017 ESPP on January 1, 2019.
12. Leases
The Company has an operating lease for its facility and operating and finance leases for certain equipment. The Company
leases office space in Cambridge, MA under an operating lease, which was last amended in January 2018, and is effective
through March 2021. The Company has an option to extend the lease term for an additional five years. The Company’s
exercise of this option was not considered reasonably certain as of December 31, 2019. The Company has remaining lease
terms of three years to five years for certain equipment, some of which may include options to purchase at fair value.
In connection with the office lease, the Company had a letter of credit agreement for the benefit of its landlord in the amount
of $321 as of each December 31, 2019 and 2018, collateralized by a money market account.
During the first quarter of 2019, the Company entered into finance leases for certain equipment. The Company recorded
assets under finance leases of $429 as property and equipment.
The components of lease expense were as follows:
Operating lease cost
Finance lease cost:
Amortization of right-of-use assets
Interest on lease liabilities
109
Year ended
December 31, 2019
2,160
$
$
$
75
20
95
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Supplemental balance sheet information related to leases was as follows:
Operating leases:
Operating lease right-of-use assets
Operating lease liabilities, current
Operating lease liabilities
Finance leases:
Property and equipment, gross
Property and equipment, accumulated depreciation
Other liabilities, current
Other liabilities
Weighted-average remaining lease term:
Operating leases
Finance leases
Weighted-average discount rate:
Operating leases
Finance leases
Supplemental cash flow information related to leases was as follows:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases
Operating cash flows from finance leases
Financing cash flows from finance leases
110
Year ended
December 31, 2019
2,598
2,219
677
429
(75)
87
275
1.3 years
3.7 years
10.3%
6.9%
Year ended
December 31, 2019
2,271
20
87
$
$
$
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Rent expense was $2,160, $1,994 and $1,834 for the years ended December 31, 2019, 2018 and 2017, respectively.
Future minimum lease payments under non-cancellable leases as of December 31, 2019 were as follows:
2020
2021
2022
2023
2024
Total lease payments
Present value adjustment
Present value of lease liabilities
13. Income Taxes
Operating leases
Finance leases
$
$
2,394 $
687
—
—
—
3,081
(186)
2,895 $
116
116
84
74
18
408
(46)
362
For the years ended December 31, 2019, 2018 and 2017, the Company recorded no income tax benefit for the net operating
losses incurred in each year, due to its uncertainty of realizing a benefit from those items.
A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations as of
December 31, 2019, 2018 and 2017 are as follows:
Income tax computed at federal statutory tax rate
State taxes, net of federal benefit
Permanent differences
Research and development expenditures
General business credits
Impact of tax reform
Impact of ownership shift
Change in valuation allowance
111
2019
2017
2018
21.0 % 21.0 % 34.0 %
5.1 %
6.5 %
6.1 %
0.6 % (0.8)%
(2.0)%
(2.3)%
— %
— %
4.2 %
10.3 %
8.2 %
— % (27.3)%
— %
— %
— %
(53.3)%
17.9 % (32.3)% (16.9)%
— %
— %
— %
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the
Company’s net deferred tax assets as of December 31, 2019 and 2018 are as follows:
Deferred tax assets:
Net operating losses
Accrued expenses
Tax credit carryforwards
Licensed technology
Deferred revenue
Lease liabilities
Depreciation
Deferred expenses
Other
Total gross deferred tax assets
Valuation allowance
Net deferred tax assets less valuation allowance
Deferred tax liabilities
Right-of-use assets
Total gross deferred tax liabilities
Net deferred taxes
2019
2018
$ 40,554 $ 27,916
1,585
10,178
1,160
12,410
—
405
112
174
53,940
(53,940)
—
2,520
2,448
1,402
1,315
791
492
—
77
49,599
(48,889)
710
(710)
(710)
$
— $
—
—
—
The Company has incurred net operating losses (NOL) since inception. At December 31, 2019, the Company had Federal and
State net operating loss carryforwards of approximately $163,465 and $98,517, respectively. Of the $163,465 of Federal net
operating loss carryforwards, $34,149 expire at various dates through 2037. The remaining $129,316 of Federal net operating
loss carryforwards do not expire. The State net operating loss carryforwards expire at various dates through 2039. At
December 31, 2019, the Company had Federal and State research and development tax credit carryforwards of approximately
$1,989 and $687, respectively, which expire at various dates through 2039.
As required by ASC 740, management of the Company has evaluated the evidence bearing upon the reliability of its deferred
tax assets. Based on the weight of available evidence, both positive and negative, management has determined that it is more
likely than not that the Company will not realize the benefits of all of these assets. Accordingly, the Company recorded a
valuation allowance of $48,889 and $53,940 at December 31, 2019 and December 31, 2018, respectively. The valuation
allowance decreased by $5,051 and increased $21,338 during the years ended December 31, 2019 and 2018, respectively,
primarily as a result of the Company’s 382 limitation and net operating losses generated during the periods, respectively.
Utilization of the NOLs and research and development tax credit carryforwards may be subject to a substantial annual
limitation under Section 382 due to ownership change limitations that have occurred previously or that could occur in the
future in accordance with Section 382, as well as similar state provisions. These ownership changes may limit the amount of
NOLs and research and development tax credit carryforwards that can be utilized annually to offset future taxable income
and tax, respectively. If a change in control as defined by Section 382 has occurred at any time since the Company’s
formation, utilization of its NOLs or research and development tax credit carryforwards would be subject to an annual
limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the
ownership change by the applicable long-term tax-exempt rate, which could then be subject to additional adjustments, as
required. Any limitation may result in expiration of a portion of the NOLs or research and development tax carryforwards
before their utilization. The Company has determined that ownership changes have occurred through November 4, 2019 and
that certain NOLs and research and development tax credit carryforwards will be subject to limitation. The amounts
112
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
presented do not include NOLs or research and development tax credit carryforwards that will expire unused due to
ownership changes.
The Company applies the accounting guidance in ASC 740 related to accounting for uncertainty in income taxes. The
Company’s reserves related to taxes are based on a determination of whether, and how much of, a tax benefit taken by the
Company in its tax filings or positions is more likely than not to be realized following resolution of any potential
contingencies present related to the tax benefit. As of December 31, 2019 and 2018, the Company had no unrecognized tax
benefits.
The Company has not conducted a study of its research and development credit carryforwards. This study may result in an
adjustment to research and development credit carryforwards; however, until a study is completed and any adjustment is
known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the
Company’s research and development credits and, if an adjustment is required, this adjustment would be offset by an
adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an
adjustment were required.
Interest and penalties related to uncertain tax positions would be classified as income tax expense in the accompanying
statements of operations. As of December 31, 2019 and 2018, the Company had no accrued interest or penalties related to
uncertain tax positions.
The Company files income tax returns in the United States federal tax jurisdiction and one state jurisdiction. The Company
did not have any foreign operations during the years ended December 31, 2019, 2018 and 2017. The statute of limitations for
assessment by the Internal Revenue Service and state tax authorities is closed for tax years prior to 2016, although
carryforward attributes that were generated prior to tax year 2015 may still be adjusted upon examination to the extent
utilized in a future period. There are no federal or state audits currently in progress.
14. Employee Benefit Plan
The Company has a defined contribution plan established under Section 401(k) of the Internal Revenue Code (401(k) Plan),
which covers substantially all employees. Employees who have attained the age of 21 are eligible to participate in the
401(k) Plan with no service requirement. Employees may contribute up to 75% of eligible pay on a pre–tax basis up to the
federal annual limits. For the years ended December 31, 2018 and 2017 and the period from January 1, 2019 to July 31, 2019,
the Company matched the employees’ contributions at 50% on the first 6% up to $6. For the period from August 1, 2019 to
December 31, 2019, the Company matched the employees’ contributions at 100% on the first 4% up to $7. For the years
ended December 31, 2019, 2018 and 2017, the Company recorded expense of $404, $332 and $273, respectively, related to
its contribution to its 401(k) Plan.
15. Commitments
License Agreements
Through December 31, 2019 the Company has licensed intellectual property from two biotechnology companies. The
consideration included upfront payments and a commitment to pay annual license fees, milestone payments, and, upon
product commercialization, royalties on revenue generated from the sale of products covered by the licenses. During the
years ended December 31, 2019, 2018 and 2017, the Company recorded expense related to milestone payments of $600, $0
and $2,750, respectively, related to these agreements.
See Note 12 for the Company’s future obligations related to leases as of December 31, 2019.
113
Table of Contents
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
16. Related Party Transactions
Included in Series C‑1 financing and the Company’s initial public offering were investments of $10,000 and $10,000,
respectively, by Takeda.
17. Subsequent Events
The Company considered the events or transactions occurring after the balance sheet date, but prior to the issuance of the
consolidated financial statements, for potential recognition or disclosure in its consolidated financial statements. All
significant subsequent events have been properly disclosed in the consolidated financial statements.
18. Selected Quarterly Financial Data (unaudited)
The following table contains selected quarterly financial information for 2019 and 2018. The Company believes that the
following information reflects all normal recurring adjustments necessary for a fair statement of the information for the
periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.
Three months ended
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Other income:
Interest income
Interest expense
to common
share attributable
share attributable
Total other income (expense), net
Net loss
Net
loss per
stockholders — basic
loss per
Net
stockholders — diluted
Weighted-average number of common shares used in
net loss per share attributable to common stockholders
— basic
Weighted-average number of common shares used in
net loss per share attributable to common stockholders
— diluted
to common
March 31, 2019 June 30, 2019 September 30, 2019 December 31, 2019
42
$
41,035 $
844 $
202 $
15,143
4,443
19,586
13,766
4,192
17,958
452
—
452
21,901 $
725
(40)
685
(17,071) $
13,701
4,436
18,137
608
(107)
501
(16,792) $
0.72 $
(0.36) $
(0.35) $
0.70 $
(0.36) $
(0.35) $
12,430
4,212
16,642
441
(87)
354
(16,246)
(0.34)
(0.34)
$
$
$
30,299,650
47,708,085
47,833,607
47,886,144
31,461,696
47,708,085
47,833,607
47,886,144
114
Table of Contents
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Other income:
loss per
Interest income
Total other income
Net loss
Net
stockholders — basic and diluted
Weighted-average number of common shares used in
net loss per share attributable to common stockholders
— basic and diluted
share attributable
to common
Mersana Therapeutics, Inc.
Notes to consolidated financial statements
(continued)
Three months ended
March 31, 2018 June 30, 2018 September 30, 2018 December 31, 2018
1,188
$
3,064 $
2,151 $
4,191 $
12,256
3,571
15,827
12,663
4,231
16,894
15,180
4,380
19,560
360
360
(12,403) $
349
349
(12,354) $
340
340
(17,069) $
19,816
4,152
23,968
349
349
(22,431)
(0.54) $
(0.54) $
(0.74) $
(0.97)
$
$
22,816,521
22,966,314
23,152,019
23,184,459
115
Table of Contents
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.
ITEM 9A. CONTROLS AND PROCEDURES
Management’s Evaluation of our Disclosure Controls and Procedures
We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be
disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported
within the time periods specified in the Securities and Exchange Commission’s rules and forms and (2) accumulated and
communicated to our management, including our principal executive and principal financial officer, as appropriate to allow
timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how
well designed and operated, can provide only reasonable assurance of achieving their objectives and our management
necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our
disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.
Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the
effectiveness of our disclosure controls and procedures as of December 31, 2019, the end of the period covered by this
Annual Report on Form 10-K. Based upon such evaluation, our principal executive officer and principal financial officer
have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.
Internal Control Over Financial Reporting
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over our financial reporting.
Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as
a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our
board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our internal
control over financial reporting includes those policies and procedures that:
·
·
·
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and
dispositions of our assets;
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in
accordance with authorizations of our management and directors; and
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or
disposition of our assets that could have a material effect on our financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2019. In
making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO) in its 2013 Internal Control — Integrated Framework. Based on our assessment, our
116
Table of Contents
management has concluded that, as of December 31, 2019, our internal control over financial reporting is effective based on
those criteria.
This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm
regarding internal control over financial reporting due to an exemption established by the Jumpstart Our Business Startups
Act of 2012 for “emerging growth companies.”
Changes in Internal Control over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange
Act) occurred during the three months ended December 31, 2019 that has materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting.
ITEM 9B. OTHER INFORMATION
None.
117
Table of Contents
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required by this Item 10 will be included in our definitive proxy statement to be filed with the SEC with
respect to our 2020 Annual Meeting of Stockholders and is incorporated herein by reference.
ITEM 11. EXECUTIVE COMPENSATION
The information required by this Item 11 will be included in our definitive proxy statement to be filed with the SEC with
respect to our 2020 Annual Meeting of Stockholders and is incorporated here by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
The information required by this Item 12 will be included in our definitive proxy statement to be filed with the SEC with
respect to our 2020 Annual Meeting of Stockholders and is incorporated herein by reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
The information required by this Item 13 will be included in our definitive proxy statement to be filed with the SEC with
respect to our 2020 Annual Meeting of Stockholders and is incorporated herein by reference.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The information required by this Item 14 will be included in our definitive proxy statement to be filed with the SEC with
respect to our 2020 Annual Meeting of Stockholders and is incorporated herein by reference.
118
Table of Contents
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
Financial Statements
PART IV
For a list of the consolidated financial statements included herein, see Index to the Consolidated Financial Statements in this
Annual Report on Form 10-K, which is incorporated into this Item by reference.
Financial Statement Schedules
No financial statement schedules have been submitted because they are not required or are not applicable or because the
information required is included in the consolidated financial statements or the notes thereto.
Exhibits
See the Exhibit Index immediately before the signature page of this Annual Report on Form 10-K. The exhibits listed in the
Exhibit Index are filed or incorporated by reference as part of this Annual Report on Form 10-K.
ITEM 16. FORM 10-K SUMMARY
None.
Exhibit
Number
3.1
3.2
4.1
4.2
Description of Exhibit
EXHIBIT INDEX
Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the
Company’s Form 8-K, File No. 001-38129, filed on July 10, 2017).
Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company’s Form 8-K, File
No. 001-38129, filed on July 10, 2017).
Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Form S-1, File
No. 333-218412, filed on June 1, 2017).
Third Amended and Restated Investor Rights Agreement, dated as of June 15, 2016, by and among Mersana
Therapeutics, Inc. and the Stockholders listed therein (incorporated by reference to Exhibit 4.2 to the
Company’s Form S-1, File No. 333-218412, filed on June 1, 2017).
4.3
Form of Exchange Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K, File No.
001-38129, filed on November 27, 2019).
4.4*
Description of Registrant’s Common Stock.
10.1†
Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Form S-
1/A, File No. 333-218412, filed on June 16, 2017).
10.2
Commercial Lease, dated February 24, 2009, between Mersana Therapeutics, Inc. and Rivertech Associates
II, LLC (incorporated by reference to Exhibit 10.2 to the Company’s Form S-1, File No. 333-218412, filed
on June 1, 2017).
119
Table of Contents
10.3
10.4+
10.5+
10.6+
10.7+
10.8
10.9+
10.10
10.11+
10.12+
10.13+
10.14+
10.15
Sixth Lease Extension and Modification Agreement, dated January 17, 2018, by and between Mersana
Therapeutics, Inc. and Rivertech Associates II LLC (incorporated by reference to Exhibit 10.1 to the
Company’s Form 10-Q, File No. 001-38129, filed on May 15, 2018).
Collaboration and Commercial License Agreement, dated June 23, 2014, by and between Mersana
Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.4 to the Company’s Form S-1,
File No. 333-218412, filed on June 1, 2017).
Amendment 1 to the Collaboration and Commercial License Agreement, dated June 1, 2016, by and between
Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.5 to the Company’s
Form S-1, File No. 333-218412, filed on June 1, 2017).
Amendment 2 to the Collaboration and Commercial License Agreement, dated August 12, 2016, by and
between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.6 to the
Company’s Form S-1, File No. 333-218412, filed on June 1, 2017).
Amendment 3 to the Collaboration and Commercial License Agreement, dated February 28, 2017, by and
between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.7 to the
Company’s Form S-1, File No. 333-218412, filed on June 1, 2017).
Amendment 4 to Collaboration and Commercial License Agreement dated May 15, 2018, by and between
Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.1 to the Company’s
Form 10-Q, File No. 001-38129, filed on August 14, 2018).
License, Development and Commercialization Agreement, dated July 9, 2015, by and between Mersana
Therapeutics, Inc. and Recepta Biopharma S.A. (incorporated by reference to Exhibit 10.8 to the Company’s
Form S-1, File No. 333-218412, filed on June 1, 2017).
First Amendment to the License, Development and Commercialization Agreement, dated August 19, 2019,
by and between Mersana Therapeutics, Inc. and Recepta Biopharma S.A. (incorporated by reference to
Exhibit 10.1 to the Company’s Form 10-Q, File No. 001-38129, filed on November 6, 2019).
Agreement Regarding LICR Technology, dated July 9, 2015, by and between Ludwig Institute for Cancer
Research, Recepta Biopharma S.A. and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit
10.9 to the Company’s Form S-1, File No. 333-218412, filed on June 1, 2017).
Collaboration Agreement, dated as of July 25, 2012, by and between Adimab, LLC and Mersana
Therapeutics, Inc. (incorporated by reference to Exhibit 10.10 to the Company’s Form S-1, File No. 333-
218412, filed on June 1, 2017).
Amendment Number One to the Collaboration Agreement, dated February 21, 2013, by and between
Adimab, LLC and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit 10.11 to the Company’s
Form S-1, File No. 333-218412, filed on June 1, 2017).
Amendment Number One, to the Collaboration Agreement dated June 17, 2014, by and between Adimab,
LLC and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit 10.12 to the Company’s Form S-
1, File No. 333-218412, filed on June 1, 2017).
Second Amendment to Amended and Restated Research Collaboration and Commercial License Agreement,
as amended, dated August 2, 2017 by and between Mersana Therapeutics, Inc. and Millennium
Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q, File No. 001-
38129, filed on August 11, 2017).
120
Table of Contents
10.16
10.17
10.18
10.19
10.20†
10.21†
10.22†
Third Amendment to the Amended and Restated Research Collaboration and Commercial License
Agreement, as amended, dated October 30, 2017 by and between Mersana Therapeutics, Inc. and
Millennium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q,
file No. 001-38129, filed on November 13.2017).
Exchange Agreement, dated November 26, 2019, by and between Biotechnology Value Fund, L.P.,
Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P. and Mersana Therapeutics,
Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K, File No. 001-38129, filed on
November 27, 2019).
Loan and Security Agreement, dated May 8, 2019, by and between Silicon Valley Bank and Mersana
Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 to the Company’s Form 10-Q, File No. 001-
38129, filed on May 9, 2019).
First Amendment to the Loan and Security Agreement, dated June 21, 2019 by and between Silicon Valley
Bank and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 to the Company’s Form 10-
Q, File No. 001-38129, filed on August 8, 2019).
Amended and Restated Offer Letter, by and between Mersana Therapeutics, Inc. and Anna Protopapas, dated
March 17, 2017 (incorporated by reference to Exhibit 10.16 to the Company's Form S-1, File No. 333-
218412, filed on June 1, 2017).
Amended and Restated-Offer-Letter, by and between Mersana Therapeutics, Inc. and Timothy B. Lowinger,
dated March 8, 2017 (incorporated by reference to Exhibit 10.18 to the Company's Form S-1, File No. 333-
218412, filed on June 1, 2017).
Offer Letter, by and between Mersana Therapeutics, Inc. and David Spellman, dated December 18, 2017
(incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q, File No. 001-38129, filed on May
9, 2019).
10.23†
2007 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.19 to the Company’s Form
S-1, File No. 333-218412, filed on June 1, 2017).
10.24†
Form of Incentive Stock Option under the 2007 Stock Incentive Plan (incorporated by reference to Exhibit
10.20 to the Company’s Form S-1, File No. 333-218412, filed on June 1, 2017).
10.25†
Form of Nonqualified Stock Option under the 2007 Stock Incentive Plan (incorporated by reference to
Exhibit 10.21 to the Company’s Form S-1, File No. 333-218412, filed on June 1, 2017).
10.26†
2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.22 to the Company’s Form S-1/A, File
No. 333-218412, filed on June 16, 2017).
10.27†
Form of Incentive Stock Option under the 2017 Stock Incentive Plan (incorporated by reference to Exhibit
10.23 to the Company’s Form S-1/A, File No. 333-218412, filed on June 16, 2017).
10.28†
Form of Nonqualified Stock Option under the 2017 Stock Incentive Plan (incorporated by reference to
Exhibit 10.24 to the Company’s Form S-1/A, File No. 333-218412, filed on June 16, 2017).
10.29†
2017 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.25 to the Company’s Form S-
1/A, File No. 333-218412, filed on June 16, 2017).
10.30†
2017 Cash Bonus Plan (incorporated by reference to Exhibit 10.26 to the Company’s Form S-1/A, File No.
333-218412, filed on June 16, 2017).
121
Table of Contents
21.1*
23.1*
31.1*
31.2*
Subsidiaries of Mersana Therapeutics, Inc.
Consent of Ernst & Young LLP.
Certification pursuant to Section 302 of Sarbanes Oxley Act of 2002 by Chief Executive Officer.
Certification pursuant to Section 302 of Sarbanes Oxley Act of 2002 by Principal Financial Officer.
32.1**
Certification of periodic financial report pursuant to Section 906 of Sarbanes Oxley Act of 2002 by Chief
Executive Officer and Principal Financial Officer.
101. *
INS
101. *
SCH
101. *
CAL
101. *
DEF
101. *
LAB
101. *
PRE
*
**
†
+
XBRL Instance Document.
XBRL Taxonomy Extension Schema.
XBRL Taxonomy Extension Calculation Linkbase.
XBRL Taxonomy Extension Definition Linkbase.
XBRL Taxonomy Extension Label Linkbase.
XBRL Taxonomy Extension Presentation Linkbase.
Filed herewith.
Furnished herewith.
Indicates a management contract or compensatory plan.
Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment
and this exhibit has been submitted separately to the Securities and Exchange Commission.
122
Table of Contents
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Dated: February 28, 2020
Mersana Therapeutics, Inc.
/s/ Anna Protopapas
Anna Protopapas
President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following
persons on behalf of the registrant and in the capacities and on dates indicated.
Signature
Title
Date
/s/ ANNA PROTOPAPAS
Anna Protopapas
(Principal Executive Officer)
President, Chief Executive Officer and Director
February 28, 2020
/s/ BRIAN DESCHUYTNER
Brian DeSchuytner
/s/ ASHISH MANDELIA
Ashish Mandelia
/s/ DAVID MOTT
David Mott
/s/ KRISTEN HEGE
Kristen Hege, M.D.
/s/ ANDREW A. F. HACK
Andrew A. F. Hack, M.D., Ph.D.
/s/ LAWRENCE M. ALLEVA
Lawrence M. Alleva
/s/ WILLARD H. DERE, M.D.
Willard H. Dere, M.D.
Senior Vice President, Finance & Product Strategy
(Principal Financial Officer)
February 28, 2020
Vice President, Controller (Principal Accounting
Officer)
February 28, 2020
Chairman of the Board
February 28, 2020
Director
Director
Director
Director
123
February 28, 2020
February 28, 2020
February 28, 2020
February 28, 2020
DESCRIPTION OF THE REGISTRANT’S SECURITIES
Exhibit 4.4
The following summary description of the Common Stock (as defined below) of Mersana Therapeutics, Inc., or
the Corporation, is based on the provisions of our fifth amended and restated certificate of incorporation, or the Restated
Certificate, our amended and restated bylaws, or Bylaws, and the applicable provisions of the General Corporation Law
of the State of Delaware, or DGCL. This information may not be complete in all respects and is qualified entirely by
reference to the provisions of the Restated Certificate, the Bylaws, and the DGCL. The Restated Certificate and Bylaws
are filed as exhibits to the Annual Report on Form 10-K to which this Description of Securities is an exhibit.
General
Our Restated Certificate authorizes us to issue 175,000,000 shares of common stock (“Common Stock”), par value
$0.0001 per share, and 25,000,000 shares of preferred stock, par value $0.0001 per share. Our Common Stock is
registered under Section 12 of the Securities Exchange Act of 1934, as amended, and listed on the Nasdaq Global Select
Market under the symbol “MRSN.”
Common Stock
Each holder of our Common Stock shall be entitled to one vote for each share of Common Stock held of record by
such holder on all matters on which stockholders generally are entitled to vote and does not have cumulative voting
rights. A contested election of directors by our stockholders shall be determined by a plurality of the votes cast by the
stockholders entitled to vote on the election; otherwise, a nominee is elected if the votes properly cast for such nominee
exceed the votes properly cast against such nominee.
Dividends of cash or property may be declared and paid on the Common Stock from funds lawfully available
therefor as and when determined by our board of directors and subject to any preferential dividend rights of any then
outstanding preferred stock. The holders of the Common Stock shall have no preemptive rights to subscribe for any
shares of any class of stock of the Corporation whether now or hereafter authorized. The Common Stock shall not be
convertible into, or exchangeable for, shares of any other class or classes or of any other series of the same class of the
Corporation’s capital stock. Upon the dissolution, liquidation or winding up of the affairs of the Corporation, whether
voluntary or involuntary, after payment or provision for payment of the debts and liabilities of the Corporation and of the
preferential and other amounts, if any, to which the holders of preferred stock shall be entitled, holders of Common
Stock shall be entitled to receive all assets of the Corporation available for distribution to its stockholders, ratably in
proportion to the number of shares held by each such stockholder.
Additional shares of authorized common stock may be issued, as authorized by our board of directors from time to
time, without stockholder approval, except as may be required by applicable stock exchange requirements.
Anti-Takeover Effects of our Restated Certificate, Bylaws and the DGCL
Authorized but Unissued Shares.
Our authorized but unissued shares of Common Stock and preferred stock are available for future issuance without
stockholder approval. Our board of directors, has the authority under our Restated Certificate to issue preferred stock
with rights superior to the rights of the holders of Common Stock. As a result, the issuance of preferred stock may have
the effect of delaying, deferring or preventing a change of control of the Corporation without further action by the
stockholders and may adversely affect the voting and other rights of the holders of Common Stock.
Exhibit 4.4
Classified Board
Our Restated Certificate provides for our board of directors to be divided into three classes, with staggered three-
year terms. As a result, only one class of directors is elected at each annual meeting of stockholders, with the other
classes continuing for the remainder of their respective three-year terms. Our Restated Certificate also provides that,
subject to any rights of holders of preferred stock to elect additional directors under specified circumstances, the number
of directors will be fixed exclusively pursuant to a resolution adopted by our board of directors.
Removal of Directors
Our Restated Certificate provides that our directors may be removed only for cause by the affirmative vote of at
least 75% of the voting power of our outstanding shares of capital stock, voting together as a single class. This
requirement of a supermajority vote to remove directors could enable a minority of our stockholders to prevent a change
in the composition of our board of directors.
Action by Written Consent; Special Meeting of Stockholders
Our Restated Certificate also requires that any action required or permitted to be taken by our stockholders must
be effected at a duly called annual or special meeting of the stockholders and cannot be taken by written consent in lieu
of a meeting. A special meeting of the stockholders may be called only by or at the direction of our board of directors
pursuant to a written resolution adopted by a majority of the total number of directors which the Corporation would have
if there were no vacancies. These provisions may have the effect of delaying, deferring or preventing a change in control
and may also delay or prevent changes in management of the Corporation.
Advance Notice Procedures
Our Bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual
meeting of our stockholders, including proposed nominations of persons for election to the board of directors.
Stockholders at an annual meeting are only able to consider proposals or nominations specified in the notice of meeting
or brought before the meeting by or at the direction of the board of directors or by a stockholder who was a stockholder
of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary
timely written notice, in proper form, of the stockholder’s intention to bring that business before the meeting. Although
our Bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates
or proposals regarding other business to be conducted at a special or annual meeting, our Bylaws may have the effect of
precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or
deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise
attempting to obtain control of us.
Super Majority Approval Requirements
Our Restated Certificate and Bylaws provide that the affirmative vote of holders of at least 75% of the total votes
eligible to be cast in the election of directors is required to amend, alter, change or repeal specified provisions. This
requirement of a supermajority vote to approve amendments to our Restated Certificate and Bylaws could enable a
minority of our stockholders to exercise veto power over any such amendments.
Exclusive Forum
Our Restated Certificate requires, to the fullest extent permitted by law, that derivative actions brought in the name
of the Corporation, actions against directors, officers and employees for breach of a fiduciary duty and other similar
actions may be brought only in specified courts in the State of Delaware. Although we believe this provision benefits us
by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the
provision may have the effect of discouraging lawsuits against our directors and officers.
Exhibit 4.4
These and other provisions are intended to enhance the likelihood of continued stability in the composition of our
board of directors and to discourage certain types of transactions that may involve an actual or threatened change of
control. However, such provisions could have the effect of discouraging others from making tender offers for our shares
and, as a consequence, such provisions also may inhibit fluctuations in the market price of our shares that could result
from actual or rumored takeover attempts.
Section 203 of the General Corporation Law of the State of Delaware
We are subject to Section 203 of the DGCL which regulates acquisitions of some Delaware corporations. In
general, Section 203 prohibits, with some exceptions, a publicly held Delaware corporation such as us from engaging in
a “business combination” with an “interested stockholder” for a period of three years following the time that the
stockholder became an interested stockholder, unless the business combination is approved in a prescribed manner. A
“business combination” includes, among other things, a merger, asset or stock sale or other transaction resulting in a
financial benefit to the interested stockholder. An "interested stockholder" is a person who, together with affiliates and
associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more
of the corporation's voting stock.
Under Section 203, a business combination between a corporation and an interested stockholder is prohibited
unless it satisfies one of the following conditions: before the stockholder became interested, the board of directors
approved either the business combination or the transaction which resulted in the stockholder becoming an interested
stockholder; upon consummation of the transaction which resulted in the stockholder becoming an interested
stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time
the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by
persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the
stockholder became interested, the business combination was approved by the board of directors of the corporation and
authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the
outstanding voting stock which is not owned by the interested stockholder.
A Delaware corporation may "opt out" of these provisions with an express provision in its original certificate of
incorporation or an express provision in its certificate of incorporation or by-laws resulting from a stockholders'
amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions.
As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented.
Exhibit 21.1
Subsidiaries of the Registrant
Entity
State of Incorporation or Organization
Mersana Securities Corp.
Massachusetts
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
Exhibit 23.1
(1) Registration Statement (Form S-3 No. 333-226055) of Mersana Therapeutics, Inc. and in the related
(2) Registration Statement (Form S-8 No. 333-230159) pertaining to the Mersana Therapeutics, Inc. 2017 Stock
Incentive Plan and the Mersana Therapeutics, Inc. 2017 Employee Stock Purchase Plan,
(3) Registration Statement (Form S-8 No. 333-222845) pertaining to the Mersana Therapeutics, Inc. 2017 Stock
Prospectus,
Incentive Plan, and
(4) Registration Statement (Form S-8 No. 333-219388) pertaining to the Mersana Therapeutics, Inc. 2007 Stock
Incentive Plan, as amended, the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan and the Mersana
Therapeutics, Inc. 2017 Employee Stock Purchase Plan;
of our report dated February 28, 2020, with respect to the consolidated financial statements of Mersana
Therapeutics, Inc. included in this Annual Report (Form 10-K) of Mersana Therapeutics, Inc. for the year ended
December 31, 2019.
Boston, Massachusetts
February 28, 2020
/s/ Ernst & Young LLP
CERTIFICATIONS
Exhibit 31.1
I, Anna Protopapas, certify that:
1. I have reviewed this Annual Report on Form 10-K of Mersana Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the registrant as of,
and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period
in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report
our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred
during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual
report), that has materially affected, or is reasonably likely to materially affect, the registrant’s internal
control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors
(or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant's internal control over financial reporting.
Date: February 28, 2020
By:
/s/ Anna Protopapas
Anna Protopapas
President and Chief Executive Officer
(Principal Executive Officer)
CERTIFICATIONS
Exhibit 31.2
I, Brian DeSchuytner, certify that:
1. I have reviewed this Annual Report on Form 10-K of Mersana Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the registrant as of,
and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period
in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report
our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred
during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual
report), that has materially affected, or is reasonably likely to materially affect, the registrant’s internal
control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors
(or persons performing the equivalent functions):
(a)
(b)
All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and
Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant's internal control over financial reporting.
Date: February 28, 2020
By:
/s/ Brian DeSchuytner
Brian DeSchuytner
Senior Vice President, Finance & Product Strategy
(Principal Financial Officer)
Exhibit 32.1
CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Annual Report on Form 10-K of Mersana Therapeutics, Inc. (the “Company”) for the year ended
December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the
undersigned officers of the company, hereby certifies, pursuant to Section 1350 of Chapter 63 of Title 18, United States
Code, that to the best of her or his knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.
Date: February 28, 2020
Date: February 28, 2020
By:
/s/ Anna Protopapas
Anna Protopapas
President and Chief Executive Officer
(Principal Executive Officer)
By:
/s/ Brian DeSchuytner
Brian DeSchuytner
Senior Vice President, Finance & Product Strategy
(Principal Financial Officer)